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alternative splicing during T cell activation using next-generation sequencing and identify hundreds of genes
that are regulated by alternative splicing during activation of a T cell line and primary human T cells.
Alternative splicing in response to T cell receptor signaling is enriched for genes encoding signaling proteins;
suggesting interplay between signaling and splicing regulation. In this thesis I describe the selection of the
JNK kinase MKK7, as a model system to understand the connections between signaling and splicing in T
cells. Specifically, I find that that in response to T cell activation, MKK7 is alternatively spliced to favor an
isoform that lacks exon 2. This isoform restores a MAPK docking site within MKK7 that is disrupted in the
larger isoform. Consistently, skipping of exon 2 enhances JNK pathway activity, as indicated by c-Jun
phosphorylation and upregulation of the c-Jun target gene TNF-alpha. Notably, signaling through JNK itself
is necessary and sufficient to promote activation-induced repression of exon 2 of the MKK7 gene. Thus, JNK-
induced MKK7 alternative splicing represents a positive feedback loop through which JNK promotes its own
signaling.
Through minigene based analysis I identify sequences within the introns flanking MKK7 exon 2 that are
necessary and sufficient to promote activation-induced skipping. Analysis of RNA-protein interactions and
knockdown experiments identified CELF2 as a protein that binds to MKK7 introns in an activation-
dependent manner and represses exon 2 inclusion. The repressive activity of CELF2 on MKK7 exon 2 is
mediated through a JNK-dependent increase in CELF2 protein, that results from stabilization of the CELF2
mRNA. Finally, I show that ~25% of T cell receptor-mediated alternative splicing events are dependent on
JNK signaling. These JNK-dependent events are also significantly enriched for CELF2-dependence. Together,
the data presented in this thesis demonstrates a broad role for the JNK-CELF2 axis in controlling splicing
during T cell activation, including a specific role in potentiating JNK signaling.
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ABSTRACT 
 
 
INTERPLAY BETWEEN SIGNALING AND SPLICING DURING T CELL ACTIVATION: A 
STUDY ON MKK7 
Nicole M Martinez 
Kristen W Lynch 
 
Alternative splicing is a mechanism of gene regulation that expands the 
genome's coding capacity. The ability to regulate alternative splicing in response to 
external signals is critical for immune responses. I profiled alternative splicing during T 
cell activation using next-generation sequencing and identify hundreds of genes that are 
regulated by alternative splicing during activation of a T cell line and primary human T 
cells. Alternative splicing in response to T cell receptor signaling is enriched for genes 
encoding signaling proteins; suggesting interplay between signaling and splicing 
regulation. In this thesis I describe the selection of the JNK kinase MKK7, as a model 
system to understand the connections between signaling and splicing in T cells. 
Specifically, I find that that in response to T cell activation, MKK7 is alternatively spliced 
to favor an isoform that lacks exon 2. This isoform restores a MAPK docking site within 
MKK7 that is disrupted in the larger isoform. Consistently, skipping of exon 2 enhances 
JNK pathway activity, as indicated by c-Jun phosphorylation and upregulation of the c-
Jun target gene TNF-alpha. Notably, signaling through JNK itself is necessary and 
sufficient to promote activation-induced repression of exon 2 of the MKK7 gene. Thus, 
JNK-induced MKK7 alternative splicing represents a positive feedback loop through 
which JNK promotes its own signaling.  
 v 
Through minigene based analysis I identify sequences within the introns flanking 
MKK7 exon 2 that are necessary and sufficient to promote activation-induced skipping. 
Analysis of RNA-protein interactions and knockdown experiments identified CELF2 as a 
protein that binds to MKK7 introns in an activation-dependent manner and represses 
exon 2 inclusion. The repressive activity of CELF2 on MKK7 exon 2 is mediated through 
a JNK-dependent increase in CELF2 protein, that results from stabilization of the CELF2 
mRNA. Finally, I show that ~25% of T cell receptor-mediated alternative splicing events 
are dependent on JNK signaling. These JNK-dependent events are also significantly 
enriched for CELF2-dependence. Together, the data presented in this thesis 
demonstrates a broad role for the JNK-CELF2 axis in controlling splicing during T cell 
activation, including a specific role in potentiating JNK signaling.   
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CHAPTER 1: INTRODUCTION 
 
The adaptive immune system is marked by its ability to detect an invading pathogen or 
foreign antigen and direct an appropriate effector response. T cells, for example, 
recognize antigen through the T cell receptor (TCR), which triggers extensive proximal 
signaling and downstream signaling cascades. These signaling events ultimately lead to 
changes in cell morphology, proliferation, secretion of cytokines and cytotoxins, 
migration and homing, and a plethora of effector function (Smith-Garvin et al. 2009). 
Studies over the past decades have focused on how transcriptional control regulates 
gene expression in an immune response. However, post-transcriptional mechanisms of 
gene regulation are increasingly emerging as important regulators of immune cell 
function. In particular, one mechanism of post-transcriptional gene regulation that has 
garnered much interest in the past few years is alternative pre-mRNA splicing. 
Alternative splicing (AS) is an essential and ubiquitous mechanism for regulated 
gene expression that goes beyond turning genes “on” and “off”. In broad terms, AS 
refers to any case of variable inclusion of an exon, intron or portion-thereof in some 
fraction of transcripts derived from a given gene. As such, AS results in the generation of 
multiple distinct mRNAs from a given gene. The most common form of AS is variable 
inclusion of an internal “cassette” exon, although essentially all other potential patterns 
have been described in at least some genes (Figure 1.1) (Wang et al. 2008). Variable 
inclusion of sequences internal to a gene (cassette exon, alternative splice site usage or 
intron retention) typically leads to alterations in coding sequence, either by adding or 
deleting a peptide domain or by introducing premature stop codons (PTCs). By contrast, 
differential splicing of the 5’ or 3’ UTRs can alter the presence of regulatory motifs and 
miRNA binding sites, thereby influencing mRNA stability, expression and/or translation  
 2 
Figure 1.1 Common patterns of AS. Rectangles represent exons and lines represent introns. 
Dotted98 lines connect exons that are joined together to form the final mRNA. Red and blue regions 
are those that can be differentially included in the mature mRNA. Dotted lines above and below 
represent the two alternate possible splicing patterns. 
 
(Sandberg et al. 2008; Moore and Proudfoot 2009; Pan et al. 2008). Thus, regardless of 
pattern, AS has a profound effect on the identity, level or expression pattern of the 
resulting protein.  
It is now well established that the majority of multi-exon mammalian genes 
(>95%) undergo AS (Wang et al. 2008; Martinez et al. 2012). Given the diversity and 
plasticity required for immune effector functions it seems inevitable that cells of the 
adaptive immune system rely on regulated pre-mRNA splicing to at least some extent to 
control protein expression and function.  
In this dissertation I explain my contribution to our understanding of how T cells 
utilize alternative splicing to achieve immune effector functions. My dissertation starts 
out broad, describing how we used profiling studies to determine the scope of signal-
 3 
induced alternative splicing during T cell immune responses, using a model T cell line 
and primary T cells from human donors. Since I found that genes encoding signaling 
proteins are enriched amongst genes that are alternatively spliced in response to T cell 
receptor signaling, this suggested an interdependent regulation between signaling and 
splicing.  I then narrow the focus of the thesis to the study of one example of this type of 
alternative splicing in the kinase MKK7. Below I provide an introduction of the breadth, 
impact and mechanisms of alternative splicing in immune responses to place my results 
in the context of what is known from the literature.  
 
Breadth and impact of alternative splicing in immune responses 
The accessibility of high-throughput genomics has shifted the way we think about AS 
from a gene centric to a networks point of view. In light of this, a flurry of high throughput 
genomic studies has emerged in an attempt to identify AS programs that are coordinated 
in response to stimuli, perturbations to cell states, and differentiation among others. In 
particular, the studies listed in Table 1.1 have provided a quantitative and defined 
analysis of AS in various functional states of primary immune cells and model cell lines, 
and support a role for widespread regulated splicing in immune responses. Specifically, 
these studies have identified hundreds of potential changes in AS during T cell 
activation, B cell stimulation and HIV (human immunodeficiency virus) infection. The 
described splicing changes include those predicted to impact the coding potential of the 
genes, as well as differential use of terminal exons which alters the presence of miRNA 
binding sites in the 3’ UTR (Table 1.1).  
One general conclusion from the profiling studies in Table 1.1 is that AS 
regulates a unique and substantial set of genes that are not altered at the level of 
 4 
transcription (Grigoryev et al. 2009; Ip et al. 2007; Lynch 2004). This suggests that 
transcription and AS contribute independently to T cell antigen responses, underscoring 
the unique role of AS in molding immune responses. Furthermore, some of the studies in 
Table 1.1 found that signal-responsive AS events are enriched in genes involved in 
many aspects of T cell biology and effector functions ((Martinez et al. 2012; Grigoryev et 
al. 2009; Ip et al. 2007) and see chapter 2). Enriched activities include canonical T cell 
signaling pathways such as NF-kB and JNK and MAP kinase signaling, Rho-mediated 
changes in lymphocyte migration, and genes involved in cell proliferation (Grigoryev et 
al. 2009; Martinez et al. 2012), again highlighting the potential impact of AS on immune 
responses.  
We note that an important aspect of the papers in Table 1.1 was providing 
sufficient data to warrant the conclusions drawn. As high-throughput analyses are 
becoming more accessible, the need for caution in data analysis and interpretation is 
essential. It is widely accepted among splicing experts that a minimum threshold for 
confidence in AS is a 10% change (i.e. 20% inclusion to 30% inclusion of a variable 
exon) (Sandberg et al. 2008; Pan et al. 2008).  Below this differential, the ability to detect 
and quantify changes is not sufficient for rigorous conclusions. Furthermore, the biologic 
significance of very minor changes in exon inclusion, even if statistically significant, is 
highly suspect. Thus, it is imperative that any profiling studies state the predicted 
differences for any AS events reported. Finally, defining the AS event beyond providing 
a gene name is necessary for any conclusions to be drawn, as there are often more than 
one potential AS event within a given gene.  
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Table 1.1: Studies identifying splicing regulation in immune cells. 
 
Cell Type Conditions Experimental 
Platform 
Reference Observations 
JSL1 Jurkat, 
primary 
human CD4+ 
T cells 
PMA (Jurkat),   
PHA (primary T 
cells) 
RNA-seq (Martinez et 
al. 2012) 
178 AS events in response to 
activation of Jurkat cells, 80% 
validation rate (43/52) by RT-PCR.  
Validated in primary CD4+ T cells.  
AS genes enriched for functions 
relevant to immune response 
primary 
human CD4+ 
T cells 
HIV-1 infection exon array (Imbeault et 
al. 2012) 
323 , 129 and 107 AS events are 
regulated in response to HIV-1 
infection of CD4+ T cells at 24, 48 
and 72 h post-infection.  
PBMCs PHA, IL-2 & 
ionomycin 
exon array (Whistler et 
al. 2010) 
472 alternatively spliced 
transcripts, >70% validation rate 
(5/7) by RT-PCR, AS genes 
enriched for splicing factors 
primary 
human 
CD2+ T, 
CD19+ B 
cells 
a -CD3/28             
(T cells),    
a -CD40, IL2 +IL10         
(B-cells) 
exon array (Grigoryev et 
al. 2009) 
Array predicts 50-70% of 
constitutively expressed genes in 
T cells and 40% in B cells are 
alternatively spliced. Only 4/22 
predictions (18%) validate by RT-
PCR 
Primary 
murine T 
cells 
a-CD3/28  exon array (Sandberg et 
al. 2008) 
Quantify and validate AS of 
alternate terminal exons.  Do not 
differentiate between mechanism 
of AS and APA 
Primary 
murine T 
cells 
naive and memory 
T cells purified 
from mice 
exon array (Wu et al. 
2008) 
Provide quantitative measure of 
individual exons in numerous 
genes that differ in array 
expression between naïve and 
memory murine T cells. No RT-
PCR validation given. 
JSL1 Jurkat, 
primary 
human CD4+ 
and CD8+ T 
cells 
PMA (Jurkat),  
PHA (primary cells) 
exon junction 
array 
(Ip et al. 
2007) 
First large scale analysis of AS in 
T cells. Initial analysis done in 
Jurkat cells, validated predictions 
in primary CD4+ and CD8+ T cells 
 
Regardless of the platform and analysis pipeline used to profile mRNA 
expression, rigorous validation of AS predictions by independent assays such as RT-
PCR are of utmost importance to define threshold criteria for meaningful data and 
ultimately confirm AS events. Importantly, validation rates differ considerably among 
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published studies (Table 1.1) thus predictions from exon array or RNA-Seq cannot be 
assumed a priori to be accurate. However, even if the conclusions from some of the 
profiling experiments are overstated, the general conclusion that AS plays a functionally 
relevant role in immune responses has been well documented. Indeed, a literature 
search reveals close to one hundred genes that have now been validated to exhibit 
significant changes in isoform expression during an immune response, including several 
instances in which the AS changes are known to impact lymphocyte function (Table 1.2).  
Many of the validated AS events in immune cells have been identified in work 
done by our group in collaboration with the lab of Dr. Benjamin Blencowe. Our 
microarray profiling of naive and activated T cells was the first large scale analysis of AS 
in T cells (Ip et al. 2007). More recently we have expanded this analysis by employing 
RNA-seq to identify further novel instances of AS (See Chapter 2) (Martinez et al. 2012).  
As mentioned above, many of the genes that we and others have validated to 
undergo changes in AS during immune responses include genes with known functions in 
immunobiology. These include cell surface receptors, kinases, phosphatases and 
adaptor proteins, transcription factors and chromatin modifying enzymes and RNA 
binding proteins and others involved in regulating mRNA processing of many messages 
(see Table 1.2). These studies have provided substantive evidence for the critical role 
that AS plays in assuring proper function of the adaptive immune response. To 
underscore the functional connection between AS and lymphocyte function, I highlight 
below a few examples where regulated pre-mRNA AS of particular classes of genes has 
been directly linked to immune responses and/ or susceptibility to autoimmune diseases. 
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Table 1.2: Validated instances of alternative splicing during immune responses. 
 
Gene Exon a Cell Type b Condition c Change Reference 
Cell Surface Receptors         
CD3-zeta intron 8 T α-CD3/28 retention (Moulton and Tsokos 2010) 
CD3-zeta intron 4 PBMC PHA retention (Atkinson et al. 2003) 
CD28 exon 3 T α-CD3/28 inclusion (Magistrelli et al. 1999) 
CD45 exon 4 Jk, CD4 various skipping (Lynch and Weiss 2000) 
CD45 exon 5 Jk, CD4 various skipping (Lynch and Weiss 2000) 
CD45 exon 6 Jk, CD4 various skipping (Lynch and Weiss 2000) 
 
CD46 mutually 
exclusive  
T α-CD3/46  inclusion 
exon 14 
(Astier et al. 2006) 
CD6 exon 5 T various skipping (Castro et al. 2007) 
CD8 exon 7  CD8 α-CD3/28 retention (Thakral et al. 2008) 
CD83 exon 3-4 PBMC various inclusion (Dudziak et al. 2005) 
CD96 exon 4 CD4, CD8 resting skipping (Meyer et al. 2009) 
CTLA-4 exon 3 T α-CD3/28 inclusion (Magistrelli et al. 1999) 
Fas exon 6 PBMC PHA inclusion (Liu et al. 1995) 
HMMR exon 3 CD4, CD8 PHA inclusion (Ip et al. 2007) 
ICAM-1  exon 2-5 T, Thy LPS variable (King et al. 1995) 
PECAM1 exon 14-15 Jk PMA skipping (Wang et al. 2003) 
SEC16A exon 29 Jk, CD4 PMA, PHA variable d (Martinez et al. 2012) 
SEC16A exon 30 Jk, CD4 PMA, PHA inclusion (Martinez et al. 2012) 
Cytokine-related         
IL-4 exon 2 T α-CD3 inclusion (Alms et al. 1996) 
IL-7Rα  exon 6 PBMC HIV  variable (Gregory et al. 2007) 
TIR8 exon 8 Jk, CD4 PMA, PHA inclusion (Martinez et al. 2012) 
Transcriptional regulators 
  
      
ATF2 exon 14 
 
 
Jk PMA inclusion (Martinez et al. 2012) 
BRD8 exon 20 Jk, CD4 PMA, PHA skipping (Martinez et al. 2012) 
EHMT2 exon 10 Jk, CD4 PMA, PHA inclusion (Martinez et al. 2012) 
FOXP3  exon 7 CD4, Tregs α-CD3/28 skipping (Kaur et al. 2010) 
GATA3  exon 4 CD4 PHA skipping (Ip et al. 2007) 
HIF1α  exon 14 CD4 PHA inclusion (Ip et al. 2007) 
 
ILF3 exon 9 CD4, CD8 PHA inclusion (Ip et al. 2007) 
IRF1 exon 7 CD4, CD8 PHA variable e (Ip et al. 2007) 
LEF1 exon 6 Jk, Thy, CD4 various variable (Ip et al. 2007; Mallory et al. 
2011) 
, Mallory 2011,Imbeault 2012 
     
RUNX1 exon 1-2 CD4 HIV-1  skipping (Imbeault et al. 2012) 
ZNF384 exon 5 Jk PMA inclusion (Martinez et al. 2012) 
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Table 1.2: (con’t) 
Gene Exon a Cell Type b Condition c Change Reference 
RNA-processing         
AUF-1 exon 2 CD4, CD8 PHA inclusion (Ip et al. 2007) 
CELF2 exon 6 Jk, CD4, CD8 PMA, PHA variable d (Ip et al. 2007) 
EIF4G2 exon 3 CD4, CD8 PHA skipping (Ip et al. 2007) 
FIP1L1 exon 8 Jk PMA skipping (Martinez et al. 2012) 
HRB exon 3 CD4, CD8 PHA skipping (Ip et al. 2007) 
 
LUC7L exon 2a Jk, CD4 PMA, PHA variable e (Martinez et al. 2012) 
RBM25 exon 6 PBMC P2I skipping (Whistler et al. 2010) 
SAM68 exon 3 CD4, CD8 PHA skipping (Ip et al. 2007) 
SFRS2 exon 2b PBMC P2I skipping (Whistler et al. 2010) 
SFRS10 intron 1 PBMC P2I removal (Whistler et al. 2010) 
SNRPB ND PBMC P2I inclusion (Whistler et al. 2010) 
TIA-1 exon 5 Jk resting skipping (Izquierdo and Valcárcel 2007) 
 
U2AF exon 11 PBMC P2I inclusion (Whistler et al. 2010) 
ZC3H14 exon 10 Jk, CD4 PMA, PHA inclusion (Martinez et al. 2012) 
Intracellular signaling/transport       
AKAP9 exon 4 Jk, CD4 PMA, PHA variable d (Martinez et al. 2012) 
CARD8 exon 5 Jk PMA skipping (Martinez et al. 2012) 
CLK2 exon 7 CD4, CD8 PHA skipping (Ip et al. 2007) 
DOCK10 mutually 
exclusive  
T resting inclusion 
of exon 1a 
(Alcaraz-García et al. 2011) 
Erk exon 6 CD8 PHA skipping (Ip et al. 2007) 
ERP29 exon 2 Jk PMA inclusion (Martinez et al. 2012) 
Fyn mutually 
exclusive  
Jk PMA inclusion 
of exon 7b 
(Rothrock et al. 2003) 
Fyn exon 9 Jk PMA skipping (Martinez et al. 2012) 
FR4 intron 3 CD4, Tregs resting retention (Jia et al. 2009) 
IRAK1 exon 11 CD4, Tregs α-CD3/28 skipping (Birzele et al. 2011) 
IRAK1 exon 12 Thy total variable (Jensen and Whitehead 2001) 
MAP2K7 exon 2 Jk, CD4 PMA, PHA skipping (Martinez et al. 2012) 
MAP3K7 exon 13 Jk, CD4 PMA, PHA skipping (Martinez et al. 2012) 
MAP4K2 exon 9 Jk, CD4 PMA, PHA variable e (Ip et al. 2007) 
PPP1R12
A 
exon 15 Jk PMA skipping (Martinez et al. 2012) 
REPS1 exon 10 Jk PMA skipping (Martinez et al. 2012) 
TRAF3 exon 7 Jk PMA skipping (Martinez et al. 2012) 
VAV1 exon 6 CD4, CD8 PHA skipping (Ip et al. 2007) 
Ion channels/binding       
ITPR1 exon 54 CD4 HIV-1  inclusion (Imbeault et al. 2012) 
K(Ca)3.1 mutually 
exclusive 
Thy Con A inclusion  
of exon 3 
(Ohya et al. 2010) 
     
TRIM26 exon 2 Jk, CD4 PMA, PHA variable e (Martinez et al. 2012) 
TRIM65 exon 3 Jk, CD4 PMA, PHA inclusion (Martinez et al. 2012) 
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Table 1.2: (con’t) 
Gene Exon a Cell Type b Condition c Change Reference 
Cytoskelet
al 
          
CCDC14 exon 5 Jk PMA skipping (Martinez et al. 2012) 
CLASP1 exon 9 CD2 α-CD3/28 skipping (Grigoryev et al. 2009) 
one 
EVI5 exon 18 CD4 HIV-1  inclusion (Imbeault et al. 2012) 
FAM21C exon 5 Jk PMA skipping (Martinez et al. 2012) 
FAM33A exon 3 Jk PMA skipping (Martinez et al. 2012) 
MACF1  exon 47 Jk PMA skipping (Martinez et al. 2012) 
MAP7D1 exon 6 Jk PMA inclusion (Martinez et al. 2012) 
MYL6 exon 3 Jk PMA inclusion (Martinez et al. 2012) 
SLMAP exon 22a Jk PMA skipping (Martinez et al. 2012) 
Tau exon 2 Jk PMA inclusion (Waterman et al. 1991) 
Mitochondrial 
  
        
ARMC10 exon 15 Jk PMA skipping (Martinez et al. 2012) 
FAM36A exon 3 Jk, CD4 PMA, PHA variable d (Martinez et al. 2012) 
TID1 exon 11 Th2 α-CD3 skipping (Syken et al. 2003) 
Oncogene 
TIMM50 exon 6 CD2 α-CD3/28 inclusion (Grigoryev et al. 2009) 
one 
Other           
LRRC28 exon 9 Jk PMA inclusion (Martinez et al. 2012) 
DDH1 exon 12 Jk PMA skipping (Martinez et al. 2012) 
FKBP1A exon 3 CD8 PHA inclusion (Ip et al. 2007) 
GALT exon 3 Jk PMA inclusion (Martinez et al. 2012) 
GZMB exon 1 CD2 α-CD3/28 intron 
removal 
(Grigoryev et al. 2009) 
HSPA14 exon 4 CD2 α-CD3/28 skipping (Grigoryev et al. 2009) 
NGLY1 exon 9 Jk, CD4 PMA, PHA skipping (Martinez et al. 2012) 
PIGQ exon 10 Jk PMA inclusion (Martinez et al. 2012) 
hTERT exon 7&8 T various inclusion  (Jalink et al. 2007) 
UGCGL1 exon 6 Jk PMA skipping (Martinez et al. 2012) 
 
Notes:      
a Exon numbers may vary depending on convention, numbers were either taken as reported in the 
references or deduced from ENSEMBL. Refer to the primary article for confirmation   
b Codes for cell types are as follows: (Jk) Jurkat, (T) Total primary T cells, (CD4) CD4+ primary T cells, 
(CD8) CD8+ primary T cells, (CD2) CD2+ primary T cells, (Thy) thymocytes,  (PBMC) peripheral blood 
mononuclear cells PBMCs, CD4+ primary Th2 cells (Th2)    
c Codes for stimuli are as follows: (PMA) phorbol myristate acetate, (PHA) phytohaemagglutinin, (a-CD3/28) 
anti-CD3 and CD28 antibodies, (ConA) conclavin A, (LPS) lipopolyssacharide, (HIV-1) human 
immunodeficiency virus 1, (P2I) PHA+IL2+Ionomycin. "Various" is used when more than 2 stimuli have been 
used.      
d Increased skipping (Jurkat)/Increased inclusion (CD4+ T cells)      
e Increased inclusion (Jurkat)/Increased skipping (CD4+ T cells)  
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Cell Surface Receptors 
CD3ζ - The T cell receptor-CD3 complex is responsible for recognition of antigens 
presented on MHC molecules (Smith-Garvin et al. 2009). In particular, it is the CD3ζ 
chain that couples antigen recognition with intracellular signaling pathways. Thus, the 
level of CD3ζ expression determines the ability of a T cell to be activated. Strikingly, AS 
of exon 8 of CD3ζ is a primary control point of CD3ζ expression (Moulton and Tsokos 
2010; Tsuzaka et al. 2003; Nambiar 2001). The 3’ UTR of the CD3ζ gene contains 
several AREs (AU-rich elements) that regulate mRNA stability, as well as a sequence 
that enhances translation (Chowdhury et al. 2006). Intriguingly, this 3’ UTR contains an 
intron that is preferentially removed in resting cells, whereas upon T cell activation the 
intron is retained (Moulton and Tsokos 2010). Removal of the intron leads to a shortened 
3ʹ′ UTR, which does not affect the coding region of the protein, but lacks two ARE motifs 
(ARE2 and ARE3) and a translation regulatory sequence (Chowdhury et al. 2006). Thus, 
the stability and translation of the intron-removed form of CD3ζ is reduced as compared 
to the intron-retained version (Chowdhury et al. 2006; 2005) while intron retention upon 
T cell activation allows for increased CD3ζ protein expression and increased T cell 
signaling (Tsuzaka et al. 2003).  
 Defects in CD3ζ intron retention have been linked to autoimmune disease 
(Nambiar 2001). T cells from patients with systemic lupus erythematosus (SLE) 
preferentially express the short (intron removed) form of CD3ζ (Nambiar 2001). 
Consistently, there is a decrease in CD3ζ protein associated with the TCR, and T cells 
are impaired in their signaling capacity and production of the proliferation cyokine 
interleukin-2 (IL-2) (Tsuzaka et al. 2003). Strikingly, not only is expression of CD3ζ 
inversely correlated with severity of SLE disease, but restoring CD3ζ in cells results in a 
 11 
rescue in IL-2 production (Nambiar et al. 2003). Thus correcting the splicing defect in 
CD3ζ provides a potential therapeutic opportunity for the treatment of SLE. 
CD45 - One of the best-documented examples of AS in response to T cell activation is 
that of the transmembrane tyrosine phosphatase CD45. In hematopoietic cells CD45 is 
involved in regulating proximal antigen receptor mediated signaling, as well as integrin- 
and cytokine- mediated signaling (Hermiston et al. 2003). Several CD45 isoforms that 
result from regulated pre-mRNA AS have been documented (Lynch and Weiss 2000). 
CD45 AS is differentially regulated in distinct cell types, developmental stages and in 
response to signaling such as antigen receptor-mediated signaling (Hermiston et al. 
2003). In peripheral T cells three variable exons 4, 5 and 6 that encode for CD45 
extracellular domains are preferentially skipped following antigen receptor-mediated 
signaling, resulting in increased expression of the smallest isoform (Hermiston et al. 
2003). The regions of the CD45 protein encoded by these variable exons are heavily 
glycosylated, and thus prevent CD45 homodimerization. Upon T cell activation, skipping 
of the CD45 variable exons leads to homodimerization at the cell surface, which leads to 
an inactive form of the phosphatase and decreased signaling through the TCR (Dornan 
et al. 2002; Xu and Weiss 2002). Thus AS of CD45 serves as a feedback mechanism for 
the maintenance of T cell homeostasis.  
 Interestingly, a single nucleotide polymorphism (SNP) in CD45 exon 4 (C77G) 
has been described that leads to aberrant inclusion of this exon (Lynch and Weiss 2001; 
Zilch et al. 1998). Consistent with the above model, in which loss of exon 4 skipping 
leads to loss of T cell attenuation, studies have shown a correlation between this 
polymorphism and susceptibility to multiple sclerosis (MS) and HIV infection (Hemmer et 
al. 2000; Tchilian et al. 2001) as would be anticipated from a hyperactive T cell 
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response. Furthermore, HIV infection itself induces exon skipping in CD45 and CD4+ T 
cells expressing the smallest isoform of CD45 (CD45 RO), which have been found to 
preferentially be infected by HIV-1 (Imbeault et al. 2012), suggesting a HIV-induced 
positive feedback loop in which CD45 AS promotes infection. 
 
Cytokines 
IL-7Rα - AS of cytokine receptors such as those in the interleukin family typically results 
in the generation of a soluble receptor that antagonizes or synergizes with the 
membrane bound receptor for ligand binding (Lynch 2004). One such example is the 
Interleukin 7 receptor alpha chain (IL-7Rα), in which differential skipping of exon 6 
excludes the transmembrane domain resulting in a soluble form of the receptor that is 
secreted in the plasma (Goodwin 1990). IL-7Rα is expressed almost solely in cells of 
lymphoid origin, and mice and humans deficient in the IL-7 signaling pathway develop 
lymphopenia (Mazzucchelli and Durum 2007). IL-7Rα is particularly critical in the 
survival of peripheral CD4+ and CD8+ and in the generation of a memory phenotype 
(Schluns et al. 2000; Kondrack et al. 2003).  
Consistent with a functional importance for IL-7Rα AS in CD4+ T cells, HIV-1 
infected individuals have lower concentrations of soluble IL-7Rα in their plasma (Rose et 
al. 2009). Moreover, similar to the example of CD45 mentioned above, there is a genetic 
association of a SNP located within exon 6 of IL-7Rα and multiple sclerosis (Gregory et 
al. 2007). Notably, the SNP located within exon 6 results in increased exon skipping and 
decreased expression of the membrane-bound IL-7Rα mRNA in PBMCs from MS 
patients harboring the SNP (Gregory et al. 2007). By contrast, the soluble IL-7Rα mRNA 
was overrepresented in SNP-containing patients relative to healthy individuals (Gregory 
et al. 2007; McKay et al. 2008).  Interestingly, AS appears to regulate IL-7 signaling at 
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multiple layers since a splice variant of IL-7 cytokine itself lacking exon 5 was shown to 
promote T cell survival and thymocyte maturation (Vudattu et al. 2009). 
 
Intracellular signaling 
Fyn - Fyn is a protein tyrosine kinase (PTK) of the Src family involved in intracellular 
signaling of various cellular processes including T cell development and activation 
(Palacios and Weiss 2004). The gene encoding Fyn generates two isoforms by 
differential inclusion of mutually exclusive exon 7s denoted 7a and 7b (MP and RM 
1989). The two exon 7s encode distinct versions of the SRC homology (SH2) domain 
and part of the kinase domain of Fyn; therefore AS of exon 7 is predicted to impact 
substrate recognition and phosphorylation (see below). The FynT isoform uses exon 7b 
and is the primary isoform expressed in T cells. FynT more efficiently mobilizes calcium 
and produces IL-2 during TCR signaling than the alternate isoform FynB, which is 
primarily expressed in the brain (Brignatz et al. 2009a; Davidson 1992; Davidson et al. 
1994). Infection with human T cell leukemia virus type 1 (HTLV-1) induces the 
expression the FynB isoform in T cells, which could serve to attenuate T cell effector 
functions (Weil et al. 1999). By contrast, T cell activation induces an even further bias 
toward inclusion of exon 7B, which may serve as a mechanism for sustaining and 
enhancing TCR signaling (Rothrock et al. 2003). 
Recently it was demonstrated that FynT more efficiently interacts with and 
phosphorylates the RNA-binding protein Sam68 than FynB (Brignatz et al. 2009b). The 
differential interaction between FynT and FynB with SAM68 was mapped to part of the 
distinct SH2 kinase linker encoded by exon 7 (Brignatz et al. 2009b). Swapping of the 
linker region of the FynT to the FynB isoform granted it the ability to strongly interact with 
and phosphorylate Sam68 (Brignatz et al. 2009b). Notably, Sam68 has previously been 
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shown to modulate AS of Bcl-x, in which it promotes use of the alternate upstream 5’ 
splice site in exon 2 to generate the pro-apoptotic Bcl-x(s) form (Paronetto et al. 2007). 
Phosphorylation of Sam68 by Fyn switches the activity of Sam68 to enhancing 
production of the Bcl-x(L) isoform (Paronetto et al. 2007). Consistent with the previous 
observations, expression of FynT but not FynB favors the expression of the Bcl-x(L) anti-
apoptotic isoform through phosphorylation of Sam68 (Brignatz et al. 2009b). These 
results suggest functional importance of the regulated Fyn AS in tuning the activity of an 
RNA-binding protein than in turn regulates AS of downstream target genes. 
 
Transcription Factors 
LEF1 - Lymphocyte enhancer factor 1 (LEF1) is an HMG-box transcription factor that is 
broadly expressed during embryonic development, and during adulthood is expressed in 
a tissue specific manner in certain lymphocyte subsets (van Genderen et al. 1994; Arce 
et al. 2006). LEF1 promotes expression of the T cell antigen receptor alpha chain (TCR-
alpha) through binding to the TCR-alpha enhancer (Travis et al. 1991; Waterman et al. 
1991). We have shown that inclusion of LEF1 exon 6 is increased during thymic 
development specifically during the double negative 3b (DN3b) to double positive (DP) 
transition (Mallory et al. 2011). Exon 6 encodes part of the context-dependent regulatory 
domain of the LEF1 protein, which allows its TCR-alpha enhancer activity. During the 
DN3a stage the mature TCR beta is expressed at the cell surface in complex with a 
surrogate TCR alpha chain called the pre-TCRα chain (Leiden and Thompson 1994). 
One of the critical consequences of pre-TCR signaling is the rearrangement and 
transcription of the TCR-alpha chain to give rise to the expression of the mature 
alpha/beta TCR complex by the DP stage. We found that increased TCR-alpha 
transcript levels correlate with increased LEF1 exon 6 inclusion during the DN3b to DP 
 15 
transition (Mallory et al. 2011). Similarly, activation of the Jurkat T cells with PMA results 
in increased LEF1 exon 6 inclusion with a corresponding increase in TCR-alpha 
expression. Importantly, the ability of LEF1 to enhance TCR-alpha transcription is a 
direct result of LEF1 exon 6 splicing, as blocking of the LEF1 exon 6 splice site results in 
a substantial decrease in TCR alpha mRNA (Mallory et al. 2011). These results suggest 
that during pre-TCR signaling regulated splicing of the LEF1 transcription factor 
contributes to the control of TCR-alpha transcription to produce functional TCR 
complexes at the cell surface. 
 
RNA Processing Factors 
CELF2 – Many RNA binding proteins regulate their own expression by an autofeedback 
loop which maintains protein expression in a particular range. The splicing factor CELF2 
accomplishes this by binding to one of its own introns to induce skipping of exon 6. This 
AS event results in a premature stop codon and loss of subsequent translation of full 
length protein when the levels of CELF2 are sufficient (Dembowski and Grabowski 
2009). Interestingly, activation of peripheral CD4+ T cells leads to an increase in CELF2 
exon 6 inclusion (Martinez et al. 2012; Ip et al. 2007; Mallory et al. 2011). Although this 
change in CELF2 splicing has not directly been linked to functional changes in T cells, 
CELF2 is known to regulate the functionally-relevant splicing of LEF1 (see above and 
below) as well as many other signal-responsive genes (Mallory et al. 2015). Therefore, 
one can readily imagine a cascade of AS events initiating with autoregulatory splicing of 
CELF2. Similarly, Sam68 and TIA-1 are RNA binding proteins that have been implicated 
in regulated AS in T cells (see below) and have themselves been validated to undergo 
changes in isoform expression following antigen stimulation of T cells (Ip et al. 2007; 
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Izquierdo and Valcárcel 2007). It remains to be shown, however, whether these proteins 
truly trigger splicing cascades following T cell activation. 
 
Pathways and RNA-binding proteins that regulate splicing 
Importance of understanding splicing mechanism 
Surprisingly, despite the interest in AS in immune responses, we only have mechanistic 
insights as to how a handful of the AS events listed in Table 1.2 are regulated (see 
below). This means that we have very little understanding of what signaling pathways, 
trans acting splicing factors and sequences are mediating AS programs in immune 
responses. Understanding the mechanisms by which splicing is regulated in normal 
immune responses is critical to understanding and treating diseases of the immune 
system. As implied above, emerging research is providing an ever growing list of mis-
regulated splicing events that correlate with autoimmune diseases and other immune 
defects (Cooper et al. 2009). Understanding how SNPs cause splicing changes, 
predicting the effects of newly identified SNPs and ultimately designing therapies to 
correct splicing defects, all require a detailed knowledge of the mechanisms that control 
particular splicing decisions. 
A second motivation for understanding the mechanisms that control splicing in 
immune cells is so that we can better predict co-regulation and functional consequences 
of AS. AS is often thought of as a fine-tuning mechanism because it allows for tweaking 
of specific functions of a protein while maintaining others. In some instances such 
tweaking is sufficient to exert a major functional change in the cell (Licatalosi and Darnell 
2010; Nilsen and Graveley 2010). More often, however, concerted changes in the 
splicing of a family of related genes is expected to be of greater functional impact than 
that generated by individual AS events (Licatalosi and Darnell 2010; Nilsen and 
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Graveley 2010). For this reason, a major step in understanding the role of splicing 
regulation in modulating immune responses is the identification of signaling pathways, 
trans-acting factors and mechanistic commonalities that orchestrate networks of 
regulated splicing. By analogy, knowledge of the binding sites and activity of 
transcription factors has allowed researchers to predict what genes are expressed 
downstream of an event such as NF-kB activation (Hoffmann and Baltimore 2006). 
Similarly, the ultimate goal of splicing research is to gain sufficient knowledge of what 
regulatory factors are activated during an immune response to be able to predict from 
Figure 1.2 General mechanism of splicing and its regulation. (A) Spliceosome assembly. The 5’ end of 
introns are defined by the 5’ splice site (GUAAGU) and the 3’ end of introns are defined by the branch point 
sequence (BPS), polypirimidine tract (PPT) and the 3’ splice site AG dinucleotides. The U1, 2, 4, 5 and 6 
represent the snRNPs which assemble with substrate and each other as shown. The NTC is an additional 
snRNA-free spliceosomal subunit. For more details see ref 58. (B) Regulation of alternative splicing. 
Enhancer auxiliary elements are denoted in green for exonic (ESE) or intronic (ISE) splicing enhancers. 
Silencer auxiliary elements are denoted in red for exonic (ESS) or intronic (ISS) splicing silencers. The 
activities of these auxiliary elements are often mediated through binding of SR and hnRNPs, two common 
families of proteins described in the text, among other RNA binding proteins. 
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the genetic sequence what genes and gene families undergo antigen-induced changes 
in splicing patterns. 
 
Basic concepts in the regulation of alternative splicing 
At the most basic level the decisions of what sequences of a gene are included in the 
final mRNA rely on the ability of the spliceosome to recognize and process the splice 
sites located at the intron-exon boundaries of a pre-mRNA. The spliceosome is the 
enzymatic complex that catalyzes intron removal and exon joining. Instead of being a 
preformed enzyme, the spliceosome is built de novo on pre-mRNA transcripts through 
sequential interactions between the substrate and subunits of the spliceosome (Figure 
1.2A). The major subunits of the spliceosome are the 5 so-called snRNPs, which each 
contain a single non-coding RNA (snRNA) and multiple proteins (Wahl et al. 2009). 
Exons are targeted to be spliced together by binding of the snRNPs to the splice sites, a 
process which is driven primarily through basepairing interactions between the snRNA 
component of the snRNPs and the splice site sequences (Figure 1.2A; (Wahl et al. 
2009)). Importantly, however, most mammalian splice sites only weakly basepair with 
the snRNAs. Therefore, auxiliary sequence elements play a crucial role in regulating 
splice site selection by modulating snRNP-substrate interactions (House and Lynch 
2006; Chen and Manley 2009).  
Cis-elements that control splicing include sequences within exons such as exonic 
splicing enhancers (ESEs) and exonic splicing silencers (ESSs) as well as sequences 
within introns such as intronic splicing enhancers (ISEs) and intronic splicing silencers 
(ISSs) (Figure 1.2B). These elements either promote (enhancers) or suppress 
(silencers) proper assembly of the snRNP on the substrate, typically by recruiting 
 19 
regulatory proteins which then interact with spliceosomal components (House and Lynch 
2006; Chen and Manley 2009). Two protein families that often function as splicing 
regulators are the serine/arginine rich (SR) proteins and heterogeneous nuclear 
ribonucleoproteins (hnRNPs) (Long and Caceres 2009; Martinez-Contreras et al. 2007). 
When bound within exons, SR proteins tend to enhance splice site usage, whereas 
hnRNPs typically induce exon skipping (Figure 1.2B); although there are exceptions to 
this generalization (House and Lynch 2006; Chen and Manley 2009; Motta-Mena et al. 
2010). Moreover, both families of proteins, as well as other RNA binding proteins, can 
have both enhancing and silencing activity when bound to an intron. The location of 
binding relative to the splice sites, the presence of neighboring regulatory proteins, and 
the relative strength of the splice site-snRNA interactions all influence the ultimate 
consequence of a particular regulatory protein on the pattern of splicing.  Finally, most 
transcripts are bound by multiple regulatory proteins such that the final decision of which 
alternative splice patterns will be used and how many distinct isoforms will be expressed 
from a single gene and pre-mRNA relies on a balance of competing regulatory factors 
(Licatalosi and Darnell 2010; Nilsen and Graveley 2010; House and Lynch 2006; Chen 
and Manley 2009).  
Another important aspect of splicing regulation, particularly in thinking about 
immune responses, is how signaling pathways can influence splicing factor activity. 
There are many ways by which cell signaling pathways can modulate the function of 
splicing regulatory factors (reviewed in (Heyd and Lynch 2011a)). First of all, T cell 
activation induces widespread transcriptional changes that can lead to differences in 
splicing factor protein expression (Martinez et al. 2012; Grigoryev et al. 2009; Ip et al. 
2007). Similarly, AS of RNA-binding and spliceosomal proteins, such as has been 
identified in studies listed in Tables 1.1 and 1.2 (see CELF2 above), is likely to influence 
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the activity of these factors and thus influence AS of downstream targets. 
Phosphorylation of splicing regulatory proteins can alter their activity, localization and 
ability to interact with other proteins. Phosphoproteomic analyses of TCR signaling have 
found that proteins involved in all aspects of T cell signaling become phosphorylated, 
including splicing factors and components of the spliceosome (Mayya et al. 2009). 
Notably, TCR-induced phosphorylations within splicing proteins was preferentially 
observed in domains that are predicted to mediate protein-protein and/or protein-RNA 
interactions (Mayya et al. 2009). Other mechanisms of signal-induced changes in the 
splicing machinery include different modes of differential protein-protein interactions, 
protein-RNA interactions, protein stability and localization (Heyd and Lynch 2011a).  
Strikingly, despite the abundance of AS in immune responses, relatively little is 
know regarding the factors, mechanisms and signaling pathways by which such changes 
in gene expression are controlled. The identity of signaling molecules and how they 
regulate the activity of splicing factors and RNA binding proteins to regulate AS have 
been elucidated in only a few of the validated genes listed in Table 1.2. Moreover, even 
in the cases where regulators have been characterized on individual genes, the breadth 
of the AS program mediated by such factors have not been well defined. Over the past 
decade the primary focus of our laboratory has been to begin to identify the proteins, 
pathways and mechanisms by which AS is regulated in human T cells. Below I describe 
the distinct proteins and mechanistic paradigms that have thus far been described by our 
lab and others to regulate splicing during T cell development and function (Figure 1.3). I 
emphasize what is known, as well as what remain critical future areas of research as we 
seek to gain a complete understanding of how splicing shapes immune function in 
normal and disease states.   
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hnRNP L 
From a mechanistic perspective most of what we know about regulated splicing in T 
cells comes from decades of detailed analysis of CD45, the first gene well-documented 
to undergo splicing changes during T cell response to antigen (see above). We initially 
demonstrated that regulation of the three CD45 variable exons is mediated by a 
sequence motif, contained within each of the exons, which we designated the activation-
responsive sequence [ARS= (A/CYYGCA)] (Rothrock et al. 2003; Tong et al. 2005). In 
exons 4 and 6 the ARS motif lies within a 60 nt exonic splicing silencer (ESS1) that is 
necessary and sufficient to confer repression of exons 4 and 6. Mutation of key residues 
within the ARS has demonstrated that this sequence is critical for the partial repression 
of exons 4 and 6 that is observed in resting T cells; as well as the activation-induced 
Figure 1.3. Splicing factors known to regulate AS in immune responses. Domain schematics for each 
factor are displayed. The abbreviations are as follows: RRM – RNA recognition motif, RRM – pseudo RRM, 
G – glycine-rich region, P – proline-rich region, RGG – arginine/glycine/glycine repeat region, P, Q – 
proline/glutamine rich, RS – arginine/serine-rich, KH – K homology domain. Binding preferences for each 
factor are specified for hnRNP L, hnRNP LL, PSF, CELF2, TIA-1, SRSF1, Sam68. 
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hyper-repression of these exons and exon 5 upon antigen stimulation (Rothrock et al. 
2003; Tong et al. 2005). Furthermore, introduction of the CD45 exon 4 ESS1 element 
into a heterologous unregulated exon imparts basal and TCR signaling-mediated exon 
repression (Rothrock et al. 2003).  
 Definition of the ARS has allowed for the identification of proteins that regulate 
CD45 splicing through this element. Arguably, the most essential factor in the regulation 
of CD45 AS is hnRNP L. Our lab first identified hnRNP L as the major ARS-binding 
activity in biochemical studies (Rothrock et al. 2005), and subsequently have confirmed 
hnRNP L to be the primary mediator of basal repression of the CD45 variable exons 
both in vitro and in cells (Figure 1.4) (Motta-Mena et al. 2010; Tong et al. 2005; Rothrock 
et al. 2005; Melton et al. 2007; Topp et al. 2008). More recently, tissue specific knock-
out studies in mice revealed that thymocytes depleted of hnRNP L exhibited aberrant 
inclusion of the CD45 exons, confirming the in vivo relevance of hnRNP L for CD45 exon 
repression (Gaudreau et al. 2012).  
  HnRNP L is a highly abundant member of the hnRNP family of splicing factors 
and contains four RRMs (Figure 1.3). It has both splicing silencer and enhancer 
activities, depending on the context in which it binds, and functions in introns or exons to 
regulate inclusion of cassette exons, intron retention and poly(A) site choice (Motta-
Mena et al. 2010; Rothrock et al. 2005; Hui et al. 2005; Hung et al. 2008).  HnRNP L 
binds preferentially to CA-rich sequences, although it can associate with CA dipeptides 
located in a wide range of contexts (Hui et al. 2005; 2003). Interestingly, the ARS itself is 
comprised of only a few, widely scattered, CA elements. Correspondingly, hnRNP L has 
only a moderate affinity for the ARS element. This use of moderate affinity is likely 
essential for appropriate regulation of CD45 as it allows some exon inclusion in resting T 
 23 
cells. Finally, the expression of hnRNP L is unchanged during T cell responses, 
consistent with it largely setting a constant basal level of CD45 exon repression in both 
resting and activated T cells. However, hnRNP L may become hyperphosphorylated in 
response to antigen which may alter some of its activities (Melton et al. 2007; Liu et al. 
2012).   
 As discussed below, there is increasing evidence of wide-spread activity of 
hnRNP L in regulating T cell splicing. The hnRNP L T cell specific knockout mice 
revealed that hnRNP L is critical for thymocyte development. In the absence of hnRNP 
L, the DN4 to DP transition is blocked causing a decrease in thymic cellularity 
(Gaudreau et al. 2012). HnRNP L was also implicated in migration of single postive 
thymocytes to the periphery. The hnRNP L T cell specific knockout mice revealed that 
hnRNP L mediates regulation of widespread AS as an RNA-seq comparison between 
hnRNP L deficient and wildtype thymocytes identified many potential hnRNP L regulated 
exons (Gaudreau et al. 2012). Our lab has recently combined CLIP-seq analysis of 
hnRNP L binding with RNA-seq of hnRNP L knockdown in Jurkat Tcells and identified 
hundreds of hnRNP-regulated cassette exons (Shankarling et al. 2014) and (Cole et al 
2015 RNA) in press. Binding maps revealed that hnRNP L can repress when bound 
upstream, downstream or within a cassette exon. Furthermore, the lab showed that 
hnRNP L enhanced exons do not present enrichment for hnRNP L binding suggesting 
this function is through an indirect mechanism ((Shankarling et al. 2014) (Cole et al 2015 
RNA)). The hnRNP L enhanced exons are flanked by short GC introns with decreased 
nucleosome occupancy, proposing a role for hnRNP L in epigenetic regulation (Cole et 
al 2015 RNA). 
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hnRNP LL 
Upon activation of T cells, hnRNP L is joined in binding the CD45 ARS by two additional 
proteins (Figure 1.4) (Melton et al. 2007; Topp et al. 2008). One of these is a paralogue 
of hnRNP L called hnRNP L-like (hnRNP LL), which is preferentially expressed in 
activated and memory T cells (Figure 1.3).  HnRNP LL was identified as a regulator of 
CD45 splicing simultaneously by our group and two others (Topp et al. 2008; Wu et al. 
2008; Oberdoerffer et al. 2008). Two of us discovered hnRNP LL through a cell-based 
screening approach (Topp et al. 2008; Oberdoerffer et al. 2008), while the third took 
advantage of mouse genetics (Wu et al. 2008).  
 The screen through which our lab identified hnRNP LL consisted of analyzing 
Jurkat T cell clones that exhibited an altered “activation-like” phenotype under resting 
conditions (Topp et al. 2008). We utilized a novel reporter construct in which CD45 exon 
4 was inserted between exons encoding the synthetic transcription activator Gal4-VP16, 
such that expression of the active form of Gal4-VP16 was dependent on skipping of 
exon 4. The expression of Gal4-VP16 was, in turn, monitored by its ability to activate 
transcription of a reporter construct encoding GFP allowing for a read-out that was highly 
sensitive to relatively small changes in CD45 exon 4 inclusion (Levinson et al. 2006). 
Cells containing this dual-reporter scheme were then infected with a retroviral-encoded 
cDNA library, and resting cells exhibiting increased levels of GFP (indicative of 
increased exon 4 skipping) were isolated. Strikingly, the one commonality among 
several of the resulting GFP-high cell clones was aberrantly high expression of hnRNP 
LL (Topp et al. 2008). We confirmed the activity of hnRNP LL in the Jurkat T cell line by 
demonstrating that direct overexpression of hnRNP LL resulted in increased exon 4 
repression, while knockdown abolishes activation-induced repression (Topp et al. 2008). 
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We also demonstrated that hnRNP LL mRNA and protein expression are normally 
upregulated in response to T cell activation, as is direct binding of hnRNP LL to the 
CD45 exon 4 ESS1 (Topp et al. 2008). Similar results were obtained from the work of 
Oberdoerffer et al who isolated hnRNP LL in an shRNA screen for factors required for 
repression of exon 4 in the endogenous CD45 gene in the JSL1 cell line (Oberdoerffer et 
al. 2008).  
The in vivo relevance of the studies regarding hnRNP LL in human T cell lines 
were supported by subsequent analysis of primary human cells (Oberdoerffer et al. 
2008) and by a ENU (N-ethyl-N-nitrosourea) mutagenesis study in mice (Wu et al. 
2008). In the mouse study, a mutant mouse line was identified that exhibited fewer 
CD4+ Th T cells. T cells from these mice, named “Thunder” mice for “Th under normal”, 
were found to have altered expression of CD45 isoforms (Wu et al. 2008). Specifically, 
memory T cells in the Thunder mice, which normally express the smallest isoform of 
CD45, aberrantly express isoforms that include the variable exons (Wu et al. 2008). This 
altered expression of CD45 was mapped to an ENU-induced missense mutation in 
hnRNP LL (V136A), which abolished hnRNP LL binding to the ARS motif in CD45 by 
destabilizing one of the RNA binding domains (RRMs) of the protein (Wu et al. 2008).  
 Despite the similarity and overlapping functions between hnRNP L and hnRNP 
LL, these proteins have distinct binding requirements (Topp et al. 2008). Although both 
CD45 exons 4 and 5 contain the ARS motif and are repressed by hnRNP L, hnRNP LL 
does not bind to exon 5 or have a functional effect on its activation-induced repression 
(Motta-Mena et al. 2010; Oberdoerffer et al. 2008).  By contrast, the affinity of hnRNP LL 
for the ARS element in exon 4 is actually higher than that of hnRNP L. However in naïve 
T cells hnRNP LL is expressed only at ~ 1/100th the level of hnRNP L, thus there is no 
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significant binding or repression of exon 4 by hnRNP LL in T cells until the expression of 
this protein is induced by antigen stimulation (Topp et al. 2008). Notably, induction of 
binding of hnRNP LL to the ARS in CD45 exon 4 results in a significant increase in exon 
skipping over that observed from the binding of hnRNP L alone. Why association of 
hnRNP LL together with hnRNP L achieves more efficient repression of exon 4 than 
hnRNP L alone remains an open question, and will require further mechanistic studies. 
However, it is clear that both proteins can bind simultaneously and independently to the 
ARS motif, and both proteins are capable of exon repression on their own (Topp et al. 
2008). 
 A second open question with regards to hnRNP LL and T cell function is how 
broadly this protein regulates splicing, and how commonly hnRNP L and hnRNP LL work 
in conjunction with one another. Although some targets of hnRNP LL splicing have been 
suggested by exon array studies in T cells (Wu et al. 2008; Oberdoerffer et al. 2008) 
none of these splicing events have been validated so no conclusions can be made 
regarding the scope of hnRNP LL function. Studies from the Goodnow lab have 
demonstrated that the regulation of CD45 by hnRNP LL is not sufficient to account for all 
the phenotypes of the hnRNP LL mutant mouse, implying the existence of additional 
physiologic targets of hnRNP LL activity (Wu et al. 2008). However, it is not known what 
such targets may be or even if all of the activity of hnRNP LL is at the level of splicing 
regulation rather than other steps of RNA processing that can be affected by hnRNP 
proteins such as mRNA stability, translation, 3’ UTR processing and even transcription.   
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PSF 
The other factor that cooperates with hnRNP L in the signal-responsive repression of 
CD45 is PTB-associated splicing factor (PSF) (Melton et al. 2007; Heyd and Lynch 
2010). PSF is not considered one of the canonical hnRNP proteins, but like the hnRNPs 
contains 2 RNA binding motifs as well as additional domains of low-complexity and 
unknown function (Figure 1.3). PSF was initially identified as an essential splicing factor, 
and has subsequently been implicated in regulating many aspects of mRNA processing 
and nuclear processes (Shav-Tal and Zipori 2002). The first direct connection of PSF to 
AS was our identification of PSF as one of the factors necessary for activation-induced 
repression of all three of the CD45 variable exons (Melton et al. 2007). We initially 
implicated PSF in the regulation of CD45 through biochemical purification of proteins 
bound to the ESS1 element in CD45 exon 4. Similar to hnRNP LL, PSF associates with 
the ARS element specifically in activated T cells (Figure 4) (Melton et al. 2007). This 
binding of PSF to the ESS1 is independent of hnRNP L or hnRNP LL, and involves 
sequences outside of the core part of the ARS motif (Melton et al. 2007; Topp et al. 
2008). However, PSF is required for maximal activation-induced repression of the CD45 
variable exons as indicated by the fact that mutation of the PSF-recognition element 
increases CD45 exon inclusion in activated cells without affecting binding of hnRNP L or 
LL (Motta-Mena et al. 2010; Melton et al. 2007; Topp et al. 2008). 
 Strikingly, unlike hnRNP LL whose transcription and protein expression are 
increased following activation, PSF mRNA and protein expression remain constant 
during an immune response (Melton et al. 2007; Topp et al. 2008; Heyd and Lynch 
2010), This finding suggested that the preferential binding of PSF to the CD45 pre-
mRNA in activated T cells is controlled at the post-translational level. Interestingly, PSF 
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is a direct substrate of glycogen synthase kinase 3 (GSK3) in naïve T cells, in which 
GSK3 is active and phosphorylates PSF at threonine 687 (Heyd and Lynch 2010). 
Phosphorylated PSF interacts with a protein called TRAP150, which prevents PSF from 
binding the CD45 pre-mRNA. Upon engagement of the TCR, GSK3 is inactivated 
leading to reduced PSF phosphorylation. The loss of T687 phosphorylation on PSF 
releases it from TRAP150, allowing PSF to bind CD45 splicing regulatory elements and 
repress exon inclusion (Heyd and Lynch 2010). Conceptually, this is one of the first 
direct links between a signaling molecule and a splicing factor in T cells. Moreover, the 
accumulation of unphosphorylated PSF following T cell activation requires de novo 
protein synthesis, which explains the observed kinetics of activation-induced CD45 exon 
repression.  
 Importantly, the mechanism by which TRAP150 regulates PSF is not by a simple 
phospho-site recognition, since deletion of part of the C-terminus of PSF which includes 
T687, does not prevent its interaction with TRAP150 (Heyd and Lynch 2010). This 
observation supports a model in which phosphorylation of PSF drives a conformational 
change that regulates the interaction between PSF and TRAP150. Our lab recently 
showed that TRAP150 binds a region of the PSF RRMs and directly blocks PSF from 
binding the CD45 pre-mRNA which is contacted by RRM2 (Yarosh et al. 2015). 
Futhermore, the lab showed that the PSF/TRAP150 complex is a means of regulation for 
a broader set of alternatively spliced pre-mRNAs.  Specifically, they found that PSF and 
TRAP150 co-regulate a set of ~40 T cell activation induced splicing events (Yarosh et al. 
2015). PSF may also have additional activities in T cells as a T cell specific knockdown 
of PSF in mice results in thymic apoptosis (Heyd and Lynch 2011b). While the extent of 
knock-down in these studies was not sufficient to induce changes in AS, we did observe 
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altered stability of several mRNAs including those encoding histones (Heyd and Lynch 
2011b).  
 
CELF2 
Another hnRNP-related protein involved in regulated splicing in immune cells is CELF2 
(Mallory et al. 2011). CELF2 is a member of the CELF family of RNA processing factors, 
which have been extensively documented to regulate splicing during heart and skeletal 
muscle development (Dasgupta and Ladd 2012). The CELF proteins all contain multiple 
RRMs and typically bind UG rich sequences to promote or repress exon recognition 
(Figure 1.3) (Faustino and Cooper 2005). We have recently determined CELF2 to 
function as a signal-responsive splicing regulator during T cell development, as well as 
in response to activation of mature T cells (Mallory et al. 2011).  
 Biochemical assays initially identified CELF2 as binding to two UG-rich ISEs that 
control inclusion of LEF1 variable exon 6 (see above; (Mallory et al. 2011)). The 
concentration of CELF2 protein, and its corresponding binding to the LEF1 ISEs, 
increases during the transition from DN and DP cells in thymic development, consistent 
with increased inclusion of LEF1 exon 6 following pre-TCR signaling. A similar change in 
CELF2 expression, function and LEF1 splicing is also observed upon activation of JSL1 
T cells. Knock-down of CELF2 in the JSL1 cells results in loss of LEF1 exon 6 inclusion 
with a concomitant decrease in TCR-alpha mRNA, consistent with the functional 
consequence of regulated LEF1 splicing (see above) and confirming the role of CELF2 
in the regulation of LEF1 (Mallory et al. 2011).  
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 Furthermore, our lab has recently shown that the increase in CELF2 protein in 
response to T cell signaling is driven by an increase in transcription and an increase in 
the stability of the CELF2 mRNA (Mallory et al. 2015). The initial increase in CELF2 
transcription is dependent on NF-kB while the increase in stablilty is mediated by an 
unknown mechanism. Importantly, they uncovered that in addition to the alternative 
splicing of LEF1 many additional splicing events are dependent on the increase in 
CELF2 protein following T cell activation (Mallory et al. 2015). These studies 
demonstrating CELF2-dependent regulation of a group of alternative splicing events 
emphasize the biological importance of CELF2 as a lymphocyte splicing factor in 
addition to its activities as a brain and muscle specific regulator.  Interestingly the related 
factor CELF1 has been shown to regulate cytoplasmic mRNA stability during immune 
responses (Beisang et al. 2012). Although CELF1 has no activity in LEF1 splicing, it is 
expressed in the nucleus of T cells and may regulate additional splicing events.  
 
TIA-1 
T cell-restricted intracellular antigen 1 (TIA-1) was first identified by monoclonal 
antibodies that reacted with intracellular antigens in T cells, but not in B-cells (Anderson 
et al. 1990). Cloning of TIA-1 revealed it to be an RNA binding protein with three RNA-
recognition motifs (Figure 1.3). Interestingly, this protein is homologous to a splicing 
factor in the yeast S. cerivisae, Nam8, which is known to bind uridine-rich sequences in 
introns (Puig et al. 1999; Förch et al. 2000; Gottschalk et al. 1998; Förch et al. 2002). 
Further studies confirmed that TIA-1 functions as a splicing factor, as well as exhibiting 
other RNA-processing functions such as silencing translation of TNF-alpha (Piecyk et al. 
2000; Del Gatto-Konczak et al. 2000).  
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TIA-1 is the primary splicing factor responsible for regulation of FAS alternative 
splicing. As shown in Table 2, Fas exon 6, which encodes the transmembrane domain of 
the protein, is inducibly included upon T cell activation (Liu et al. 1995). Skipping of Fas 
exon 6 produces a soluble version of the receptor, which can inhibit Fas signaling and 
therefore control apoptosis (Cheng et al. 1994; Cascino et al. 1995). Knockdown of TIA-
1, or the realated TIAR (TIA-1 related protein), results in increased exon 6 skipping 
(Izquierdo et al. 2005). A uridine-rich sequence located downstream of the exon 6 5’ 
splice site was identified as an ISE required for the ability of TIA-1 to enhance exon 6 
inclusion (Izquierdo et al. 2005). 
In an interesting case of positive feedback regulation, TIA-1 is phosphorylated by 
Fas-activated serine/threonine kinase (FASTK) which, as its name implies, is a kinase 
that becomes activated in Jurkat T cells in response to Fas engagement with ligand 
(Tian et al. 1995). Strikingly, knockdown in Jurkat cells or overexpression in HeLa cells 
of FASTK phenocopies modulation of TIA-1 expression with regards to Fas exon 6 
inclusion (Izquierdo and Valcárcel 2007). In addition, FASTK has little effect on Fas 
splicing in cells in which TIA-1 and TIAR were depleted or the uridine-rich ISE was 
mutated (Izquierdo and Valcárcel 2007). Together, these results suggest that 
phosphorylation of TIA-1 by FASTK promotes the ability of TIA-1 to enhance exon 6 
inclusion. Moreover, these studies propose that Fas signaling can use AS to enhance 
itself in a feedforward manner in which initial Fas signaling activates FASTK and TIA-1 
to increase expression of membrane-bound receptors. Whether, this pathway is involved 
in the T cell activation-induced exon 6 inclusion remains unanswered. Furthermore it is 
unknown whether the many other targets of TIA-1 function that have been identified are 
likewise alternatively spliced in response to Fas or TCR signaling (Dember et al. 1996; 
Aznarez et al. 2008; Wang et al. 2010). 
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SRSF1 
Alternative Splicing Factor/Splicing Factor 2 (ASF/SF2 now called SRSF1) is a member 
of the ubiquitous SR family of splicing factors that promote constitutive and alternative 
splicing (Long and Caceres 2009). Like all SR proteins, SRSF1 contains N-terminal 
RRM type RNA binding motifs and a C-terminal domain rich in Arg-Ser dipeptides 
(Figure 1.3) (Long and Caceres 2009). The C-terminal Arg-Ser (RS) domain provides 
the SR protein family their name and is thought to function primarily as a protein-protein 
interaction domain that promotes recruitment of the snRNPs and enhancement of exon 
inclusion (Long and Caceres 2009). The splicing of most exons is controlled in at least 
some manner by SR proteins. Therefore it is not surprising that, where investigated, SR 
proteins have activities in controlling splicing in immune cells.  
One example of SR protein function in immune-related AS comes, not 
surprisingly, from studies of CD45. Specifically, we implicated SRSF1 in regulation of 
CD45 exon 5. Like the other CD45 variable exons, CD45 exon 5 contains the two copies 
of the ARS motif, however, they are separated by a strong ESE (Tong et al. 2005). 
Although hnRNP L and PSF mediate exon 5 repression through binding to the ARS, the 
ESE is also important for regulation and specifically for promoting the relatively high 
level of inclusion of this exon (Motta-Mena et al. 2010; Tong et al. 2005). We identified 
SRSF1 as a protein that binds to the exon 5 ESE and promotes exon inclusion in an 
ESE-dependent manner (Motta-Mena et al. 2010). Furthermore, we demonstrated that 
hnRNP L counters the SRSF1 enhancer activity, by directly competing for binding exon 
5. Therefore, although it is now apparent that the ESE also functions at the level of 
transcription (see CTCF below), we conclude that the balance of hnRNP L and SRSF1 
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contributes to the degree of CD45 exon 5 inclusion, consistent with the notion that the 
balance of hnRNP and SR activities plays a fundamental role in many splicing decisions. 
We also note that several other SR proteins, including SRSF2 (SC35), SRSF3 (SRp20) 
and SRSF7 (9G8) have also been correlated to changes in CD45 AS (Dam et al. 2000; 
Wang et al. 2001), although the mechanism of activity and even whether these are direct 
or indirect effects has not been determined. 
SRSF1 also mediates the activation-induced CD3ζ AS highlighted in Table 2 
(Moulton and Tsokos 2010). As described above, following T cell activation there is a 
shift toward the CD3ζ isoform that retains an intron within the 3’ UTR, thus promoting 
protein expression. SRSF1 regulates CD3ζ AS by binding to the ARE2 element within 
the 3’ UTR and promoting intron retention at the 3’ UTR (Moulton and Tsokos 2010). 
Consistent with the intron-retained version of the CD3ζ message being the functional 
version of this mRNA, depletion of SRSF1 resulted in decreased CD3ζ protein 
expression while overexpression resulted in increased intron retention and CD3ζ protein 
production (Moulton and Tsokos 2010). Furthermore, during T cell activation, increased 
levels of SRSF1 correlate with an increase in the intron-retained CD3ζ 3’UTR. SRSF1 
protein levels has been further linked to CD3ζ protein levels in T cells from SLE patients 
(Moulton and Tsokos 2010). Interestingly, several SR proteins in addition to SRSF1 
show altered expression (both increased and decreased) in response to antigen 
stimulation of T cells. Given the abundant functional role of SR proteins, such changes in 
SR protein expression are likely to affect widespread changes in splicing efficiency and 
AS patterns (Screaton et al. 1995). 
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SAM68 
Sam68 is a member of the Signal-Transduction and RNA (STAR) family of proteins that 
contain a KH type RNA-binding domain as well as binding sites for signaling proteins 
(Figure 1.3) (Lukong and Richard 2003). STAR family proteins typically have activities in 
mRNA stability and translation; however, Sam68 has been shown to regulate several AS 
events including the T cell activation-induced regulation of CD44 splicing (Matter et al. 
2002). CD44 is a cell surface adhesion molecule involved in T cell homing, and some of 
its splice variants have been correlated with tumor malignancy (reviewed in (Lynch 
2004)). The CD44 gene contains 10 variable exons that are differentially included in T 
cells in various combinations. Whereas naïve T cells express the shortest CD44 isoform 
that lacks all of the variable exons, antigen stimulation induces the inclusion of various 
combinations of the additional 10 variable exons (Arch et al. 1992; König et al. 1998). AS 
of exon v5 is the most investigated of the CD44 variable exons. Deletion experiments of 
CD44 exon v5 identified both an ESS and an ESE that regulate its inclusion (König et al. 
1998). Activation-induced inclusion of CD44 exon v5 in T cells was also shown to be 
dependent on the Ras-Raf-MEK-ERK signaling pathway (Weg-Remers et al. 2001). The 
Ras signaling cascade leads to interactions between Sam68 and the SR-related protein 
SRm160 to form a complex which binds the ESE and promotes exon inclusion (Matter et 
al. 2002; Cheng and Sharp 2006). Furthermore, Sam68 can also interact with the Brm 
subunit of SWI/SNF a complex involved in chromatin-remodeling (Batsche et al. 2006). 
Upon activation by the ERK pathway Sam68 binds to CD44 exon v5 and then interacts 
with or signals to Brm, to promote Pol II stalling (Matter et al. 2002; Batsche et al. 2006). 
As part of a growing recognition of the mechanistic interplay between transcription and 
splicing, it is known that slowing Pol II elongation rates can promote inclusion of variable 
exons, by providing the spliceosome time to recognize and assemble on weak splice 
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sites (Kornblihtt 2006). Consistent with this model, recruitment of Brm to CD44 through 
Sam68 promotes inclusion of the variable v5 exon of this gene through transcriptional 
pausing (Batsche et al. 2006). Thus, Sam68 regulation of CD44 is an example of how an 
RNA-binding protein can influence AS by modulating transcription rates. A recent report 
shed light on the link between Erk signaling and the change in activity of SAM68.  They 
showed that when Erk is activated it phosphorylates a nuclear matrix associated protein 
SMAR1 that mediates a complex between HDAC6 and Sam68 (Nakka et al. 2015). This 
phosphorylation of SMAR1 dissociates the complex and prevents HDAC6 from 
deacetylating Sam68 and allows acetylated Sam68 to promote CD44 variant exon 
inclusion (Nakka et al. 2015). 
 
CTCF 
Another excellent example of AS mediated by regulation of transcription comes from 
recent studies on the DNA-binding protein CCCTC-binding factor (CTCF) (Shukla et al. 
2011). CTCF binds DNA and has classically been thought of as an insulator that binds in 
intergenic chromosomal regions (Singh et al. 2012). However, recently, CTCF was 
shown to bind extensively within genes, where it correlates with sites of Pol II pausing. 
Remarkably, CTCF binding sites are also enriched in or near alternative exons, raising 
the possibility that binding of CTCF regulates elongation of Pol II to favor exon inclusion. 
Proof of this model was provided for CD45 exon 5 (Shukla et al. 2011). Specifically, it 
was shown that B-cell lines with high expression of CD45 exon 5 (CD45RB high) 
exhibited greater CTCF binding to exon 5 than cells that were CD45RB low. Surprisingly, 
the binding site for CTCF was shown to encompass the ESE previously identified as 
essential to high inclusion of exon 5 (Figure 1.4) (Motta-Mena et al. 2010; Tong et al. 
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2005). In cells and in vitro CTCF binding to exon 5 promoted Pol II pausing upstream of 
CTCF binding sites (Shukla et al. 2011). Importantly, CTCF depletion results in loss of 
CD45 exon 5 inclusion, as does mutation of the CTCF binding site, providing a direct 
causal link between CTCF binding and AS (Shukla et al. 2011). 
Importantly, CTCF promoted exon 5 inclusion is independent of hnRNP LL, 
which does not influence CD45 exon 5 skipping in the transition from naïve to activated 
T cells (Oberdoerffer et al. 2008; Shukla et al. 2011). Instead, CTCF binding to exon 5 is 
inhibited by DNA methylation, and this correlates with loss of exon inclusion (Shukla et 
al. 2011). Notably, memory T cells, which express reduced amounts of CD45 exon 5, 
Figure 1.4. Mechanism for the regulation of CD45 alternative splicing. The CD45 ARS is depicted in 
orange/red and the ESE in green. In resting cells hnRNP L (L) regulates basal levels of exon 4 repression, 
while SRSF1 mediates basal levels of exon 5 inclusion. Exon 5 inclusion is further regulated at the level of 
transcription. CTCF binds to the exon 5 ESE at the DNA level and promotes Pol II pausing around that 
region to promote exon 5 inclusion. Upon activation hnRNP LL and PSF join hnRNP L at the exon 4 and 6 
ARSs to promote further repression, while only hnRNP L and PSF associates to exon 5. 
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have increased DNA methylation and decreased CTCF binding at exon 5 relative to 
naive T cells (that show high levels of exon 5 inclusion) (Shukla et al. 2011). RNA-seq of 
CTCF depleted B-cell lines combined with CTCF ChIP-seq, revealed genome wide 
effects of CTCF regulated AS (Shukla et al. 2011). Furthermore, comparison of the 
CTCF binding sites identified by ChIP-seq in B-cells with publicly available studies in 
primary CD4+ T cells revealed conservation of CTCF binding sites. Therefore, regulation 
of CTCF binding is likely to contribute broadly to the regulation of AS. 
 
Splicing networks and the importance of identifying regulatory features 
Although the detailed dissection of the regulation of individual genes is essential, to 
ultimately understand the full functional consequence of AS in immune responses we 
need to have a broader understanding of the networks of genes that are coordinately 
regulated to achieve a concerted functional outcome. This is particularly true given the 
concept of AS as a fine-tuning mechanism discussed above. While the RNA binding 
proteins discussed above are good candidates for directing programs of coordinated 
splicing, predicting targets of these proteins is not simple. While, some of the known 
splicing factors have stringent binding specificity, others bind more promiscuously to pre-
mRNAs (Figure 1.3). Furthermore, combinatorial control of splicing by multiple RNA-
binding proteins that bind to pre-mRNAs independently, or in complex with one another, 
adds many layers of control, as seen in the example of CD45 regulation (Figure 1.4). 
Such modular binding and/or function of proteins allows tight control of the extent to 
which a given AS event is expressed (Motta-Mena et al. 2010; Preussner et al. 2012; 
Motta-Mena et al. 2011), but precludes straightforward prediction of functional targets. 
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 Global mRNA profiling during various immune responses, or in cells depleted of 
various regulatory proteins, is an increasingly common method to identify co-regulated 
AS events. In the case of protein depletion, such profiling studies combined with 
transcriptome-wide binding maps generated by approaches such as CLIP-seq, are an 
important first step toward differentiating between direct and indirect effects of various 
regulatory proteins. Such genome-wide analyses also aids in defining binding signatures 
that are predictive of particular splicing patterns. However, even when predicted events 
are validated, profiling studies are simply a starting place for deeper understanding. 
Detailed analysis of individual genes and/or biochemical analysis of particular regulatory 
factors is ultimately required in order to truly understand the mechanisms by which 
genes are regulated and how specific combinations of proteins lead to changes in 
splicing during immune responses. 
The recent analysis of CTCF function in B cells described above is an example of 
a thorough comparison of factor binding with functional effects on splicing in 
lymphocytes (Singh et al. 2012). RNA-seq and microarray analysis of mRNAs following 
depletion of a splicing factor in T cells has also been applied to hnRNP L and hnRNP LL 
(Gaudreau et al. 2012; Wu et al. 2008; Oberdoerffer et al. 2008). For hnRNP L, mRNA 
from thymocytes of hnRNP L depleted versus wild type mice was analyzed by RNA-seq 
(Gaudreau et al. 2012). Importantly, this study detected no major changes in gene 
transcription upon hnRNP L depletion, suggesting that the observed differences in 
mRNA profiles were due solely to AS (Gaudreau et al. 2012). The investigators found 
that hnRNP L target genes were enriched in microtubule and cytoskeletal functions. 
Although upwards of 200 AS events were predicted by RNA-seq, only 4 events were 
validated (Gaudreau et al. 2012). More recently our lab has utilized two techniques: 
RNA-seq and RASL-seq to identify splicing changes triggered by hnRNPL knockdown in 
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T cells with a high validation by RT-PCR. They have combined these with an analysis of 
hnRNP L binding sites determined by CLIP-seq to thoroughly catalogue of hundreds of 
direct hnRNP L regulated AS events and indirect events as decribed above (Cole et al 
RNA 2015). Furthermore, they find a negligible role for hnRNP L in regulating gene 
expression levels in Jurkat T cells, in agreement with its function in thymocytes (Cole et 
al RNA 2015).  
For hnRNP LL, exon array analysis of resting and activated hnRNP LL depleted 
T cells suggested several hnRNP LL dependent AS events (Oberdoerffer et al. 2008), as 
did analysis of naïve and memory T cells from hnRNP LL mutant mice (Wu et al. 2008). 
Both studies propose that hnRNP LL regulates a set of AS events upon T cell activation; 
although in neither case were any of the array predictions confirmed by RT-PCR, so the 
validity of the predictions remains unknown. Two other regulatory proteins known to 
exhibit increased activity during T cell response are PSF and CELF2 (see above; 
(Mallory et al. 2011; Heyd and Lynch 2010)). Both of these proteins have been shown in 
other cell types to regulate the splicing of multiple genes (Dembowski and Grabowski 
2009; Faustino and Cooper 2005; Ray et al. 2011; Kim et al. 2011; Ladd et al. 2005; 
Kalsotra and Cooper 2011). Recent work from our lab indicates that CELF2 and PSF 
regulate a substantial program of activation-induced splicing events in T cells (Mallory et 
al. 2015; Yarosh et al. 2015). Consistent with this finding, many of the exons that we 
have identified as undergoing activation-responsive AS in T cells are flanked by 
sequence motifs that match the binding consensus for CELF2 (Martinez et al. 2012). For 
PSF, the binding site is less well defined and thus less predictive (Shav-Tal and Zipori 
2002). Genome wide analysis of PSF binding during T cell activation could help to define 
a consensus PSF binding site. 
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Of the other proteins thus far implicated in T cell splicing, various studies have 
shown that TIA-1 preferentially binds U-rich elements, and that alternative exons with U-
rich intronic sequences downstream of 5’ splice sites are frequently regulated by TIA-1 
(Dember et al. 1996; Wang et al. 2010). Whether some of the TIA-1 regulated AS events 
identified in other cell types are also regulated in T cells or whether there are others 
remains an open question. Similarly, Sam68 and SRSF1 have been implicated in the 
regulation of many AS events including during the processes of adipogenesis, neuronal 
development, apoptosis and heart development (Paronetto et al. 2007; Huot et al. 2012; 
Iijima et al. 2011; Xu et al. 2005). However, thus far there are no studies inquiring the 
broad scope of either Sam68 or SRSF1 in AS regulation in immune responses. 
In addition to defining the scope of genes that are substrates of various 
regulatory proteins in lymphocytes, much remains to be learned about the connections 
between signal transduction and splicing factors during immune responses. Several 
canonical signaling pathways are activated downstream of the T cell receptor and co-
stimulatory receptors (Smith-Garvin et al. 2009). Future studies will be needed to 
discover signaling axes involved in the coordinated regulation of AS. Attributing 
regulatory control of splicing to signaling pathways will provide a higher resolution 
understanding of how signal transduction is coupled to splicing. Signaling pathways that 
modulate the activity of splicing factors in T cells remain largely undescribed. For the 
regulatory proteins described above we know only a few of the upstream signaling 
molecules that regulate their activity such as GSK3 for PSF, ERK for Sam68 and FASTK 
for TIA-1 (Figure 1.5). Importantly, a single signaling pathway may regulate the activity of 
multiple factors, and various pathways may impinge on the same factor. For example, a 
particularly interesting question with regards to PSF is whether all activities are regulated 
by its phosphorylation by GSK3 and/or interaction with TRAP150 described above. As 
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the cellular phenotype of PSF knock-down is distinct from the TRAP150-inhibited 
condition (Heyd and Lynch 2011b), it is strongly predicted that PSF has both 
GSK3/TRAP-dependent and independent activities 
 To begin to define networks of AS we have compared the responsiveness of 
specific signal-induced AS events to various stimuli in cultured and primary T cells 
(Martinez et al. 2012). We classified distinct networks of signal-induced AS events by 
their responsiveness to ionomycin relative to PMA. Strikingly we found the different 
networks identified in this way are enriched for distinct sequence features (Martinez et 
al. 2012) and see chapter 2. Among the enriched motifs we identified the ARS motif as 
Figure 1.5.  Networks of signaling pathways that regulate AS in T cells. Summary of several 
known kinases (blue/purple diamonds) and RNA binding factors (orange/red ovals) that have 
been shown to be regulated in response to antigen (Ag) stimulation or Fas Ligand (FasL) 
signaling in T cells, and the genes (text) that they regulate. Solid arrows and lines indicate direct 
activities, dotted arrows/lines indicate known relationships that are likely indirect. “other” indicates 
the fact that there are likely many other signaling pathways that are also involved in mediating 
antigen-induced changes in AS that are yet to be discovered. Question marks are meant to 
emphasize that although each signaling pathway so far has only been linked to regulation of 1-2 
genes, each branch likely regulates a program of co-regulated genes. Cross-coordination 
between branches is also anticipated, as observed for CD45. See text for detailed description of 
each pathway. 
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present in several exons that respond to PMA signaling alone in addition to CD45 
(Martinez et al. 2012). Some of the additional motifs identified in this study may likewise 
regulate specific networks of genes distinct from CD45; however, individual experiments 
will be required to test the functionality of these motifs. Mapping regulatory motifs also 
serves to predict splicing outcome of other AS events that contain particular motifs. For 
examples, our initial definition of the ARS motif allowed us to predict T cell activation 
responsive exons in the Tau and Fyn genes that we subsequently validated (Rothrock et 
al. 2003).  
 Finally, motif mapping is important to enhance our predictive capacity of disease 
causing SNPs. For example, our group has made important contributions to 
understanding how the SNP in CD45 exon 4 (C77G) affects AS. Despite the link 
between the C77G SNP and susceptibility to MS and HIV infection (see above), the 
molecular consequences of this disease relevant SNP had remained unexplored. The 
C77G disrupts the ESS1 and confers aberrantly high exon 4 inclusion without affecting 
the protein coding capacity (Lynch and Weiss 2001; Zilch et al. 1998). We recently found 
that the C77G polymorphism weakly affects the binding of hnRNP L to exon 4 and 
dramatically abrogates the binding of two additional hnRNP proteins, hnRNP E2 and 
hnRNP K (Motta-Mena et al. 2011). Even though hnRNP K and hnRNP E2 make little 
contribution to CD45 exon splicing under normal conditions, upon depletion of hnRNP L 
these proteins play a compensatory role (Rothrock et al. 2005; Melton et al. 2007; Motta-
Mena et al. 2011). The C77G mutation both reduces the binding of hnRNP L and 
prevents the compensatory function of hnRNP K and E2, to result in a significant overall 
loss of splicing repression. Therefore, a thorough biochemical understanding of the 
essential regulatory element controlling exon 4 expression, and the proteins that 
associate with this sequence, permitted a mechanistic explanation for the phenotype of 
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the C77G SNP. Such a detailed appreciation of the molecular basis of disease is the first 
step toward predicting the consequences of similar polymorphisms and designing 
approaches to correct or override such genetically encoded defects.  
 In summary, several lines of evidence suggest broad regulation of AS during 
immune responses. A handful of cases have been described in which AS serves to 
modulate lymphocyte activity. Furthermore, a few of the signaling pathways, splicing 
factors, and auxiliary elements that drive these AS events in immune effector functions 
have been characterized. However, many more genes and regulatory factors have yet to 
be investigated, and even the full spectrum of AS regulation in lymphocytes during 
different phases of an immune response remains to be rigorously explored. My 
dissertation has addressed the extent to which splicing is regulated during one phase of 
immune response, that of T cell activation. Through profiling studies of Jurkat T cells and 
primary human CD4+ T cells in unstimulated and activated states using next-generation 
sequencing, we have identified hundreds of alternative splicing events that have altered 
splicing pattern in response to T cell activation. I find that signal-responsive AS events 
are enriched in genes involved in many aspects of T cell biology and effector functions 
(Martinez et al. 2012; Grigoryev et al. 2009). Enriched activities include canonical T cell 
signaling pathways, MAPK kinase signaling and cell proliferation, highlighting the 
potential impact of AS on immune responses. I also find no overlap between 
differentially expressed genes and genes that are alternative spliced, suggesting that 
these two process have distinct roles in controlling T cell activation responses. 
Furthermore, I find that not all activation-induced alternative splicing events are sensitive 
to the same activation stimuli, including calcium signaling, suggesting that several 
distinct signaling pathways regulate alternative splicing in T cells.  
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 Given the potential for AS to broadly shape cellular function and the growing 
number of instances in which aberrant splicing is known to contribute to defects in 
immune function, future studies will undoubtedly continue to uncover new and exciting 
connections between AS and immune responses and suggest novel approaches to the 
treatment of human disease. Finally, defining novel cis-regulatory elements and trans-
acting factors that may function to co-regulate networks of genes in response to T cell 
activation will further our understanding of how alternative splicing can shape T cell 
functions. Given our limited knowledge regarding the mechanisms and consequences of 
splicing regulation in T cells, studies on individual genes that are subject to alternative 
splicing have the potential to reveal unprecedented insight into T cell regulation. 
  In this dissertation I describe the new mechanistic insight that we have gained 
based on the MKK7 gene as a case study for studying signal-induced splicing regulation. 
Through the study of MKK7 splicing regulation I identify intronic cis-regulatory elements, 
factors that interact in trans with these sequences and describe a new connection 
between a T cell signaling pathway and a splicing factor. First, I performed a screen for 
functional differences between the two isoforms of each of 5 of the genes that are 
regulated similarly in Jurkat T cells and primary T cells (see above). The results from this 
screen led to the selection of the JNK kinase MKK7 for further study. The last chapters 
of my dissertation focus on MKK7, as it was alternatively spliced in response to T cell 
activation signaling in a manner that I predicted would change MKK7 protein function 
and it was amenable to splicing mechanistic studies. Furthermore, MKK7 is a kinase 
within the JNK signaling cascade, allowing me to explore the interplay between signaling 
and splicing. I find that alternative splicing of MKK7 in response to T cell activation 
produces an isoform of MKK7 with increased docking activity for its substrate, the kinase 
JNK. This enhances JNK signaling, leading to a downstream increase in the activity of 
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the transcription factor c-jun and upregulation of the c-jun target gene and immune 
cytokine, TNF-a. Moreover, the splicing of MKK7 is regulated by JNK itself. Thus I 
demonstrate a positive feedback loop in JNK signaling that involves the JNK-dependent 
alternative splicing of MKK7. I further show that the regulation of MKK7 splicing is 
dependent on intronic regulatory sequences flanking its exon 2 and a JNK-dependent 
increase in the protein expression of the splicing factor CELF2. Finally, I show that the 
JNK/CELF2 signaling module is a major pathway controlling TCR-induced alternative 
splicing. 
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CHAPTER 2: PROFILING OF ALTERNATIVE SPLICING DURING T CELL 
ACTIVATION	  
 
Introduction 
As discussed in Chapter 1, a hallmark of the human adaptive immune system is the 
ability of T cells to detect foreign antigen and direct an appropriate functional response. 
The detection of foreign antigen occurs through the T cell receptor (TCR), and triggers 
an extensive array of receptor-proximal signaling proteins that in turn initiate a broad 
network of signaling cascades (Smith-Garvin et al. 2009). These antigen-activated 
signaling pathways coordinate effector activities (Smith-Garvin et al. 2009).  Not 
surprisingly, many of these antigen-induced changes in cellular activity are conferred 
through changes in gene expression (Naito et al. 2011). Thus, the activity of the human 
immune system relies on the ability of T cells to undergo extensive changes in protein 
expression in response to antigen-triggered signaling pathways. 
 Although many protein expression changes upon T cell activation are mediated 
by transcription (Smith-Garvin et al. 2009; Beurel et al. 2010; Naito et al. 2011), 
increasing evidence suggests that post-transcriptional gene control is also an important 
feature of T cell activation (Lynch 2004; Sandberg et al. 2008). Relatively little is known 
about the regulation and biological roles of alternative pre-mRNA processing following 
stimulation of the immune system. A few genes such as CD45, CD3, IL-7Ralpha, Fyn 
and LEF1 have well characterized alternative splicing events that undergo pronounced 
changes in response to T cell activation, in a manner that has important physiological 
consequences for immune function (as described in Chapter 1). The examples of 
functionally relevant alternative splicing provide precedent for it’s importance in immune 
responses, and suggests that determining the full profile of alternative splicing changes 
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induced by T cell stimulation is critical for a complete understanding of the cellular 
consequences of antigen challenge. Other studies querying alternative splicing in T cells 
have utilized exon arrays thus not exploring the full transcriptome (See Table 1.1).  
 In collaboration with the Blencowe lab our lab utilized high-throughput RNA 
sequencing (RNA-seq) to investigate global changes in alternative splicing in a cultured 
T cell line and in primary human T cells. In collaboration with colleagues from the Lynch 
and Blencowe labs I identified 178 genes that are predicted to exhibit robust signal-
induced changes in isoform expression in cultured T cells, and provide independent 
confirmation of such changes for ~40 of these genes. Importantly, at least 80% of these 
signal-induced splicing changes have not previously been described as regulatory 
events. A large percentage of these genes are enriched in functions related to 
immunobiology, including components of several of the critical signaling pathways that 
mediate T cell effector function, thus underscoring the likely importance of these 
alternative splicing events for proper T cell function. Finally, by comparing alternative 
splicing induced by different stimuli in the cultured cell line with that in primary cells, I 
provide evidence for several distinct signaling pathways leading from cell stimulation to 
alternative splicing. One of these pathways is shared between the primary and cultured 
T cells; while I also identify alternative splicing events that are unique to primary human 
peripheral T cells or the cultured T cell line. Collectively, our results significantly expand 
knowledge of genes that are regulated at the level of alternative splicing in response to 
cellular signaling, and also the signals that lead to such changes.  
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Results 
Global analysis of signal-induced alternative splicing and gene expression changes in a 
Jurkat T cell line 
Given previously reported examples of the physiological relevance of signal-induced 
changes in gene expression to T cell activity ((Smith-Garvin et al. 2009; Lynch 2004; 
Sandberg et al. 2008; Naito et al. 2011) and see Chapter 1), it is important to gain a 
more comprehensive view of how alternative splicing is used to control protein 
expression downstream of TCR-mediated signaling. To accomplish this we used RNA-
Seq to quantify differential expression of alternate mRNA isoforms using the Jurkat 
human T cell line (JSL1). Stimulation of JSL1 cells with PMA triggers signals that mimic 
aspects of mature TCR signaling ((Lynch and Weiss 2000) and see below). Total RNA 
was harvested from three independent samples each of resting and PMA-stimulated 
JSL1 cells; these samples were pooled, polyA+ mRNA was then isolated and used to 
generate cDNA libraries for RNA-Seq analysis which was performed by our collaborators 
Qun Pan and Benjamin Blencowe (see Materials and Methods). Between 45 and 48 
million reads were obtained from the resting and PMA-stimulated samples and were 
mapped to genomic DNA sequence. Non-mapping reads were then aligned to a 
reference database comprising a comprehensive set of cDNA/EST-supported splice 
junction sequences ((Pan et al. 2008), Fig 2.1A). By counting the relative ratios of reads 
that map uniquely to junctions representing exon inclusion and exon-skipping, estimates 
for the percentage of transcripts with alternative exon inclusion (%In) were derived.  
 By applying minimal RNA-Seq read coverage levels required to derive reliable 
estimates for alternative splicing levels, %In values could be determined for 
approximately 11,000 exons in both the resting and stimulated cell samples (Table S1 
from Martinez et al. 2012). Approximately 10% (929 of 10637) of these exons exhibited 
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at least a 10-point change in predicted %In between the resting and stimulated cells 
(Table S1 from Martinez et al. 2012). This rate of predicted differential inclusion is 
consistent with a previous, smaller scale analysis in which changes in %In were 
detected in 5-10% of profiled alternative exons upon T cell stimulation (Ip et al. 2007).  
 
 
 
Figure 2.1.  RNA-Seq and RT-PCR validation of alternative splicing in resting and PMA-
stimulated JSL1 cells. (A) Work flow of RNA-Seq analysis of isoform expression in JSL1 cells. (B) 
Representative RT-PCR of genes newly predicted by RNA-Seq analysis to exhibit differential isoform 
expression in resting (-PMA) versus stimulated (+PMA) JSL1 cells.  % inclusion of variable exon 
shown is an average of at least three independent experiments. (C) Plot of differential in % exon 
inclusion in resting versus stimulated cells as calculated by RNA-Seq (Y-axis) and RT-PCR (X axis).  
Pearson coefficient is calculated as 0.894. 
 
 50 
 To focus on the most pronounced signal-dependent alternative splicing events, 
we identified a set of 178 exons in 168 genes that have at least a 20-point differential in 
%In between resting versus stimulated cells (Table A1.1). Among these signal-induced 
changes in alternative splicing, 90 (51%) of the exons displayed increased inclusion and 
88 (49%) of the exons displayed increased skipping upon PMA stimulation. Notably, this 
list of “top candidates” captures previously defined and biologically important signal-
responsive exons, including all three of the immune-regulated alternative exons in the 
CD45 gene, and also exons in the FYN, CUGBP2, and MAP4K2 genes (Lynch and 
Weiss 2000; Rothrock et al. 2003; Ip et al. 2007; Mallory et al. 2011).   
Next, my colleagues from the Lynch lab and I used low cycle RT-PCR to validate 
predicted changes in the levels of inclusion of 46 additional exons among the list of 178. 
These events were chosen at random to represent a range from largest to smallest 
predicted changes in %In, and included sets of exons that display either increases or 
decreases in %In upon stimulation. For 32 of these exons, we observe differential %In 
values between resting and stimulated cells that are largely consistent with the RNA-Seq 
predictions, while an additional five genes exhibited smaller yet statistically significant 
differential %In values (Table 2.1, Fig 2.1B, C; p<0.05 for all; paired student’s t-test). 
Together with the six exons validated in previous studies, the results from the RT-PCR 
validation experiments confirmed changes in %In levels between resting and stimulated 
cells for 80% (43/52) of the tested events (Table 2.1, A1.1), with a Pearson correlation 
coefficient of 0.894 between %In values derived from the RNA-Seq and RT-PCR-based 
measurements (Fig 2.1C). As further validation of the RNA-Seq predictions, 11 of 12 
exons predicted to have no notable change in %In (<5-point differential) between resting 
and activated JSL1 cells also showed a lack of signal-responsiveness by RT-PCR 
analysis (Table A1.2). 
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Table 2.1: Signal-Responsive Exons in JSL1 Cells Validated by RT-PCR (n=>3). 
 
Gene 
%Inc        
-PMA         
RT-PCR 
StDv 
%Inc 
+PMA       
RT-PCR 
StDv RT-PCR       Differential 
% Inc       
-PMA  
RNA-seq 
% Inc 
+PMA  
RNA-seq  
RNA-seq 
Differential 
SLMAP 74 2 11 2 -63 81 7 -74 
FAM36A 69 2 31 2 -38 90 48 -42 
CELF2 84 5 48 1 -36 92 63 -29 
TRAF3 95 1 59 3 -36 98 78 -20 
BRD8 70 2 37 1 -33 71 29 -42 
NGLY1 70 6 43 2 -27 94 59 -35 
ZC3H14 56 2 81 3 25 55 84 29 
SEC16A-E1 32 1 8 2 -24 53 17 -36 
PPP1R12A 27 2 3 1 -24 68 9 -59 
MACF1 28 2 5 1 -23 41 12 -29 
REPS1 89 2 67 2 -22 95 75 -20 
AKAP9 55 1 33 2 -22 72 41 -31 
CD45-E6 31 2 11 2 -20 80 52 -28 
H2AFY 94 1 74 2 -20 83 52 -31 
TRIM26 46 5 64 4 18 77 97 20 
EHMT2 73 2 91 3 18 56 87 31 
DDHD1 29 3 12 4 -17 55 16 -39 
MAP4K2 52 4 68 6 16 65 90 25 
TIR8 49 4 64 4 15 55 91 36 
LUC7L 12 3 27 3 15 48 88 40 
CD45-E4 20 2 5 1 -15 33 8 -25 
PIGQ 23 2 37 3 14 67 94 27 
SEC16A-E2 61 3 75 3 14 71 91 20 
CD45-E5 94 1 80 4 -14 94 69 -25 
MAP2K7 47 5 33 2 -14 61 39 -22 
 
CARD8 21 2 8 4 -13 88 58 -30 
Fyn 30 3 18 1 -12 100 76 -24 
ZNF384 64 2 76 2 12 47 87 40 
ERP29 66 2 77 1 11 49 95 46 
TRIM65 85 3 96 3 11 76 100 24 
CKB 39 4 50 4 11 65 86 21 
FAM21C 36 3 25 2 -11 78 46 -32 
UGCGL1 21 1 10 2 -11 62 16 -46 
MAP7D1 57 1 67 1 10 64 84 20 
FIP1L1 33 1 23 2 -10 71 31 -40 
LRRC28 77 2 87 2 10 73 94 21 
MYL6 79 4 89 3 10 73 93 20 
CCDC14 51 2 41 1 -10 94 75 -19 
GALT 71 3 80 1 9 54 93 39 
MAP3K7 12 1 4 0 -8 35 8 -27 
ATF2 56 1 63 2 7 44 68 24 
ARMC10 56 1 49 1 -7 89 68 -21 
FAM33A 44 1 38 1 -6 90 63 -27 
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 In general, predictions based on fewer than 20 reads per splice junction, or 
based on %In changes between resting and stimulated JSL1 cells of <15%, were not 
supported by RT-PCR results (data not shown). Therefore, I focused subsequent 
analyses on the set of 178 exons that are associated with a high rate of validation. Given 
the number and length of the RNA-Seq reads analyzed in this study, we estimate that 
the list of 178 regulated exons we have detected are represented by the top ~40% most 
highly expressed genes in JSL1 cells (Blencowe et al. 2009).  However, given the 
unbiased nature of RNA-Seq and our subsequent analysis (see below), we anticipate 
that these 178 alternative splicing events are representative of the larger set of signal-
responsive cassette alternative exons in JSL1 cells.   
 To address whether signal-induced changes in mRNA expression levels may 
have affected our detection of %In changes, I next compared changes in total mRNA 
expression with changes in alternative splicing. In our previous, smaller-scale analysis of 
mRNA expression in JSL1 cells we determined that upon PMA treatment a similar 
percentage of genes exhibited alternative splicing changes as transcriptional changes. 
However there was no significant overlap between the sets of genes affected by each 
process (Ip et al. 2007). In the present study, of 10,374 genes for which we obtained 
reliable sequence coverage in either resting or stimulated cells (10 or more reads per 50 
basepairs of gene length), 312 exhibit a change of 2-fold or greater in mRNA expression 
between resting and stimulated cells (Table S3 from Martinez et al. 2012). As observed 
in previous studies profiling gene expression in T cells (Lin et al. 2003; Ip et al. 2007), 
I observe that a larger number of genes are upregulated upon stimulation than are 
repressed (207 vs. 115). Importantly, further consistent with our previous studies (Ip et 
al. 2007), none of the 178 differentially spliced exons are located within this set of 312 
transcriptionally-regulated genes. Therefore, while alternative splicing and transcriptional  
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Figure 2.2.  Genes that undergo signal-responsive alternative splicing in JSL1 cells are enriched for 
activities required for T cell function.  (A) The 178 exons identified as signal-responsive in this study were 
analyzed by IPA (Ingenuity Systems,www.ingenuity.com) for functional categories.  Categories graphed 
show above-threshold significance (-log(p-value) > 1.5) in enrichment relative to the 11,000 exons which 
were detectable in the RNA-Seq analysis.  Numbers above the bar graph represent the number of genes 
that score for each category. (B) Same as (A) but genes were analyzed for their involvement in canonical 
signaling pathways. 
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changes affect a similar percentage of genes, in general these regulatory processes do 
not directly impact one another in the context of signal-induced changes in JSL1 cells.  
 Interestingly, by performing an ingenuity pathway analysis, I find that the signal-
responsive exons we have identified are significantly enriched in genes involved in many 
aspects of cellular development and activity relevant to T cell function, including cell 
signaling and gene expression; as well as functions that are specifically related to 
lymphocyte biology such as Immune Cell Trafficking, Inflammatory Response, 
Immunologic disease and Cell-mediated Immune Response (Fig 2.2A, Table A1.3A; 
p<0.03; Fischer’s exact test). Importantly, when I scored the genes containing the set of 
178 exons for involvement in specific signaling pathways, I observe enrichment in many 
of the signaling cascades that are triggered in response to T cell activation and which 
are required for T cell effector functions, such as NF-kB, JNK and MAP kinase signaling, 
as well as Rho-mediated changes in cell migration (Fig 2.2B, Table A1.3B; (Smith-
Garvin et al. 2009)). Together, these results strongly suggest that alternative splicing 
likely plays a major role in shaping the T cell response to stimulation. Moreover, in light 
of previous work demonstrating important functional roles for a few alternative splicing 
events in T cells (Hemmer et al. 2000; Lynch 2004; Mallory et al. 2011), I predict that 
many of the new examples of regulated exons we identify here also contribute to an 
optimal immune response. 
Genes that displayed differential expression at the transcript level were also 
significantly enriched for functions related to T cell biology, including almost all of the 
functional categories enriched among the genes with regulated alternatively splicing 
events (Table A1.4AB; Fig 2.3; p<0.03). Interestingly, only “RNA Trafficking” was 
identified as a function uniquely enriched among the alternatively spliced genes (A1.4B). 
By contrast, transcription appears to regulate a broad spectrum of functions not 
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impacted by alternative splicing, including general functions such as protein synthesis 
and trafficking, cellular morphology and mobility, and functions related to metabolism 
(Table A1.4A,B; Fig 2.3B). Functions enriched among transcripts up-regulated by cell 
stimulation were largely overlapping those enriched among repressed genes (Fig 2.3A). 
Strikingly, however, the pathways enriched among the up-regulated and down-regulated 
genes are entirely distinct (Table A1.4C,D; Fig 2.3C). Moreover, only one signaling 
pathway (NF-kB) includes genes regulated at both the level of transcription and 
alternative splicing (Fig 2.3D). Therefore, whereas both transcriptional and splicing 
regulation have the ability to influence T cell biology, these mechanisms appear to do so 
through distinct signaling or functional pathways. 
 
 
Figure 2.3: Comparison of IPA analysis of gene expression (GE) changes upon stimulation of JSL1 
cells.   (A) Functional categories enriched in genes up-regulated (red) vs. down- regulated (blue) upon 
stimulation. (B) Functional categories enriched in all genes that change expres- sion (GE, red) vs. splicing 
(AS, blue). (C) Signaling pathways enriched in genes up-regulated (red) vs. down-regulated (blue) upon 
stimulation. (D) Signaling pathways enriched in all genes that change expression (GE, red) vs. splicing (AS, 
blue).  
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A subset of signal-responsive exons in Jurkat T cells have similar behavior in primary T 
cells 
I next asked whether the signal-responsive exons detected in JSL1 cells are also 
regulated in response to antigen challenge of mature, peripheral T cells. CD4+ 
peripheral T cells were isolated from multiple donors and stimulated in culture with the 
lectin PHA, which functions as a surrogate antigen to stimulate the canonical T cell 
receptor signaling pathways. I then assayed alternative splicing changes for the top 25 
genes in Table 1 by RT-PCR analysis of RNA harvested from resting or stimulated T 
cells from multiple independent donors. This revealed that 68% (17/25) of the tested 
exons show a statistically significant change in %In following PHA stimulation, whereas 
the remaining eight exons did not detectably respond to antigen stimulation (Table 2.2; 
Fig 2.4A-D). Similar results to those observed in the CD4+ T cells were obtained in 
CD8+ peripheral T cells, and also when either CD4+ or CD8+ T cells were stimulated 
with anti-CD3/CD28 antibodies instead of PHA (data not shown). 
 Although the majority (10/17) of the PHA-dependent changes in alternative 
splicing in CD4+ primary cells were in the same direction (i.e. more or less exon 
inclusion) as the changes seen upon PMA treatment of JSL1 cells (Table 2.2, Fig 2.4A, 
B), some of the PHA-responsive exons (7/17) showed an opposite change in the PHA 
stimulated primary cells compared to the PMA-stimulated JSL1 cells (Table 2.2, Fig 
2.4A, C). Similar reciprocal changes in alternative splicing between JSL1 and CD4+ cells 
has been noted in previous studies (Ip et al. 2007; Mallory et al. 2011). This difference in 
directionality of the splicing change suggests cell type specific differences in T cell 
signaling.   
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A PMA-sensitive pathway in Jurkat T cells uniquely mimics TCR-signal induced 
alternative splicing in primary T cells 
The classical model of T cell signaling posits that antigen-challenge and pre-TCR 
engagement activate Ras and Calcium-dependent signaling pathways that synergize to 
achieve an optimal response (Smith-Garvin et al. 2009). PMA is thought to primarily 
trigger the Ras-dependent branch of this signaling cascade, while the calcium ionophore 
Ionomycin induces calcium signaling. However, there is much evidence suggesting 
Figure 2.4.  Analysis of activation-induced splicing in CD4+ primary cells relative to JSL1 cells.  (A) 
Graphical representation of the change in % exon inclusion between resting and PHA-stimulated CD4+ 
cells (purple bars) compared to the change observed between resting and PMA-stimulated JSL1 cells (gray 
bars).  % exon inclusion differential was calculated by RT-PCR from at least 3 independent experiments 
(JSL1) or donors (CD4+).  Exons were further grouped in one of three categories: (I) responding similarly in 
both cell types (red tint), (II) responding in an opposing manner in the two cell types (blue tint), or (III) 
showing no statistically significant change upon PHA-treatment of CD4+ cells.  See also Tables 1 and 2 for 
details.  (B-D) Representative RT-PCR of isoform expression in resting (-PHA) versus stimulated (+PHA) 
CD4+ primary T cells, for genes in categories I (B), II (C) or III (D). % inclusion of variable exon shown is an 
average of at least three independent experiments. 
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overlap or cross-talk between these pathways in JSL1 cells. Most conspicuously, PMA 
alone triggers maximal expression of TNFa in JSL1 cells with no synergy observed upon 
the addition of Ionomycin (Fig 2.5A). This result is striking since transcription from the 
TNFa promoter has been well-documented to require Ca+2 signaling along with Ras 
stimulation (Tsai et al. 1996b; López-Rodríguez et al. 2001). Moreover, treatment of 
JSL1 cells with Ionomycin results in at least partial expression of the cell-surface protein 
CD69 (Fig 2.5B), which is traditionally considered a marker of Ras activation 
(D'Ambrosio et al. 1994).  Therefore, PMA and Ionomycin stimulation of JSL1 cells does 
not fit a clear-cut model of independent Ras and Ca+2 signaling respectively. 
 Given the apparent nonconventional signaling in JSL1 cells I wished to better 
delineate the pathways through which the various “PMA responsive” genes are 
regulated. In particular I sought to determine the relative contribution of Ionomycin-
induced signaling in the alternative splicing events we have identified. Notably, I find that 
10 of the top 25 PMA-responsive genes show at least 50% of the maximal PMA-
response when stimulated with Ionomycin alone (Table 2.2, Fig 2.5C, left most 10 
genes). By contrast the other 15 genes did not display statistically significant or robust 
changes in alternative splicing upon Ionomycin treatment ((Fig 2.5C), gene names 
between dotted lines). In no case did I observe any synergy following co-stimulation with 
PMA and Ionomycin (data not shown). Therefore, I conclude that there are at least two 
distinct signaling pathways leading from PMA stimulation to alternative splicing, one of 
which is triggered by both PMA and Ionomycin and another, which is responsive only to 
PMA.  
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 To ask whether differential signaling pathways might explain the distinct classes 
of alternative splicing response patterns observed when analyzing different cell types, I 
directly compared the Ionomycin-response data with the data from CD4+ T cells. 
Strikingly, I observe that all (10/10) of the exons displaying the same directionality of 
change in splicing upon stimulation of CD4+ and JSL1 cells are responsive only to PMA, 
while 6 of the 7 genes that had an opposite splicing pattern in CD4+ and JSL1 cells are 
also responsive to Ionomycin. To investigate whether this correlation might be predictive, 
Figure 2.5.  Analysis of signaling pathways in JSL1 cells and their effect on alternative splicing. (A) 
Induction of TNF-alpha expression in response to PMA and/or Ionomycin treatment of JSL1 cells. TNF-alpha 
mRNA was measured by RT-PCR and the average of 2 experiments is shown. (B) Cell-surface expression 
of CD69, as measured by flow-cytometry, in JSL1 cells grown under resting (gray), PMA stimulated (red) or 
Ionomycin stimulated (blue) conditions.  (C) Analysis of Ionomycin-induced alternative splicing of the top 25 
PMA-responsive genes.  Ionomycin responsiveness was quantified by RT-PCR from at least three 
independent experiments and the difference in exon inclusion between resting and Ionomycin-stimulated 
cells was graphed as a % of splicing changed observed upon PMA stimulation (PMA differential set to 
100%). (D) Model of signaling pathways in JSL1 versus CD4 cells as indicated by alternative splicing 
responsiveness. 
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I next assayed three additional genes that we have previously found to be anti-correlated 
in response to stimulation of JSL1 and CD4+ cells (Lck, LEF1, Pyk2; (Ip et al. 2007)). 
Remarkably, each of these genes displays a change in splicing in response to Ionomycin 
that is similar to the response to PMA in JSL1 cells (Fig 2.5C). By contrast, the one 
additional gene (TRIM65) we have thus far found to be spliced similarly in both PHA-
stimulated primary cells and PMA-stimulated JSL1s, is entirely unresponsive to 
Ionomycin (Fig 2.5C). 
 Taken together, these results suggest that for 40% (10/25) of the genes initially 
characterized as “PMA-responsive” in JSL1 cells, the signaling pathway that leads to 
splicing modulation overlaps with an Ionomycin-triggered cascade (Fig 2.5D). Moreover, 
this Ionomycin-triggered or “overlapping” pathway in JSL1 cells is distinct from signaling 
cascades triggered by antigen-stimulation of CD4+ cells, and in some cases is even 
counter to the effects of TCR signaling, at least in terms of alternative splicing regulation 
(Fig 2.5D). These differences in alternative splicing of some genes may account for 
important cell type specific splicing regulation. By contrast, we conclude that there is a 
PMA-induced pathway in JSL1 cells that mimics, at least at the level of alternative 
splicing, antigen-stimulation of mature peripheral T cells. Such a model is further 
consistent with the fact that I observe full TNF-alpha expression with PMA alone, 
demonstrating that PMA is sufficient in JSL1 cells to induce at least some transcriptional 
events that typically require both a Ras and Ca+2 signal. However, I note that not all 
PMA-only-induced alternative splicing events in JSL1s are seen in CD4+ T cells, 
suggesting that at least one PMA-induced mechanism in JSL1 cells is not functional in 
primary T cells (Table 2.2, Fig 2.4D).  
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Table 2.2: Exon expression in mature human T cells (n=>3) 
Gene CD4+ 
Resting 
 CD4+  
PHA 
 P< 0.05 CD4+    
Differential 
JSL1    
Differential 
Ionomycin 
responsive? 
CD45-E5 53 13 27 6 * -26 -14 N 
CD45-E6 25 8 5 2 * -20 -20 N 
MAP2K7 39 3 26 3 * -13 -17 N 
CD45-E4 10 2 1 2 * -9 -15 N 
NGLY1 64 7 56 7 * -8 -27 N 
BRD8 47 4 41 1 * -6 -33 N 
TIR8 30 12 70 12 * 40 15 N 
SEC16A-E2 59 4 70 2 * 11 14 N 
EHMT2 58 2 67 2 * 9 18 N 
ZC3H14 76 3 82 4 * 6 25 N 
          LUC7L 64 8 16 8 * -48 15 Y 
MAP4K2 78 3 47 4 * -31 16 Y 
TRIM26 88 4 58 6 * -30 18 Y 
CELF2 40 4 75 9 * 35 -36 Y 
FAM36A 51 6 61 6 * 10 -38 N 
SEC16A-E1 11 1 17 3 * 6 -24 Y 
AKAP9 67 2 72 3 * 5 -22 Y 
          DDHD1 47 7 52 4  5 -17 Y 
SLMAP 56 9 61 5  5 -63 Y 
H2AFY 94 4 98 1  4 -20 N 
PPP1R12A 7 5 10 1  3 -24 Y 
REPS1 76 3 77 6  1 -22 N 
MACF1 12 3 12 3  0 -23 Y 
PIGQ 82 5 81 3  -1 14 N 
TRAF3 90 3 88 0  -2 -36 N 
Distinct sequences correlate with discrete signal-responsive categories of alternative 
splicing  
Finally, to begin to address whether the different sets of signal-induced alternative 
splicing events detected in our transcriptomic analysis are regulated by distinct factors, 
we investigated whether they are significantly enriched in specific sequence motifs 
indicative of binding sites of splicing regulators. An implication of the model in Figure 
2.5D is that exons that are regulated by a common signaling pathway (i.e. one of the 
colored arrow in Fig 2.5D), are likely regulated by similar or overlapping mechanisms. 
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As most alternative splicing relies on the binding of regulatory proteins to cis-acting 
control sequences (Chen and Manley 2009), and in light of previous observations that 
co-regulated sets of alternative exons tend to be regulated by one or more common 
regulatory factors, we reasoned that exons which fell into a given regulatory category 
might share specific regulatory motifs. Brian Cole a graduate student in the Lynch lab 
queried each of the three categories of genes in Table 2.2 using the motif finder MEME 
(Bailey et al. 2009) to search for sequences that are significantly enriched in the 
Figure 2.6.  Motif enrichment among signal-responsive alternative exons.  (A) Logos of motif identified 
as enriched among category I exons and e-value of the enrichment (left) along with the location and p-value 
of the motif in each of the 5 exons in which it was identified (right). (B) Logos and corresponding e-values of 
the five motifs identified within the flanking introns of exons from categories I, II and III, along with the 
names of the genes in which each motif is found. Detail of motifs and locations are provided in Figure 2.7. 
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regulated exons or their flanking intron sequences (see Materials and Methods). For the 
exons we only found a single statistically-enriched motif among the “category I” exons 
regulated similarly in JSL1 and CD4 cells (Fig 2.6A). Strikingly, this enriched motif 
identified by MEME encompasses the “activation-response sequence” (ARS = 
(A/C)YYGCA) that we have previously demonstrated to be critical for the regulation of 
each of the three CD45 variable exons (Rothrock et al. 2003; Motta-Mena et al. 2011). 
MEME indeed identifies two copies of the enriched motif in each of the CD45 variable 
exons, as we have previously identified (Rothrock et al. 2003), and also identifies 
previously unrecognized occurrences of this sequence motif in two additional exons in 
category I (Fig 2.6A). This motif is not found in categories II or III, nor is it enriched in the 
validated “non-responsive” exons. 
 In contrast to these results, we observe significantly enriched sequence motifs 
within intronic sequences flanking the regulated exons belonging to each of the three 
categories (Fig 2.6B, Fig 2.7). For categories I and II, two distinct sequence motifs are 
enriched. Matches to these motifs were found in the intron both upstream and 
downstream of the variable exons. We also were able to identify a single motif in 
category III, however this motif is present in only two of the eight genes in the category 
and has a relatively low e-value.  Notably the sequence motifs flanking the signal-
responsive exons are similar but not identical between the three categories, suggesting 
functional differences between the regulatory factors that mediate signal-induced 
alternative splicing of these sets of genes. This observation is consistent with the distinct 
signaling requirements for the regulation of alternative exons belonging to classes I, II 
and III. In sum, we conclude that there are likely multiple, distinct connections between 
signaling pathways and the regulatory factors that control splicing in T cells. 
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Discussion 
 Alternative splicing is an important but under-investigated mechanism of regulation of T 
cell function during immune responses. In this study we use RNA-Seq to identify genes 
that express distinct isoforms in response to stimulation of a human T cell line.  We 
identified 178 exons in 168 genes that are subject to signal-induced alternative splicing. 
Figure 2.7. Details of enriched motif analysis.  Exact sequences and locations thereof for the 
sequences which match enriched motifs identified in Figure 2.6.  Data presented as provided by 
MEME suite analysis (Bailey et al., 2009). 
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The vast majority of these genes also exhibit differential isoform expression in naive and 
activated primary T cells.  
 Importantly, only a few of the 178 exons belong to genes previously described to 
undergo signal-induced alternative splicing in T cells or in any other system. For 
example, only 25 of these exons were among the high-confidence set of alternative 
splicing level predictions generated by our previous quantitative alternative splicing 
microarray profiling study (Ip et al. 2007). Conversely, many of the signal-induced 
alternative splicing changes predicted to occur based on our previous microarray 
profiling study were not detected by RNA-Seq analysis. This can be attributed to the 
observations that a substantial number of the microarray-profiled exons lack sufficient 
read coverage required to generate reliable predictions for splicing changes, that the 
microarray platform is associated with a higher false-positive detection rate for splicing 
changes than is RNA-Seq analysis, and possibly also because of false-negative 
detection in the RNA-Seq analysis (data not shown). Thus, while both systems are 
capable of generating reliable predictions for alternative splicing changes on a large-
scale, RNA-Seq has the main advantage of affording relatively unbiased detection of 
exons within expressed transcripts and, based on comparisons of relative RT-PCR 
validation rates (this study and (Ip et al. 2007)), is generally more quantitative.  
Regardless, our results greatly expand the repertoire of known signal-regulated splicing 
events. Moreover, because of the unbiased nature of RNA-Seq analysis, these events 
are likely to be representative of the total spectrum of alternative exons that are 
regulated during T cell activation. This is further reflected by the enrichment of the set of 
178 exons in gene function categories that are specifically associated with the immune 
response. 
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 Strikingly, the 178 exons are significantly enriched in genes involved in mediating 
critical T cell effector functions, such as cell signaling, proliferation and development and 
immune cell trafficking.  For example, MKK7 is a MAP kinase that controls the activity of 
the c-Jun transcription factor that is essential for expression of immune cytokines (see 
chapter 4), EHMT2 is a methyl transferase that has been implicated in regulating gene 
expression and controlling apoptosis (see chapter 3), and TIR8 regulates Toll-like 
receptor signaling and the inflammation response (Hoffmann et al. 2008; Drexler et al. 
2010; Huang et al. 2010; Wang et al. 2007). Therefore, although the precise functional 
impact of most of the splicing events we have uncovered remain unexplored, alternative 
splicing is predicted to play a significant role in shaping the ability of T cells to mount a 
robust and appropriate immune response. 
 Finally, in addition to providing novel examples of signal-induced alternative 
splicing, our data reveal important insight into the diversity of signaling pathways that 
control splicing. Specifically, comparison of the responsiveness of splicing to various 
stimuli in the cultured versus primary T cells enabled grouping of the signal-responsive 
exons into at least three distinct networks. Importantly, we find that each regulatory 
network is characterized by distinct sequence features, further suggesting independent 
regulatory mechanisms including multiple signaling pathways.  
 The relevance of our motif analysis is strongly suggested by the unbiased 
identification of the known ARS regulatory motif among the category I genes. We have 
previously shown that the ARS motif functions by recruiting hnRNP L, LL and PSF to 
regulate the category I exons in the CD45 gene (Rothrock et al. 2005; Topp et al. 2008; 
Melton et al. 2007; Motta-Mena et al. 2010; Tong et al. 2005). Our identification of the 
ARS motif in EHMT2 and TIR8 suggests that hnRNP L, LL and/or PSF may also 
regulate at least a subset of additional category I exons. Interestingly, however, a G-rich 
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motif was also identified in the introns of EHMT2 and TIR8, implying potential cross-talk 
between signaling pathways and/or regulatory factors in mediating the final outcome of 
splicing of these genes. Moreover, the fact that the ARS motif was not enriched in exons 
outside category I underscores the likelihood that the category II and III exons are 
regulated by pathways and factors other than those described for the ARS-containing 
CD45 gene. Further identification of the regulatory factors will be required to fully 
delineate the signaling networks that control diverse alternative splicing events; 
however, our studies clearly demonstrate the presence of distinct regulatory pathways. 
Therefore, in summary, the data presented in this chapter provide a valuable basis for 
the future characterization of the function and mechanisms of alternative splicing 
networks controlled by distinct signal-induced pathways during T cell stimulation. Indeed, 
chapter 3 uses the information gained from this study to select one of the identified 
candidate genes (MKK7) for further analysis. Finally, chapters 4 and 5 describe the 
biological impact of MKK7 alternative splicing and reveal the mechanism by which MKK7 
splicing is regulated. Specifically, I identify a network of alternative splicing controlled by 
a new signaling connection between a canonical T cell signaling pathway and a splicing 
factor. 
 
 
 
 
 
 
 
 
 
 68 
CHAPTER 3: SELECTION OF AN ALTERNATIVE SPLICING EVENT FOR 
FUNCTIONAL AND MECHANISTIC STUDIES 
 
 
Introduction  
Our global analysis of alternative splicing during T cell activation identified over 178 
alternative splicing events in 168 genes (Table 2.1). For most of these genes, the effect 
of differential isoform expression on T cell function and the molecular mechanism 
controlling alternative splicing is unexplored. In order to understand the impact of 
alternative splicing on lymphocyte biology, performing detailed studies of alternative 
splicing of individual genes is critical to reveal novel paradigms of splicing regulation and 
its functional implications. To identify experimentally tractable models to further dissect 
the functional role of T cell activation-induced alternative splicing, I focused my effort on 
the list of alternative splicing events that we validated as being regulated similarly upon 
activation of both Jurkat T cells and primary human CD4+ T cells (Table 2.7). The 
conserved regulation of these events suggests potential functional importance for T cell 
function, and the availability of a model T cell line facilitates biochemical analysis.  I then 
narrowed this list to novel alternative splicing events that have not been previously 
explored: the JNK kinase MKK7; the histone methyltransferase EHMT2; the 
transcriptional co-activator BRD8; the RNA-binding proteins ZC3H14; the 
deglycosylating enzyme NGLY1. This chapter describes the data I accumulated on 
these genes and the selection process that identified MKK7 among the five candidates 
as the focus of further studies described in Chapters 4 and 5.  
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Results 
Screen for T cell activation-induced alternative splicing events for further studies 
As a starting point for selecting a candidate gene I aimed to identify alternative splicing 
events that impacted protein expression and T cell functions. The criteria that I tested to 
select a candidate gene for further study were as follows: functional differences between 
splice variants including (1) expression of T cell activation markers, (2) cell viability, (3) 
known protein activities and (4) minigenes that recapitulate endogenous regulation.  
First, I transfected splice site blocking antisense morpholino oligos (AMOs) 
complementary to a splice site of the cassette exon in each of the 5 candidate genes 
MKK7, EHMT2, BRD8, ZC3H14 and NGLY1 to force skipping of this exon (Fig 3.1). 
Most of the AMOs were able to force skipping of their target exons in both unstimulated 
and PMA-activated conditions. However, the AMO targeted to the NGLY1 cassette exon 
did not force exon skipping, but instead had a limited effect on enhancing exon inclusion 
(Fig 3.1).  
Figure 3.1 Antisense splice site blocking morpholino olgos (AMOs) force skipping of cassette 
exons. Percent inclusion determined by RT-PCR analysis of RNA from cells that were transfected with 
AMOs (15 nmol) targeting either the 5’ or 3’ss of alternative exons in EHMT2, MKK7, ZC3H14, NGLY1and 
BRD8 compared to a control AMO in unstimulated and PMA activated Jurkat T cells.  
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 I then asked whether modulating isoform expression with these AMOs affected 
the expression of well-established markers of T cell activation such as the cell surface 
receptors CD69 and CD25 (Fig 3.2) (Fazekas De St Groth et al. 2004). I found that the 
induced expression of CD69 and CD25 on the cell surface, as measured by flow 
cytometry, following T cell activation by PMA for 24h was unchanged following treatment 
with the AMOs compared to a control AMO (Fig 3.2). Similarly, treatment with the AMOs 
did not affect basal expression of these T cell activation markers.  
 Another hallmark and consequence of T cell activation is increased T cell 
proliferation (Smith-Garvin et al. 2009). Having found no differences in cell surface 
expression of two canonical T cell activation markers, I determined whether alternative 
splicing of any of the five genes impacted the cell viability of Jurkat T cells. I performed a 
MTS cell viability assay in cells that were treated with the splice site blocking AMOs. 
MTS is converted by cells to formazan and the amount of formazan, as measured by 
Figure 3.2 Analysis of cell surface activation markers in AMO-transfected cells. (A) Jurkat T cells 
transfected with AMOs (5 and 15nmol) to modulate splicing of EHMT2, MKK7, ZC3H14, NGLY1 and BRD8 
left unstimulated or activated with PMA were stained with anti-CD25 FITC (top) or anti-CD69 PE (bottom) 
and fluorescence analyzed by flow cytometry.  
 
 71 
absorbance at 490nm, is proportional to the number of living cells. I first performed a 
calibration curve of absorbance (490nm) versus cell number to demonstrate the linear 
Figure 3.3 Analysis of cell viability in AMO-transfected cells. (A) Calibration curve of absorbance versus 
cell number showing linear range of the MTS assay used to analyze cell viability. (B) Growth curves plotting 
cell number, as determine by absorbance at 490nm MTS assays, as a function of time after transfection with 
the AMOs targeting each splicing event at a low dose (5 nmol). (C) Same as B, but at a high dose (15 
nmol). 
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range of the assay (Fig. 3.3A). I plated cells transfected with a control AMO or with 
AMOs at a low dose (5 nmol) and a high dose (15 nmol) to the cassette exons in either 
MKK7, EHMT2, BRD8, ZC3H14 and NGLY1 and monitored absorbance at 490nm with 
the MTS assay every ~12h up to 72h (Fig 3.3B,C). I did not observe marked differences 
in the cell growth curves for cells transfected with the splicing modifying AMOs relative to 
a control AMO. I concluded that alternative splicing of MKK7, EHMT2, BRD8, ZC3H14, 
or NGLY1 does not have a considerable effect on cell viability of T cells. 
 Another important criteria in the selection of a candidate gene for further study 
was the ability to generate a minigene that recapitulates the endogenous activation-
induced splicing regulation. Minigenes allow for mutational analysis to identify splicing 
regulatory sequence elements and associated trans-acting factor. A minigene contains 
the genomic sequences of interest typically including the alternative exon and a portion 
of the flanking introns placed in the context of heterologous flanking exons in a plasmid. 
Cis-regulatory elements usually reside within a few hundred nucleotides of the 
alternative exon. Thus, inclusion of 100-500nt of introns is a generally sufficient 
sequence to encompass the regulatory elements. With the help from Chris Yarosh and 
Sam Allon, I made minigenes containing the alternative exons in MKK7, BRD8, NGLY1 
and ZC3H14 and a few hundred nucleotides of the upstream and downstream introns 
flanked by Beta-globin sequences (Fig 3.4). For the EHMT2 alternative exon we made a 
minigene containing the entire upstream and downstream intron and constitutive exons 
since they were all <1kb (Fig 3.4). Out of these minigenes only the EHMT2 and BRD8 
minigines recapitulated the activation-responsive regulation of the variable exons 
observed in the endogenous gene as quantified by RT-PCR with minigene specific 
primers (Fig 3.4). However, shortening of the MKK7 intron sequences to about 100nt 
resulted in a signal-responsive minigene, presumably through the loss of a strong 
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silencer that was preventing the exon from being included at all in the minigene context. 
These minigenes allowed me to narrow down my candidate list to MKK7, EHMT2 and 
BRD8 because we were able to produce minigenes that recapitulate the signal-
responsive alternative splicing observed in T cells to enable mechanistic and 
biochemical studies. The function of BRD8 as a transcriptional co-activator is not well 
characterized, therefore there was no hypothesis on which to design further analysis of 
functional differences in the isoforms. However, MKK7 and EHMT2 have clear, important 
biological functions that allowed me to hypothesize about the functional implications of 
regulated splicing of these genes. I evaluated MKK7 and EHMT2 in parallel, but the rest 
of the chapter discusses EHMT2 since MKK7 is the topic of Chapters 4 and 5. 
 
Preliminary analysis of the mechanism and function of EHMT2 alternative splicing 
As described in Chapter 2, EHMT2 (also called G9a) contains two of the motifs that were 
bioinformatically identified as enriched among genes that are regulated similarly in 
Jurkat T cells and primary human T cells (Fig 2.6A,B). One of these motifs is the 
activation-responsive sequence (ARS) that has been previously shown by the Lynch 
laboratory to be required to confer signal-responsive splicing of CD45 and its consensus 
sequence has been experimentally validated to be MCYYGCA (Rothrock et al. 2003; 
Motta-Mena et al. 2010). Basal repression of CD45 variable exons is mediated by 
binding of hnRNP L to the ARS motif located within the CD45 variable exons. The ARS 
in CD45 lies in an exonic splicing silencer element termed (ESS1), upon T-cell activation 
the splicing factors PSF and hnRNP LL are recruited to the ESS1 in a manner that is 
dependent on the ARS to confer signal-responsiveness (Rothrock et al. 2003; Melton et 
al. 2007; Tong et al. 2005; Oberdoerffer et al. 2008). In addition to the ARS motif we also 
found a second enriched motif in the flanking EHMT2 introns, resembling a CTCF 
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binding site (Fig 2.6B). As discussed in Chapter 1, CTCF can promote inclusion of 
alternative exon by enhancing Pol II pausing (Shukla et al. 2011).  
 Given the precedence for the ARS and CTCF motifs as splicing regulatory 
sequences I decided to test the importance of these elements by replacing the ARS and 
CTCF motif sequences with a heterologous sequence in the context of the EHMT2 
minigene stably transfected into Jurkat T cells.  Indeed replacing both the ARS and the 
CTCF motif impacted inclusion of EHMT2 exon 10 (Fig 3.5A, left). However, 
Figure 3.4 Evaluation of minigene signal-responsiveness. Left, schematic of MK7, BRD8, EHMT2, 
NGLY1 and ZC3H14 minigenes. Sequences derived from candidate genes are shown in color and beta-
globin sequences are shown in gray. Right, representative RT-PCR gel of exon inclusion in unstimulated 
and PMA activated conditions for each minigene. Below the RT-PCR gel is the quantification of the 
average percent inclusion for each case (n=3 independent clones). 
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replacement of either sequence affected only basal inclusion of EHMT2-E10, but left the 
activation responsiveness unaffected (Fig 3.5A, right). Given the differences in basal 
inclusion upon substitution of the ARS motif, I analyzed EHMT2 splicing in hnRNP L 
knockdown samples from a technician in the lab, Michael Mallory, to evaluate whether 
hnRNP L is responsible for promoting EHMT2-E10 inclusion. I found that knockdown of 
hnRNP L decreased basal inclusion of this exon (Fig 3.5B). The effect of hnRNP L as an 
enhancer of exon inclusion is consistent with the minigene mutational analysis that 
 
Figure 3.5 Identification of sequences and factors involved in EHMT2 splicing regulation. (A). Top, 
schematic of EHMT2 minigene annotated with the locations of the ARS and downstream CTCF sites that 
were substituted in the minigene mutational analysis. Left, graph of average % inclusion as determined 
by RT-PCR with minigene specific primers of the parental EHMT2 minigene and minigenes with either 
the CTCF or ARS sequences swapped for heterologous sequences. Right, graph of average fold 
activation (ratio of included to skipped isoform in stimulated over unstimulated conditions) as determined 
by RT-PCR (n=3 clones). (B) Left, western blot showing mock treated or knockdown of hnRNPL (from 
Cole et al. 2015). Right, corresponding graph of endogenous percent EHMT2-E10 inclusion as 
determined by RT-PCR in cells left unstimulated or activated with (PMA 48h). (C) Same as (B), but with 
CTCF knockdown (n=3). 
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demonstrated the ARS in EHMT2 serves as an enhancer, suggesting that hnRNP L may 
act through the ARS as in the case of CD45. 
 Next I knocked down CTCF to establish whether CTCF regulates EHMT2 
splicing given the functional role of the CTCF binding motif. Knockdown of CTCF caused 
only a minor decrease in exon 10 inclusion (Fig 3.5C). It is possible that the achieved 
levels of CTCF knockdown were not sufficient to see major changes in exon inclusion. 
This mutational analysis of EHMT2 identified sequences that were required for basal 
exon 10 inclusion and identified at least one splicing factor that contributes to overall 
basal levels of inclusion. However, neither motif impacted the activation-induced 
inclusion of EHMT2-E10 in T cells. 
 In parallel to the minigene sequence analysis I tested the biological 
consequences of alternative splicing of exon 10 on EHMT2 protein. The Euchromatic 
histone lysine N-methyltransferase (EHMT2) preferentially methylates Histone 3 at 
Lysine 9 (H3K9) via its catalytically active SET domain. EHMT2 thus plays a role in 
regulating gene expression by rearranging and controlling chromatin structure. Among 
the functional roles for EHMT2 are gene silencing of developmental and neuronal genes 
(Tachibana 2002; Roopra et al. 2004). EHMT2 is critical during embryogenesis as mice 
lacking EHMT2 are early embryonic lethal (Feldman et al. 2006). The role of EHMT2 in 
lymphocytes has been less explored. It was found that although EHMT2 was not 
essential for T-cell development as CD4+ and CD8+ T-cell numbers were unaffected in 
lymphocyte specific EHMT2-deficient mice (Thomas et al. 2008). However, a recent 
report highlighted that EHMT2 plays a critical role in the differentiation of adult peripheral 
CD4+ T-cell into Th cell lineages (Lehnertz et al. 2010). Specifically, Th cells lacking 
EHMT2 are impaired in their ability to differentiate into a Th2 phenotype and in their 
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ability to express cytokines IL-4, IL-5, and IL-13 that are markers of the Th2 subset of T 
cells. EHMT2 mediated activation of these cytokines is independent of its 
methyltransferase activity. Furthermore, EHMT2-deficient CD4+ T-cells were unable to 
protect against infection with a pathogen requiring Th2 responses. Together this 
evidence suggests that EHMT2 plays a role in modulating effector functions of adult 
peripheral blood T-cells.  
 To begin to characterize the functional differences between EHMT2 isoforms, I 
analyzed EHMT2 protein expression to determine if the splicing change was manifested 
at the protein level. Western blot analysis of EHMT2 protein in unstimulated and PMA-
activated Jurkat T cells shows a shift toward the longer isoform of EHMT2 upon PMA 
treatment (Fig 3.6A) consistent with increased exon 10 inclusion upon PMA treatment as 
quantified by RT-PCR (Fig 3.6B).  
 Since EHMT2’s most prominent role is as a lysine methyl transferase, we 
hypothesized that although the alternative exon 10 of EHMT2 lies at N-terminus, distal 
from the SET domain it could impact catalytic activity. To test this prediction, I utilized a 
splice site-blocking AMO to force EHMT2-E10 skipping, followed by PMA activation or 
left unstimulated (Fig 3.6C). The EHMT2 AMO forces robust exon skipping (Fig 3.6C), 
however has no specific effect on global H3K9 tri-methylation compared to a control 
AMO, as assessed by Western blot analysis with an H3K9me3-specific antibody (Fig 
3.6D). The analysis of H3K9 methylation was performed by Jiajun Zhu in Shelly Berger’s 
lab at Penn. 
 EHMT2 was shown to be required for appropriate expression of Th2 cytokines, 
the most prominent being IL-4 in a catalytically-independent manner. To test whether 
skipping of EHMT2-E10 altered IL-4 expression, I analyzed IL-4 mRNA levels by RT-
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PCR in the AMO-treated Jurkat cells in unstimulated and stimulated conditions.  As 
shown in Fig 3.6E, treatment with the EHMT2 AMO does not significantly alter IL-4 
mRNA levels compared to the control AMO in either condition.  
Figure 3.6 Analysis of functional impact of EHMT2 alternative splicing on known EHMT2 protein 
activities. (A) Representative western blot showing shift in EHMT2 isoform expression at the protein level 
upon PMA activation of Jurkat T cells. (B) Corresponding, RT-PCR quantification of average percent 
inclusion in unstimulated compared to PMA-activated Jurkat T cells. (C) Graph of average percent inclusion 
for Jurkat T cells transfected with a low (5nmol) and high (15nmol) dose of a control AMO against a splice 
site in an unrelated gene (Cont) or the AMO blocking the 3’ splice site of EHMT2 exon 10 (MKK7) in the 
presence and absence of PMA (48h). (D) Corresponding, Western blot analysis showing H3K9 methylation 
relative total H3. (E) RT-PCR analysis of IL-4 mRNA relative to actin mRNA in cells treated as in panel C 
(PMA 48h). 
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 I did not pursue EHMT2 splicing regulation further as I was unable to see any 
functional differences between EHMT2 splice variants in either global H3K9 methylation 
or expression of Th2 cytokines in Jurkat T cells, two known activities of EHMT2. It is 
possible that alternative splicing of EHMT2 impacts H3K9 methylation of specific genes 
or that the splicing event alters other EHMT2 functions.  
 
Discussion 
The results presented in this chapter were critical in the decision to pursue the study of 
MKK7 pre-mRNA splicing regulation. Importantly, I found that antisense splice site 
blocking morpholino oligos were an effective strategy to manipulate isoform expression 
and investigate the functional output of each isoform on protein activity and T cell 
activation. I further found that alternative splicing of MKK7, EHMT2, BRD8, ZC3H14 and 
NGLY1 did not alter the expression of known markers of T cell activation, including 
expression of cell surface markers CD69 and CD25. Furthermore, manipulating the 
isoform ratio of these events did not influence cell viability under unstimulated 
conditions.  
 The prioritization strategy outlined in these studies for selecting alternative 
splicing events allowed me to eliminate candidate genes and focus on alternative 
splicing of EHMT2 and MKK7 that could be studied in model systems. Since I was 
unable to find differences between EHMT2 isoforms in two known EHMT2 activities and 
I did not identify signal-responsive sequences in EHMT2, I decided to focus my thesis on 
the regulation of MKK7 alternative splicing. However, my findings support that alternative 
splicing of EHMT2 could play a role in the regulation of H3K9 methylation around 
specific genes or that it affects some of the other described functions of EHMT2 that are 
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independent of catalytic activity. Consistent with my finding that EHMT2-E10 inclusion 
does not affect global methylation levels, the Kornhblitt group observes no differences in 
the catalytic activity of the EHMT2 splice variants in neuronal cells, but rather sees an 
increase in the nuclear localization of the EHMT2 isoform that includes exon 10 
(personal communication). This EHMT2 isoform affects alternative splicing of EHMT2 
itself perhaps through increased H3K9 methylation around EHMT2-E10.  Similar to my 
results in T cells, they observe an increase in EHMT2-E10 inclusion during neuronal 
differentiation. Together, these results support that the splicing change in EHMT2 
following T cell activation may also serve to redirect EHMT2 to the nucleus to alter some 
of its regulatory activities. 
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CHAPTER 4: JNK-INDUCED ALTERNATIVE SPLICING OF MKK7 
GENERATES A POSITIVE FEEDBACK LOOP TO AMPLIFY JNK SIGNALING 
IN ACTIVATED T CELLS.  
 
Introduction 
As described in chapter 2, antigen-induced signaling through the T cell receptor (TCR) 
controls the splicing of hundreds of genes involved in a large array of T cell effector 
functions, including the secretion of cytokines and cytotoxins. I also find in chapter 2, 
that genes encoding signaling molecules are particularly enriched amongst targets of T 
cell activation-induced alternative splicing, suggesting a complex interplay of signaling 
and splicing. However, we still know little about the functional consequences of 
regulated splicing on specific signaling pathways (Martinez and Lynch 2013; Lynch 
2004).  
A particularly intriguing, but unexplored, example of alternative splicing of a signaling 
molecule is that of the gene encoding MAP kinase kinase 7 (MKK7, also called 
MAP2K7) (Chapter 2). MKK7 activates the c-Jun kinases JNK1 and JNK2 in response to 
T cell activation signals, leading to phosphorylation and activation of the c-Jun 
transcription factor that mediates T cell gene expression programs and cytokine 
expression (Fig 4.1A) (Tournier et al. 1997; Matsuda et al. 1998; Sasaki et al. 2001). 
Consistently, CD4+ T cells from MKK7 and JNK deficient mice fail to differentiate into 
appropriate T helper subsets or carry out appropriate effector functions (Dong et al. 
1998; 2000). Beyond T cells, JNK and MKK7 are broadly important kinases involved in 
cellular responses to stresses such as UV damage, oxidative stress, as well as cell 
growth and apoptosis in a variety of cell types (Wang et al. 2007; Haeusgen et al. 2011; 
Asaoka and Nishina 2010). 
 82 
 
In the global transcriptome analysis described in chapter 2, we detected that exon 2 
of MKK7 is amongst the many exons that are differentially included in response to 
activation of a cultured T cell line. As explained in chapter 3, I did not observe 
differences in the expression of T cell activation markers or cell viability as a result of 
modulating MKK7 splicing. However, MKK7’s best-described role is as a specific JNK 
kinase, which led me to hypothesize that alternative splicing MKK7-E2 could alter 
MKK7’s ability to activate JNK. MKK7 interacts with JNK1/2 through three canonical 
MAPK docking sites (Ho et al. 2006). Interestingly, inclusion of exon 2 disrupts the 
second, and highest affinity, docking site within MKK7 (Fig 4.3A,B). Based on our 
understanding of docking sites I predicted that the long isoform including exon 2 (MKK7-
L) would be less effective in activating JNK than the short isoform (MKK7-S), although 
the functional consequence of MKK7 exon 2 inclusion had not been directly studied, 
Moreover, the mechanism by which the MKK7-S isoform is generated is also unknown.  
In this chapter, I demonstrate that expression of MKK7-S increases upon activation 
of both cultured and primary human T cells, and that increased expression of MKK7-S 
enhances JNK docking interaction, JNK pathway activity and cytokine production. 
Remarkably, we find that, in turn, JNK activity is both necessary and sufficient to 
promote skipping of MKK7 exon 2 via TCR-initiated signaling. Thus, I identify a positive 
feedback loop involving alternative splicing in which initial signaling through the MKK7-
JNK pathway induces alternative splicing of MKK7 to enhance JNK pathway activity.  
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Results 
MKK7 is alternatively spliced in response to activation of primary human CD4+ T cells 
and a model Jurkat T cell line 
I previously detected signal-induced skipping of MKK7 exon 2 (MKK7-E2) during a 
transcriptome-wide analysis of splicing in a Jurkat T cell line stimulated with PMA, a 
commonly used mimic for antigen signaling in T cells (chapter 2) (Fig 4.1B). To confirm 
that MKK7 is also regulated in primary T cells I assessed inclusion of MKK7-E2 in 
primary human CD4+ T cells following activation with antibodies that engage the 
physiologic T cell surface receptors CD3 and CD28 (Fig 4.1B). Importantly, both the 
extent and time course of the change in MKK7-E2 inclusion between stimulated and 
unstimulated cells is highly similar in both Jurkat and primary T cells (Fig 4.1B, 4.2A), 
Figure 4.1. MKK7 is alternatively spliced in response to activation of primary human CD4+ T cells 
and a model Jurkat T cell line. (A) Schematic of JNK pathway activation in the context of T cell receptor 
signaling. (B) Left panel, representative RT-PCR gel and quantification of MKK7-E2 inclusion in 
unstimulated and activated (anti-CD3/CD28, 48 h) primary human CD4+ T cells (n=9). Right panel, 
representative RT-PCR gel and quantification of MKK7-E2 inclusion in unstimulated and activated (PMA, 
48h) Jurkat T cells (n=14). Throughout all figures, error bars represent standard deviation. P < 0.005, 
student’s t-test. 
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suggesting a common mechanism of regulation in these related cell types.   
 
Alternative splicing of MKK7 positively regulates JNK signaling  
Given the conserved regulation of MKK7 splicing upon activation of both primary and 
cultured T cells, and the role of JNK signaling in T cell biology, I wanted to determine the 
functional relevance of this isoform switch. I predict skipping of exon 2 increases MKK7’s 
ability to activate JNK by generating a smaller isoform that contains a more optimal JNK 
docking site (MKK7-S, Fig 4.2B, 4.3A,B). Consistently, I find that the MKK7-S co-
precipitates with JNK1 more efficiently than MKK7-L in co-transfection studies (Fig 
4.3C).  
 
Figure 4.2. MKK7 is alternatively spliced with similar kinetics in primary human CD4+ T cells and a 
model Jurkat T cell line. (A) Time course of average MKK7-E2 inclusion in response to (left) activation 
(anti-CD3/CD28) in primary human CD4+ T cells or (right) activation (PMA) in Jurkat T cells as quantified by 
RT-PCR (n=3). (B) MKK7 domain schematic displaying the predicted outcome of MKK7-E2 inclusion on its 
MAPK docking site.  
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To directly test the functional consequence of MKK7-E2 skipping I used a splice site 
blocking antisense morpholino oligo (AMO) complementary to the 5’ splice site of MKK7-
E2 (Fig 4.4A). Although the minimal size difference between MKK7-L and MKK7-S 
proteins precludes their discrimination by Westerns, by RT-PCR I confirmed that 
transfection of the AMO results in forced skipping of MKK7-E2 and preferential 
production of the MKK7-S isoform (Fig 4.4B). To activate JNK signaling, MKK7 needs to 
Figure 4.3. Details of MKK7 docking site. (A) The nucleotide and encoded protein sequence of MKK7 
Exon 2 (red brackets) and two halves of the second docking site (black boxes). (B) Consensus sequence of 
MAPK docking sites. (C) Western blot of FLAG-tagged MKK7-L and MKK7-S co-associated with c-myc-
tagged JNK1 following immunoprecipitation with anti-c-myc from lysates of co-transfected HEK293 cells.  
Lysate input (IN) and precipitated material (IP) are both shown. 
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be phosphorylated and activated by an upstream kinase, such as TAK1, before 
activating JNK (Fig 4.1A) (Blonska et al. 2007; Wan et al. 2006). Consequently, I find no 
phosphorylation of the JNK-target c-Jun in unstimulated cells, even in the presence of 
the AMO (Fig 4.4C). However, AMO treatment results in a marked increase in c-Jun 
phosphorylation when MKK7 has been activated by PMA (Fig 4.4C). Furthermore, I 
observe a 3-fold increase in TNF-alpha mRNA, a target of c-Jun mediated transcription 
Figure 4.4. Alternative splicing of MKK7 positively regulates JNK signaling (A) Schematic of the MKK7 
5’ splice site blocking AMO on the pre-mRNA and it’s effect on the MKK7 protein. (B) Representative RT-
PCR gel of MKK7-E2 and average percent inclusion (n>3) for Jurkat T cells transfected with a control AMO 
against a splice site in an unrelated gene (Cont) or the AMO blocking the 5’ splice site of MKK7 exon 2 
(MKK7) in the presence and absence of PMA (48h). (C) Corresponding western blot of Jurkat T cells treated 
as in panel b, blotted for phospho-c-Jun (Ser73), total c-Jun and total MKK7 (PMA 2h). (D) Quantification of 
TNF-alpha mRNA normalized to B2M by RT-PCR (n=4) in cells treated as in panel b (PMA 48h). Error bars 
represent standard deviation. * P < 0.005, student’s t-test. 
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(Tsai et al. 1996b; 1996a; Lawrence et al. 2011), in activated cells that have been 
treated with the MKK7 AMO (Fig 4.4D). Importantly, the increased c-Jun phosphorylation 
and TNF-alpha expression cannot be attributed to increased MKK7 protein, as the AMO 
does not alter total MKK7 protein levels (Fig 4.4C). Together, these data demonstrate 
that skipping of MKK7-E2 generates an isoform that is more effective in activating JNK 
and enhancing JNK pathway activity, including increased c-Jun activation and up-
regulation of the immune cytokine TNF-alpha.  
	  
JNK activity is necessary and sufficient for activation-induced MKK7-E2 skipping 
Having determined the functional significance of MKK7 alternative splicing, I next sought 
to identify the signaling pathway that triggers repression of MKK7-E2. Multiple signaling 
pathways are activated both downstream of antigen engagement in T cells and upon 
PMA stimulation of Jurkat cells, including those involving Erk, Akt, mTOR and JNK 
(Smith-Garvin et al. 2009; Harris and Lawrence 2003; Zheng et al. 2007; Su et al. 1994). 
Strikingly, amongst these signaling pathways, only inhibition of JNK signaling blocks 
PMA-induced MKK7-E2 skipping (Fig 4.5A). By contrast, inhibition of the Erk (DeSilva et 
al. 1998), Akt (Yang et al. 2004) and mTOR (Brown et al. 1994) pathways have no 
significant effect on PMA-induced repression of MKK7-E2 (Fig 4.5A). Consistent with 
previous reports (Jin et al. 2009), I do observe that the JNK inhibitor used (SP600125) 
partially inhibits mTOR, as indicated by a decrease in phospho-S6K. However, since 
direct inhibition of mTOR with rapamycin has no effect on MKK7-E2 repression (Fig 
4.5A), I conclude that the effect of SP600125 on MKK7-E2 splicing is not mediated via 
mTOR. I also find that inhibition of GSK3 signaling, previously shown to be responsible 
for the PMA-induced regulation of CD45 alternative splicing in Jurkat and primary T cells 
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(Heyd and Lynch 2010), has no effect on MKK7-E2 inclusion (Fig 4.6A). 
 Importantly, SP600125 blocks activation-induced MKK7-E2 skipping in a dose 
dependent manner, plateauing near 50 µM, consistent with the cellular IC50 for this 
compound (Fig 4.5B) (Bennett et al. 2001). Moreover, inhibition of JNK in primary human 
CD4+ T cells is also sufficient to significantly block the anti-CD3/CD28 enhanced 
Figure 4.5. JNK activity is necessary for activation induced MKK7-E2 skipping (A) Top, average 
percent MKK7-E2 inclusion (n=3) in Jurkat T cells pre-treated with the following inhibitors prior to PMA 
treatment: JNKi (SP600125 50µM), MEKi (U0126 20µM), Akti (Triciribine 1µM) or mTORi (Rapamycin 
100nM). Bottom, western blot analysis of downstream substrates: phospo-c-Jun (JNK), phospho-Erk (MEK), 
phospho-S6K (mTOR), the Akt activating auto-phosphorylation site Ser473 (Akt) and hnRNPL as a loading 
control. Protein samples were harvested 2 h after PMA, while RNA was harvested after 48 h. Note that the 
samples from mTOR inhibition were run on the same gels as the other samples but with a spacer lane that 
has been removed. (B) Average MKK7-E2 inclusion (n=3) with 12.5µM, 25µM, 50µM and 100µM JNK 
inhibitor SP600125 prior to PMA treatment (48h) (C) Average MKK7-E2 percent inclusion (n=2) of primary 
human CD4+ T cells treated with JNK inhibitor SP600125 and/or anti-CD3/CD28 (48h). See also Fig S2B. 
(D) Average percent MKK7-E2 inclusion (Top) and western analysis (Bottom) in two independent Jurkat T 
lines depleted of JNK by an shRNA grown in the absence or presence of PMA (48h). * P < 0.005, student’s 
t-test. 
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repression of MKK7-E2 (Fig 4.5C, 4.6B). Finally, as an additional test of the requirement 
for JNK in the regulation of MKK7 splicing Michael Mallory, a techinician in the lab, 
helped generate stable Jurkat T cell lines expressing a small hairpin RNA targeting JNK. 
As shown by Western blot, JNK2 and at least one isoform of JNK1 are dramatically 
depleted from the cells expressing the JNK shRNA (Fig 4.5D, bottom). While I cannot 
differentiate whether JNK1 or JNK2 are the primary drivers, I find that JNK depletion in 
Jurkat cells largely abrogates MKK7-E2 repression in response to PMA activation (Fig 
4.45, top). I thus conclude based on both genetic and pharmacologic studies, that JNK 
signaling is necessary for antigen- promoted skipping of MKK7-E2. 
To determine if JNK activity is also sufficient to promote MKK7-E2 skipping I 
expressed constitutively active JNK1 or JNK2 (CAJNK1/2) (Lei et al. 2002) in HEK293 
cells, as these cells are more amenable to transient transfection and protein expression 
than Jurkat cells. Inclusion of MKK7-E2 in untransfected HEK293 cells is less than that 
observed in unstimulated Jurkat cells, but is still readily detectable (Fig 4.7A). Strikingly, 
the presence of either FLAG-tagged CAJNK1 or CAJNK2 is sufficient to completely 
inhibit inclusion of MKK7-E2 (Fig 4.7A). Expression of CAJNK1 and CAJNK2 similarly 
Figure 4.6. Further data on signaling requirements for MKK7 alternative splicing (A) Inclusion of MKK7 
exon 2 in Jurkat cells left unstimulated (resting), stimulated with PMA, which inhibits GSK3, or in which GSK3 
is directly inhibited with the small molecule SB216763. (B) Representative RT-PCR gel of splicing of MKK7 in 
human CD4+ T cells treated with (+) and without (-) anti-CD3/CD28 stimulating antibodies in the absence (-) 
or presence (+) of the JNK inhibitor SP600125.  
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induce the expected activity as assessed by c-jun phosphorylation (Fig 4.7B). The 
induced skipping of MKK7-E2 is observed even at the lowest amounts and activity of 
CAJNK1 detectable (Fig 4.7C). Thus, I conclude that JNK signaling is both necessary 
and sufficient for MKK7 alternative splicing. Moreover, the fact that JNK signaling is 
sufficient to induce MKK7-E2 skipping in HEK293 cells highlights that the regulation of 
MKK7 by JNK is not cell type specific, but rather is a general feature of this signaling 
pathway. 
	  
Discussion 
Previous studies have established that alternative splicing is widely regulated in 
response to various cell stimuli, such as T cell activation (Martinez and Lynch 2013; Fu 
and Ares 2014). Conversely, genes encoding signaling proteins are themselves subject 
to such regulation (Martinez and Lynch 2013), implying reciprocal regulation between 
signaling and splicing. However, specifics regarding the signaling pathways that connect 
Figure 4.7. JNK activity is sufficient to induce activation induced MKK7-E2 skipping. (A) 
Representative (n=3) RT-PCR gel of MKK7-E2 inclusion (Top) and corresponding western analysis of 
FLAG-CAJNK expression (bottom) from HEK293 cells transfected with vector control or constitutively active 
JNK1 and 2 (CAJNK1 or CAJNK2). (B) Western blot of phospho-c-Jun, as a marker for activity of CAJNK1 
and CAJNK2 in transfections shown in panel A. (C) Same as panel E but with 0.01µg, 0.1µg and 1µg of 
CAJNK1. Phospho-c-Jun, as a marker for CA-JNK activity, is also shown. Error bars represent standard 
deviation. 
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T cell activation to alternative splicing, and the functional consequences of signal-
induced splicing changes, remain poorly characterized. In this chapter I identify one 
target of JNK-dependent splicing, that of the JNK-kinase MKK7. Specifically, I show that 
JNK activation is necessary and sufficient for MKK7 alternative splicing and that MKK7 
alternative splicing, in turn, augments JNK signaling creating a positive feedback loop.  
Negative feedback loops involving alternative splicing have previously been 
reported. For example, activation of the IL-1 receptor promotes expression of a small 
isoform of Myd88 that in turn negatively regulates IL-1 (Janssens et al. 2002; 2003). 
There are also examples of indirect feed-forward loops, such as Ras-mediated inclusion 
of CD44 exon 6 to generate an isoform that serves as a co-receptor for growth factors 
that in turn trigger Ras signaling (Cheng 2006). By contrast, I have identified here a 
direct positive feedback loop in which signaling through JNK promotes alternative 
splicing of its upstream kinase MKK7. The increase in c-Jun phosphorylation and TNF-
alpha expression upon forced MKK7-E2 skipping, together with the fact that this splicing 
event peaks at around 48 hours following T cell activation, strongly suggests a role for 
alternative splicing of MKK7 in propagating JNK signaling and augmenting T cell effector 
functions following initial activation. Thus, the interplay of JNK and MKK7 provides both 
a new type of connectivity between signaling and splicing and one that is critical for full T 
cell responses.  
MKK7 alternative splicing also highlights the breadth of mechanisms through which 
splicing can modulate kinase activity. In the examples of A-Raf, IRAK1, and TrkB/C, the 
kinase domain itself is subject to alternative splicing (Tsuzaka et al. 2003; Rauch et al. 
2011; Jensen and Whitehead 2001; Middlemas et al. 1991; Allen et al. 1994; Tsoulfas et 
al. 1996; Esteban 2006; Palko et al. 1999). By contrast, inclusion of alternative exons 
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encoding the C-terminus of ROCK2 during muscle differentiation causes inhibition of a 
distal kinase domain (Singh et al. 2014). Moreover, cancer cells express a spliced form 
of the MAP kinase MNK2 that lacks its docking domain (Maimon et al. 2014). This 
docking domain deficient isoform of MNK2 was shown to be oncogenic as it is unable to 
activate the downstream kinase p38 (Maimon et al. 2014). I now show that alternative 
splicing of MKK7 favors MKK7-S, the isoform with an intact MAPK docking domain that 
interacts more effectively with JNK and activates downstream signaling. The discovery 
of alternative splicing to modulate MAPK docking sites in both MNK2 and MKK7 
suggests that this may be a common mechanism to regulate MAPK activity.  
In summary, in this chapter I show that an important functional consequence of JNK 
signaling is amplification of its own activity through inducing alternative splicing of MKK7. 
I demonstrate that during T cell activation the JNK signaling pathway has a new role, in 
addition to its established role in transcriptional regulation, in the control of gene 
expression through promoting alternative splicing.  
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CHAPTER 5: JNK-DEPENDENT UPREGULATION OF CELF2 REGULATES 
ALTERNATIVE SPLICING OF MKK7 DURING T CELL ACTIVATION  
 
  
Introduction 
In chapter 4, I demonstrate that in response to T cell activation, the JNK-kinase MKK7 is 
alternatively spliced to favor an isoform that lacks exon 2. This isoform restores a JNK 
docking site within MKK7 that is disrupted in the larger isoform. Consistently, I show that 
skipping of MKK7 exon 2 enhances JNK pathway activity, as indicated by c-Jun 
phosphorylation and up-regulation of TNF-alpha. Moreover, this splicing event is, itself, 
dependent on JNK signaling. Thus, MKK7 alternative splicing represents a positive 
feedback loop through which JNK promotes its own signaling. The mechanisms 
controlling alternative splicing of MKK7 and hence the positive feedback loop in JNK 
signaling is unknown. 
Alternative splicing is typically controlled by cis-regulatory elements within the 
alternative exon and/or flanking introns (Fu and Ares 2014). These regulatory elements 
commonly serve as binding sites for trans-acting proteins that can promote or repress 
alternative exon inclusion, including members of the SR and hnRNP families of proteins, 
as well as additional RNA binding proteins such as CELF, MBNL and RbFox proteins 
(Fu and Ares 2014). However, there have been no studies linking any of these proteins 
to MKK7 splicing, nor information regarding how T cell signaling regulates this process. 
In this chapter I further characterize the mechanistic basis for JNK-dependent 
repression of MKK7 exon 2, demonstrating the critical role of the intronic sequences 
flanking exon 2 and recognition of these regulatory elements by JNK-induced CELF2. 
Finally, we show that JNK signaling mediates activation-induced alternative splicing not 
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just of MKK7, but of approximately a quarter of TCR-induced splicing surveyed in 
primary human CD4+ T cells, thus serving as a widespread mechanism for controlling 
gene expression. Strikingly, JNK-induced splicing events are significantly enriched for 
responsiveness to CELF2, supporting a pervasive role for the JNK-CELF2 signaling arm 
in the regulation of gene expression in response to T cell activation.  
 
Results 
MKK7 intronic sequences are required for activation-induced skipping of exon 2 
I next sought to determine the molecular mechanism by which T cell activation leads to 
skipping of MKK7-E2. As a first step to identifying the sequences and trans-acting 
factors by which MKK7 is regulated in response to T cell activation, I made a chimeric 
MKK7 minigene containing MKK7-E2 and about a hundred nucleotides of the flanking 
introns, inserted between exons from the heterologous beta-globin gene ((Fig 5.1A, 
5.2A) and is also shown in chapter 3 (Fig 3.4)). The minigene was transfected into Jurkat 
T cells and inclusion of MKK7-E2 was quantified by RT-PCR with minigene specific 
primers. This minigene (MKK7) recapitulates the activation-induced MKK7-E2 skipping 
observed in the endogenous gene (eMKK7, Fig 5.1A,B), and exhibits a similar level of 
basal inclusion in unstimulated cells (Fig 5.2B). Swapping out the exonic or intronic 
sequences from MKK7 with those from the beta-globin gene demonstrates that the 
introns alone are sufficient for activation-induced skipping of a constitutive heterologous 
exon, while the exonic sequence does not seem to contain any signal-responsive 
element (Introns, Fig 5.1A,B). A control minigene containing the heterologous exon 
placed between beta-globin introns shows that this exon does not contribute to the 
signal-responsiveness (Control, Fig 5.1A,B). Strikingly, I find that replacing the upstream 
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or downstream intron with a corresponding beta-globin intron abrogates MKK7-E2 
skipping in activated cells, suggesting that the MKK7 introns act cooperatively (Up or 
Down, Fig 5.1A,B). Together, these results demonstrate that ~100 nucleotides of the 
upstream and downstream introns are necessary and sufficient to enhance MKK7-E2 
skipping in activated cells. 
Trans-acting factors recognize the regulatory intronic sequences 
To identify proteins that bind in trans to the MKK7 introns I performed UV crosslinking 
with radiolabeled in vitro transcribed RNA including MKK7-E2 and the flanking introns, 
and nuclear extract made from unstimulated (-PMA) and activated (+PMA) Jurkat T 
cells. Strikingly, I observe a dramatic difference between these two extracts in the 
binding pattern of 4 protein bands on an SDS-PAGE gel (Fig 5.3A). Three of these 
proteins exhibit stronger binding in the activated versus unstimulated extracts, while the 
fourth protein is enriched in the unstimulated condition. At least one additional protein 
Figure 5.1 MKK7 intronic sequences are required for activation-induced skipping of exon 2. (A) 
Schematic of MK7 minigenes. MKK7 sequences are orange and beta-globin sequences are gray. (B) Graph 
of average fold repression (ratio of included to skipped isoform in stimulated over unstimulated conditions) 
as determined by RT-PCR of MKK7 minigenes with minigene specific primers.  
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binds with similar intensity in activated relative to unstimulated nuclear extracts (Fig 
5.3A). Importantly, UV crosslinking with the intronic sequences that are necessary and 
sufficient for activation-induced skipping reveal the same binding pattern as with the 
same construct that includes MKK7-E2, while a construct lacking these introns lacks the 
binding pattern (Fig 5.3A). These results are consistent with our minigene data, showing 
that both intronic sequences are important for signal-responsive regulation, while exon 2 
is dispensable.  
 To determine the identity of the proteins associating with the MKK7 introns, I 
performed the UV crosslinking assay followed by immunoprecipitation of candidate 
proteins. Candidates were chosen based on the size of the crosslinked species and the 
Figure 5.2. MKK7 sequences and minigene information. (A) Sequences of endogenous MKK7 that are 
included in the various minigenes. In black are the sequences of the upstream ~100 nucleotides and the 
downstream ~80 nucleotides introns flanking exon 2. In red are is the sequence of MKK7 exon 2. (B) Graph 
of average percent basal exon inclusion of MKK7 minigenes as determined by RT-PCR, n=3 and error bars 
represent standard deviation. 
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sequences of the MKK7 introns (Fig 5.3A, 5.2A). By this method I identified the four 
differential MKK7 intron binding proteins as CELF2 (50kD), hnRNPC (40kD), HuR 
(30kD) and SRp20 (20kD) (Fig 5.3B). As predicted from the total binding pattern, binding 
of CELF2 and SRp20 increases; binding of hnRNP C decreases; and binding of HuR is 
similar in activated compared to unstimulated nuclear extracts (Fig 5.3B). Importantly, 
antibodies to several additional potential candidates, including PSIP1, hnRNPA1, 
hnRNPE, SRSF1 and 9G8 do not precipitate any bound species (Fig 5.3B and data not 
shown).  
 
Figure 5.3. MKK7 intronic sequences recruit RNA-binding proteins. (A) UV crosslinking with nuclear 
extracts from Jurkat T cells (–/+ PMA, 60 h) to radiolabeled in vitro transcribed MKK7 RNAs, followed by 
RNase digestion and resolution on an SDS-PAGE. Note that (+PMA) sample for the MKK7 construct was 
run on the same gel as the (–PMA) sample but with a spacer lane that has been removed. (B) 
Immunoprecipitation of UV crosslinking reactions of the introns construct in panel A after RNase digestion 
with antibodies shown.  
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 As an additional approach to identify proteins bound to the MKK7 intronic sequences 
I performed an RNA affinity purification experiment followed by mass spectrometry (Fig 
5.4A). We filtered the list for proteins with at least 10 spectral counts across conditions 
and sorted based on fold change in activated compared to unstimulated extract (Table 
A2.1). Remarkably, the top induced binding protein from the mass spectrometry list is 
CELF2, consistent with the observed binding pattern by UV crosslinking. Furthermore, 
hnRNPC, HuR and SRp20 were also identified in this list. A western blot of the RNA 
affinity purification experiment confirmed the increase in CELF2 protein in activated 
nuclear extract compared to HuR which is not induced in activated nuclear extract, 
supporting the mass spectrometry analysis (Fig 5.4B). Subsequent UV crosslinking IP 
and western blot analysis of RNA affinity purification experiments failed to validate any 
other proteins other than CELF2, hnRNPC, HuR and SRp20 (Table A2.1).  
Figure 5.4. RNA affinity purification of MKK7 introns. (A) Schematic of RNA affinity purification 
experiment. RNA containing the MKK7 introns or the control RNA (from Fig 4A) were biotinylated, incubated 
with unstimulated or PMA stimulated nuclear extracts, and isolated by streptavidin-agarose. Following 
washing the entire reactions were submitted for mass spectrometry. (B) Western blot of CELF2 and HuR 
from RNA affinity purification of the MKK7 introns. See also Table 5.1. 
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JNK induces CELF2 protein expression through mRNA stabilization, which drives 
activation-induced skipping of MKK7-E2 
 Having identified several proteins that bind differentially to the MKK7 introns in 
activated compared to unstimulated states, I sought to determine if any of these proteins 
drives activation-induced skipping of MKK7-E2 in the endogenous gene. I therefore 
knocked down each of the proteins that bind to the MKK7 intronic regulatory sequences 
and examined endogenous MKK7-E2 inclusion levels by RT-PCR (Fig 5.5 A-D). We find 
that depletion of HuR, SRp20 or hnRNP C result in only modest changes in the inclusion 
of MKK7-E2 (Fig 5.5A-C). In stark contrast, knockdown of CELF2 with either of two 
shRNAs targeted to distinct sequences dramatically increases basal inclusion levels of 
MKK7-E2, and abolishes activation-induced skipping (Fig 5.5D, 5.7A).  
 As a complementary approach I tested if an increase in CELF2 protein is sufficient to 
promote skipping of MKK7-E2 through the identified intronic binding sites, by co-
expressing CELF2 cDNA and the MKK7 miningenes in HEK293 cells. Notably, 
overexpression of CELF2 is sufficient to promote exon skipping of the parental MKK7 
Figure 5.5. The MKK7 inton-binding protein CELF2 is necessary for activation-induced skipping of 
MKK7-E2. (A-D) Top, western blot showing mock treated or knockdown of each MKK7 intron binding protein 
left unstimulated or activated with (PMA 48h) n=3. Bottom, graph of endogenous percent MKK7-E2 inclusion 
as determined by RT-PCR for corresponding knockdown. (A) HuR knockdown. (B) SRp20 knockdown. (C) 
hnRNPC knockdown. (D) CELF2 knockdown.  
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minigene (Figure 5.6A). Moreover, I find that the repressive activity of CELF2 is 
mediated through the introns, with no effect on MKK7-E2 itself or the control minigene 
(Figure 5.6A). We therefore conclude that CELF2 acts as a primary repressor of MKK7-
E2 inclusion. 
 We have previously shown that CELF2 protein expression increases following T cell 
activation, and that inhibition of the Erk pathway does not impact this response (Mallory 
et al. 2011; 2015). Strikingly, however, JNK knockdown or inhibition markedly diminishes 
the increase in CELF2 protein expression that is observed upon activation with PMA, 
with little or no effect on the protein levels of the other MKK7 intron binding proteins (Fig 
5.6B, 5.7B). Importantly, the decrease in CELF2 upon JNK knockdown or inhibition 
correlates with a decrease in CELF2 mRNA levels (Fig 5.8A). We have recently 
published that the TCR-signaling induced expression of CELF2 is driven by two 
mechanisms; an initial increase in transcription followed by an increase in the stability of 
the CELF2 mRNA via a yet-unknown pathway (Mallory et al. 2015). We have also shown 
Figure 5.6 JNK induces CELF2 protein expression, which drives activation-induced skipping of 
MKK7-E2. (A) Top, RT-PCR analysis of MKK7 minigenes that were co-transfected with FLAG-CELF2 in 
HEK293 cells. Bottom, corresponding western blot for CELF2 overexpression. (B) Representative western 
blot analysis of proteins that bind MKK7 introns in wildtype Jurkat cells or Jurkat cells depleted of JNK by 
shRNA grown under unstimulated conditions or activated with PMA (48 h). See also Figure 5.6.  
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that the increase in transcription is not sensitive to JNK inhibition (Mallory et al. 2015). 
Therefore, I hypothesized that JNK may be regulating CELF2 protein expression through 
controlling stabilization of the CELF2 mRNA. Consistently, upon inhibition of 
transcription with actinomycin, Michael Mallory observes that JNK depletion or inhibition 
blocks the increase in message stability that is induced upon PMA activation of cells, 
bringing CELF2 mRNA to unstimulated levels (Fig 5.8B). In sum, I conclude that upon T 
cell activation a JNK-dependent increase in CELF2 mRNA stability results in an increase 
in CELF2 protein. Moreover, this increase in CELF2 protein is sufficient to account for 
increased binding of CELF2 to the MKK7 intronic regulatory sequences to repress 
MKK7-E2 inclusion. 
 
 
  
Figure 5.7. CELF2 protein expression. (A) RT-PCR analysis of independent Jurkat T lines depleted of 
CELF2 with two distinct shCELF2 targeting sequences CELF2 A and CELF2 B. The averages from these 
two targeting sequences are presented in Figure 5D. (B) Representative western blot analysis of total 
expression of proteins that bind MKK7 introns in Jurkat T cells that have been left unstimulated, activated 
with PMA or activated in cells that have been pre-treated the JNK inhibitor SP600125. See also Figure 5F. 
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JNK signaling mediates a network of TCR-induced alternative splicing in primary T cells 
The JNK-dependent control of MKK7-E2 skipping raises the question of whether JNK 
signaling is a dedicated pathway for regulated splicing of MKK7 in the context of the 
positive feedback loop, or whether JNK has a broader role in regulating TCR-induced 
splicing. I thus wanted to test JNK-dependent splicing changes in the physiological 
context of signal transduction initiating at the TCR in primary human T cells. As these 
cells are not readily amenable to genetic manipulation I took advantage of the widely-
used JNK inhibitor SP600125 (Bennett et al. 2001) to identify antigen-induced alternative 
splicing events that require JNK signaling in primary human T cells. To query 
widespread JNK-dependent splicing changes I used RNA-mediated oligonucleotide 
annealing, selection and ligation coupled with sequencing (RASL-seq) (Zhou et al. 2012; 
Li et al. 2001) on RNA from primary CD4+ T cells that were unstimulated, stimulated with 
anti-CD3 and CD28 or pretreated with the JNK inhibitor prior to stimulation with anti-CD3 
and CD28. The RASL-seq protocol was performed on my CD4+ T cell samples by our 
collaborators Jinsong Qiu and Xiang-dong Fu. This method uses primers complementary 
Figure 5.8 JNK signaling stabilizes CELF2 mRNA. (A) Quantification of total CELF2 mRNA normalized to 
actin in Jurkat T cells that have been left unstimulated, activated with PMA (48h) or activated in cells in 
which JNK is depleted (shJNK) or inhibited (JNKi, SP600125). Quantification was done by RT-PCR, n=3. (B) 
Quantification of CELF2 mRNA following actinomycin-induced inhibition of transcription in Jurkat T cells that 
have been left unstimulated, activated with PMA (48h) or activated in cells in which JNK is depleted (shJNK) 
or inhibited (JNKi, SP600125). 
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to sequences at ~5600 alternative spliced junctions to quantify changes in isoform ratio 
between two conditions. Focusing on the events for which we obtained an average of 
>10 reads across samples (~3000 events, Table S2 from Martinez et al. 2015 in press), 
we identified those that have an absolute differential inclusion (change in percent spliced 
isoform or ΔPSI) of greater than 10 comparing unstimulated to anti-CD3/CD28 
stimulated conditions (|PSIunstim-PSIαCD3/CD28|>10, p<0.05, paired t-test). This analysis 
yielded 420 anti-CD3/CD28-responsive alternative exons (Table A1.2, Fig 5.7A, B). This 
number of antigen-induced splicing events in primary human CD4+ T cells is consistent 
with our previous reports that ~10-15% of known alternative exons exhibit altered 
splicing upon activation of Jurkat cells (Ip et al. 2007; Martinez et al. 2012), and greatly 
expands our knowledge of the overall scope of alternative splicing in normal human T 
cells. 
To quantify the effect of JNK inhibition on anti-CD3/CD28-induced alternative splicing 
I next identified from among the list of 420 anti-CD3/CD28-responsive events those that 
showed a significant difference (|ΔPSI| >10, p<0.05) when treated with anti-CD3/CD28 in 
the absence versus presence of the JNK inhibitor. This led to the identification of 99 
alternative splicing events for which JNK inhibition significantly reduces stimulation-
responsive changes in splicing (“JNK dependent”; Fig 5.9A, Table A2.2). For the majority 
of these 99 events the magnitude of the JNK-dependence is similar to the magnitude of 
the CD3/CD28-induced change (Fig 5.9B, Table A2.2, pearson’s r=0.94, p<1.3e-51). 
Thus, I conclude that approximately 25% of the splicing changes induced upon TCR 
signaling are primarily driven through the JNK signaling pathway. The specific 
dependence of these events on JNK signaling is underscored by a parallel analysis with 
the GSK3 pathways that we have previously implicated in T cell signal-induced splicing 
(Heyd and Lynch 2010), in which we find that only a fifth of the JNK-dependent exons 
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are also responsive to GSK3 (Fig 5.9C, Table A2.2).  
Gene ontology analysis reveals that JNK-dependent alternative splicing events are 
Figure 5.9. JNK signaling mediates a network of TCR-induced alternative splicing in primary T cells. 
(A) Venn diagram  and (B) Heat map of total significant alternative splicing events induced by anti-
CD3/CD28 (48h) and those dependent on JNK. Anti-CD3/CD28 sensitivity and JNK dependence are as 
defined in text. Color scale for heat map is on left. See also Table S3. (C) Pie chart comparing JNK-
dependent versus GSK3-sensitive anti-CD3/CD28 induced events. See also Table S3. (D) GO terms and 
KEGG Pathways enriched (p-value < 0.05) in significant JNK-dependent alternative splicing events as 
determined by DAVID analysis. (E) Scatter plot comparing RASL-seq calculated changes in isoform 
expression versus that determined by RT-PCR. (F) Representative RT-PCR gel of RASL-Seq identified 
JNK-dependent alternative splicing events upon inhibition of JNK with either SP600125 and IN-8. Percent 
inclusion (% inc) is the average of three independent experiments. See also Figure S7. 
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enriched for spliceosomal components and mRNA binding/processing activity, as 
compared to the ~3,000 genes queried by RASL-Seq. Additional categories involved in 
gene regulation, such as chromatin-related factors, metal ion binding proteins and 
transcription factors, are also enriched amongst JNK-dependent genes (Fig 5.9D, Table 
A2.3, A2.4A). This “JNK-dependent” gene ontology enrichment is distinct from the 
“GSK3-dependent” enrichment (Table A2.4A,B), consistent with JNK and GSK3 
controlling different target genes. Importantly, 11 of 14 RASL-seq identified JNK-
dependent alternative splicing events were also observed in RT-PCR assays (Fig 
5.9E,F, Fig 5.8); while the other three events show a more modest JNK-dependence by 
RT-PCR but still trending with the RASL-seq data (Fig 5.10A,B). I performed these RT-
PCR assays with help from my summer student Laura Agosto. This high correlation 
between RASL-seq and RT-PCR (R2= 0.80, Fig 5.7E) is consistent with other studies 
employing RASL-seq (Zhou et al. 2012; Shao et al. 2014). We further confirmed the 
JNK-dependence of these events with a second highly selective JNK inhibitor (JNK-IN-8) 
that covalently inhibits JNK through a distinct mechanism than SP600125 (Zhang et al. 
2012). Importantly, we find that for 10 of the 10 JNK targets tested, the antigen-induced 
splicing change is equally inhibited by either SP600125 or JNK-IN-8 (Fig 5.9F, Fig 
5.10C). Michael Mallory performed RT-PCR analysis of the JNK target genes in samples 
from Jurkat T cells treated with JNK-IN-8.  Together our data demonstrate that JNK 
serves as a broad regulator of alternative splicing in T cells, which is likely to influence a 
wide range of cellular functions in addition to amplification of its own signaling pathways 
through the alternative splicing of MKK7. 
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Figure 5.10. RASL-Seq and RT-PCR data on JNK-dependent splicing in primary human CD4+ T cells. 
(A) Isoform expression change of 14 genes upon treatment of primary human CD4+ T cells with anti-
CD3/CD28 in the presence or absence of the JNK inhibitor SP600125. Delta PSI values are calculated as 
the difference between percent expression of the longest isoform relative to total in cells treated with anti-
CD3/CD28 alone minus that in cells treated with anti-CD3/CD28 in the prencese of the JNK inhibitor. The 
absolute inclusion values calculated by RT-PCR are also given. (B) Representative RT-PCR gels for data 
shown in panel A. Final numbers presented in panel A are derived from triplicate RT-PCR experiments.  
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Figure 5.10. RASL-Seq and RT-PCR data on JNK-dependent splicing in primary human CD4+ T 
cells. (C) Graphs show the average percent inclusion and standard deviations from 3 primary human CD4+ 
T cell donors treated with anti-CD3/CD28 in the presence or absence of the JNK inhibitor SP600125 or 
JNK-IN-8.  
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JNK signaling and CELF2 co-regulate alternative splicing in T cells 
Interestingly, I noticed that among the JNK-dependent alternative splicing events 
were genes that we have previously found to be regulated by the splicing factor CELF2 
((Mallory et al. 2015), Fig 5.11A). In particular, I find that about a third of JNK-dependent 
splicing events overlap with our recently published set of CELF2-regulated exons 
((Mallory et al. 2015), Fig 5.11A). Our published set of CELF2-regulated exons used a 
high threshold for CELF2-dependence to limit false-positives (Mallory et al. 2015); 
therefore, we recognize that we may be under-estimating the number of JNK-responsive 
exons that are sensitive to CELF2. We thus asked our collaborators Matthew Gazzara 
and Yoseph Barash to utilize the AVISPA algorithm (Barash et al. 2013; Gazzara et al. 
2014) to identify motifs enriched among all JNK-responsive events (Table A1.2) relative 
to the alternative cassette exons queried by RASL-seq that are not responsive to JNK 
(|ΔPSI|<3 and p>0.5, Table 5.2). Remarkably, we find CELF2 binding sites to be highly 
enriched in both the upstream and downstream introns (Fig 5.11B), consistent with the 
pattern of CELF2 binding in MKK7. Indeed, CELF2 binding sites are the top- scoring 
motif in the downstream introns of JNK-responsive events (Fig 5.11B). The functional 
significance of these CELF2 motifs were validated in two JNK-dependent splicing events 
in DDR1 and MTHFD2L (Fig 5.11C), which exhibit altered splicing upon knockdown of 
CELF2 despite not having met the threshold for CELF2-responsiveness in our previous 
RASL-seq study (Mallory et al. 2015). Together, our data demonstrate that CELF2 not 
only regulates MKK7, but also mediates a substantial proportion of JNK-dependent 
splicing in T cells.  
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Discussion 
Through the work presented in chapter 4 and this chapter (5) I demonstrate that JNK 
signaling is a major pathway through which T cell activation induces alternative splicing, 
and provide the first link between JNK signaling and a splicing factor (CELF2) that 
regulates a sizeable fraction of JNK-responsive exons. Moreover, I find that one of the 
targets of JNK/CELF2-dependent splicing is the JNK-kinase MKK7. While it remains 
possible that other signaling pathways fine-tune the regulation of MKK7, I show that JNK 
Figure 5.11. JNK signaling and CELF2 co-regulate alternative splicing in T cells. (A) Pie chart of overlap 
of significant JNK-dependent alternative splicing events from Figure 6 with published CELF2-dependent 
alternative splicing events (Mallory et al. 2015), and list of genes containing alternative exons that are co-
regulated by JNK and CELF2.  (B) Enriched motifs around JNK responsive exons in primary CD4+ T cells as 
determined by the AVISPA algorithm. (C) Analysis of two cassette exons in two JNK-dependent alternative 
splicing events that are predicted to be co-regulated by CELF2 on the basis of containing an AVISPA 
determined CELF2 motif. Representative RT-PCR gel quantifying percent inclusion in wildtype (WT) versus 
CELF2 knockdown (KD) samples from Jurkat T cells.  
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activation is necessary and sufficient for MKK7 alternative splicing and that MKK7 
alternative splicing, in turn, augments JNK signaling.  
 In addition to providing insight into the functional impact of splicing on signaling, my 
studies of MKK7 have also revealed novel mechanistic insights on how JNK signaling 
impacts splicing. First, I define intronic regulatory elements within the upstream and 
downstream introns that promote activation-induced skipping of MKK7-E2. These 
intronic sequences are highly conserved across vertebrates, implying these are 
important for proper regulation of MKK7 in other cell types. Secondly, I identify several 
proteins that bind to the intronic regulatory sequences and contribute to overall inclusion 
levels of MKK7-E2, including HuR, SRp20, hnRNPC and CELF2. I note that while the 
effects of HuR, SRp20 and hnRNPC knockdown are subtle, these changes are at least 
consistent with their binding patterns in activated compared to unstimulated nuclear 
extracts. However, while these and additional factors may influence MKK7-E2 inclusion, 
we find that CELF2 is a major repressor of MKK7-E2 inclusion upon T cell activation. It 
also remains to be determined how CELF2 promotes MKK7-E2 skipping, however, we 
note that CELF2 regulates at least one other target in T cells, LEF1 exon 6, through 
binding to both of the flanking introns (Mallory et al. 2011).  Therefore, cooperativity or 
competition across an exon may be a common theme through which CELF2 functions. 
 Consistent with the role of CELF2 in regulating MKK7, a JNK-dependent increase in 
CELF2 protein following T cell activation correlates with an increase in CELF2 protein 
binding to the MKK7 intronic regulatory elements. We have recently published that TCR-
signaling induced expression of CELF2 protein is driven by two mechanisms; an initial 
increase in transcription that is driven by NF-kB (JNK-independent) and an increase in 
the stability of the CELF2 mRNA contributes to the increase in the stability of the CELF2 
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mRNA by an uncharacterized mechanism. We now show that in response to T cell 
activation JNK signaling stabilizes CELF2 mRNA, to increase CELF2 protein expression 
and directly impact alternative splicing. Thus, I provide a novel mechanism by which 
extracellular signals can be transmitted from the TCR through the JNK signaling 
cascade to the splicing factor CELF2 and result in changes in gene expression.  
Coincident with regulation of MKK7, JNK signaling also controls about ~25% of 
activation-induced alternative splicing events in primary T cells, with at least a third of 
these events also responsive to CELF2. Because previous large-scale studies of 
alternative splicing in primary human T cells only generated limited events, our 
identification of ~400 TCR-responsive splicing events greatly expand our knowledge of 
splicing regulation during the human immune response. Furthermore, the specific 
identification that ~100 of these TCR-responsive events are dependent on JNK 
activation adds new insight into the role of JNK signaling in biology. Through regulating 
alternative splicing of factors involved in different aspects of gene expression, such as 
mRNA processing, chromatin remodeling and transcription, JNK signaling potentially 
affects a greater breadth of biological processes than previously appreciated. For 
example, JNK-dependent alternative splicing of apoptosis regulators such as Cell cycle 
and apoptosis regulator 1 (CCAR1) and of BCL2-associated X protein (BAX) may serve 
to turn off apoptosis and promote T cell proliferation, a hallmark of T cell activation 
(Czabotar et al. 2013) 
The regulation of MKK7 and other target genes in response to JNK signaling is 
unlikely to be restricted to T cells. I show in chapter 4 that activation of JNK regulates 
MKK7 splicing in HEK293 cells as well as in T cells. Moreover, other studies have 
implicated JNK in the regulation of Fibronectin splicing in epithelial cells, and have 
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shown JNK to interact with and phosphorylate at least a few known splicing factors 
although the impact of this regulation has not been linked to changes in splicing (Pelisch 
et al. 2005; Habelhah 2001; Hutchins and Szaro 2013). As JNK is activated by many 
cellular stress conditions, including oxidative stress and DNA damage, these data 
suggest that JNK-mediated alternative splicing may play a much broader role in the 
cellular response to a wide range of stress conditions and cell types. Whether CELF2 
contributes to JNK-dependent splicing in other cell types remains to be determined. 
Clearly proteins other than CELF2 additionally contribute to JNK-dependent splicing in T 
cells, and may also do so in other cell types. However, we note that CELF2 is one of the 
splicing factors most frequently downregulated in multiple cancer types (Sveen et al. 
2015). Given the role of CELF2 in MKK7 splicing shown here, and the role of JNK in pro-
apoptotic signaling (Dhanasekaran and Reddy 2008), these data suggest the possibility 
that loss of CELF2 leads to decreased JNK activity in cancer. 
In sum, in chapter 4 and 5 I demonstrate a broad role for JNK signaling in controlling 
splicing in human T cells and specifically show that an important functional consequence 
of JNK-induced splicing is amplification of its own activity through the alternative splicing 
of MKK7. These data provide important precedent for the regulation of JNK signaling in 
other cell types and for the reciprocal regulation of signaling and splicing in general 
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CHAPTER 6: CONCLUSIONS AND FUTURE DIRECTIONS 
 
Conclusions 
As discussed in Chapter 1, despite the pervasiveness of alternative splicing as a 
mechanism of gene regulation and the profound impact that it can impart, there is a 
shortage of proven examples of alternative splicing that lead to distinct changes in 
protein expression.  One advantage of alternative splicing is that it can change specific 
regions of a protein to alter specific activities while leaving other activities intact, thereby 
allowing fine tuning of protein functions in the cell. Another advantage of alternative 
splicing is its ability to change gene expression in response to environmental signals. As 
discussed in chapter 1, T cells must respond to invading pathogens and mount an 
appropriate immune response, including proliferation and expression of cytokines and 
other effector molecules. The process of how antigen is sensed at the T-cell receptor 
(TCR) and how downstream signals are transmitted through intracellular signaling 
cascades to transcription factors in the nucleus that upregulate the expression of 
activation cytokines such as IL-2 and TNF-alpha is well characterized. However, how the 
same signals are transmitted to nuclear splicing factors to change alternative splicing 
and alter protein expression is largely unknown.  
 In Chapter 2, I describe how we have utilized transcriptome-wide profiling to 
identify hundreds of alternatively spliced genes in response to T cell activation of a 
Jurkat T cell line, revealing that alternative splicing has the potential to shape T cell 
immune responses by affecting a host of genes (Martinez et al. 2012). I find that many 
alternative splicing events are conserved upon activation of Jurkat T cells with PMA and 
of primary human CD4+ T cells with antibodies to the TCR (anti-CD3/28), indicating that 
this phenomenon is consistently observed in T cells. Furthermore, consistent with 
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previous reports I find little overlap between genes that are regulated by altering mRNA 
levels and genes that are regulated by alternative splicing. This suggests that these two 
mechanisms to regulate gene expression may have distinct functions in protein 
expression and immune response. Genes that are alternatively spliced in activated T 
cells are enriched in categories related to immune function and cellular immune 
signaling, suggesting potential interplay between TCR signaling and splicing regulation. 
Furthermore, we find that splicing events are differentially sensitive to T cell activation 
stimuli, implying that more than one of the TCR-triggered signaling cascades impact 
splicing during activation. Detailed analysis of the functional consequences and 
mechanism regulating the alternative splicing of any of the identified genes would be 
valuable in gaining understanding on the impact of alternative splicing in T cells.  
 To select a gene that could serve as a model system, in chapter 3, I screened 
five alternatively spliced genes (MKK7, EHMT2, BRD8, NGLY1 and ZC3H14), that were 
identified in chapter 2, for events that showed isoform-specific differences in protein 
function or T cell phenotypes. I utilized antisense morpholino oligos to manipulate 
isoform expression and examined differences in cell viability and expression of canonical 
T cell cytokines. Alternative splicing of any of these genes did not result in significant 
differences in these parameters in Jurkat T cells. Next, I screened these genes for their 
experimental tractability in minigene assays to be used in follow-up mechanistic studies 
and also examined the literature to identify splicing events that affect domains with 
known biological functions. With this approach, I selected MKK7 as the focus of chapter 
4 & 5 since the MKK7 splice variants affected an exon encoding for a JNK docking 
domain and had generated an activation-responsive minigene to study the sequences 
and trans-acting factors responsible for the splicing change. 
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 In Chapter 4 I show that in response to T cell activation, the JNK-kinase MKK7 is 
alternatively spliced to favor an isoform that lacks exon 2. This isoform restores the 
integrity of the MAPK domain that is a JNK docking site within MKK7 that is disrupted in 
the larger isoform. Consistently, we show that skipping of MKK7 exon 2 enhances 
docking and JNK pathway activity, as indicated by downstream signaling hallmarks such 
as c-Jun phosphorylation and up-regulation of TNF-alpha. Moreover, this splicing event 
is itself dependent on JNK signaling. Thus, MKK7 alternative splicing represents a 
positive feedback loop through which JNK promotes its own signaling: TCR stimulation 
increases JNK signaling that promotes skipping of MKK7 exon 2, which further 
enhances JNK signaling. This JNK signaling/MKK7 splicing feedback loop is one of few 
examples of direct positive feedback due to alternative splicing. Furthermore, this 
positive feedback appears to be a general property of JNK signaling, as we observe 
skipping of MKK7-E2 in non-T cells as well.  
MNK2 is one other example of alternative splicing of a MAPK domain that has 
been described, but in this case the docking domain is encoded within the alternative 
exon (Maimon et al. 2014). Therefore, alternative splicing results in complete inclusion or 
exclusion of the MAPK domain. In contrast, with MKK7 I describe a new mode of 
regulating kinase substrate interaction, in which inclusion of the alternative exon disrupts 
the MAPK docking site. These two instances suggest that alternative splicing may serve 
to broadly regulate MAPK docking sites, thus it would be interesting to identify other 
cases of this type of regulation in other MAP kinases. 
 Chapter 5 provides mechanistic details on how the activation-induced skipping of 
MKK7-E2 is achieved. I show that repression of MKK7 exon 2 is dependent on the 
presence of flanking intronic sequences and the JNK-induced expression of the RNA-
binding protein CELF2, which binds to these regulatory elements. Furthermore, we find 
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that JNK induces CELF2 protein expression through message stabilization. The results 
in chapters 4 and 5 describing the regulation and consequence of MKK7 alternative 
splicing in JNK signaling are summarized in the model depicted in Fig 6.1. I also find that 
~25% of T cell receptor-mediated alternative splicing events are dependent on JNK 
signaling. Strikingly, these JNK-dependent events are also significantly enriched for 
responsiveness to CELF2. Together, my results demonstrate a widespread role for the 
JNK-CELF2 axis in controlling splicing during T cell activation, including a specific role in 
propagating JNK signaling.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1. Model depicting the MKK7 positive feedback loop. A JNK-dependent increase in CELF2 
protein promotes MKK7 exon 2 skipping and the generation of the MKK7-S protein, that in turn enhances 
JNK signaling. 
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Finally, results in the appendix demonstrate that alternative splicing also serves 
as a mechanism of gene regulation during the critical developmental transition from the 
maturation of double negative to double positive thymocytes. Furthermore, we expand 
the number of genes known to undergo alternative splicing in thymocytes at this stage of 
development that involves pre-TCR signaling. Strikingly, we find that about 30% of the 
identified events are pre-mRNA that are sensitive to CELF2 protein levels in Jurkat T 
cells. These results suggest that CELF2 may also regulate alternative splicing during 
pre-TCR signaling. We had previously shown that there is also an increase in CELF2 
expression in the double positive thymocyte populations relative to double negative 
populations (Mallory et al. 2011). It is possible that JNK signaling also promotes CELF2 
expression in developing thymocytes, further broadening the prevalence of this unique 
mechanism of gene regulation.  
 
Perspectives and Future Directions 
 Reflecting on the introduction in chapter 1, I provide an example of how multiple 
signaling pathways converge on the same splicing factor to affect its activity. 
Specifically, my work in combination with our previous work (Mallory et al. 2015) shows 
that NF-kB and JNK signaling impinge on the same splicing factor CELF2 to orchestrate 
an increase in this protein that results in major changes in alternative splicing. 
Conversely, my work also demonstrates that one signaling pathway can affect multiple 
splicing factors to diversify gene expression. I find that JNK signaling accounts for about 
one fourth of TCR-induced alternative splicing and that 1/3 of the JNK-dependent events 
are co-regulated by CELF2. Therefore, the remaining JNK-dependent events are likely 
regulated by other splicing factors that we have yet to identify. JNK signaling could, in 
parallel with regulating CELF2 protein, regulate the activity of other splicing factors. JNK 
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is a kinase and therefore it is possible that it directly phosphorylates other splicing 
factors to impact splicing. A phosphoproteomic mass spectrometric study in activated T 
cells in the presence and absence of JNK inhibitors and/or JNK knockdown, would be a 
useful strategy to evaluate this hypothesis. Importantly, the RNA-binding protein hnRNP 
K has been shown to be a substrate of JNK, although this has not been linked to its 
activities in splicing control (Hutchins and Szaro 2013). Similarly, mass spectrometry 
analysis of total splicing factor protein levels under the same conditions could reveal 
other instances in which JNK signaling regulates the expression of splicing factors either 
transcriptionally, translationally or through message stability, as is the case with CELF2. 
 Another interesting question is what other signaling pathways shape alternative 
splicing during TCR activation of T cells. My results indicate that JNK signaling controls 
one fourth of TCR-induced splicing events, while GSK3 controls about another fourth. 
This implies that other uncharacterized signaling/splicing factor branches mediate 
alternative splicing in T cells. The model derived in this thesis may serve as a prototype 
for the identification of new connections between signaling pathways and splicing 
factors. Finally, whether several pathways converge to impact common alternative 
splicing networks to impart an additional layer of regulation will be an interesting area of 
investigation. Applying a similar approach to the one presented in chapter 5, where I 
utilized JNK inhibitors and performed RASL-seq to determine the activation-induced 
splicing events that are JNK-dependent could be performed. RNA isolated from primary 
T cells left unstimulated or activated (anti-CD3/CD28) in the presence and absence of 
inhibitors (Table 6.1) to the other canonical TCR-stimulated signaling pathways such as 
p38, MEK, mTOR, NFAT, PKC, NF-kB and others (Smith-Garvin et al. 2009), could be 
analyzed in parallel by RASL-seq. This approach would define other signaling pathways  
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Table 6.1 Inhibitors to canonical T cell signaling pathways 
Pathway Inhibitors References 
GSK3  SB216763, Lithium (Cohen and Goedert 2004) 
JNK SP600125, JNK-IN-8 (Bennett et al. 2001; Zhang et al. 2012) 
PI3K Wortmanin, LY294002 
(Arcaro and Wymann 1993; Sanchez-Margálet et 
al. 1994) 
Akt MK-2206, Triciribine (Hirai et al. 2010; Yang et al. 2004) 
PKC Gö6976, Gö6983, R0-31-8220 (Way et al. 2000) 
NFAT Cyclosporin A, FK506 (Shaw et al. 1995) 
MEK U0126, PD98059 (Favata et al. 1998; Dudley et al. 1995) 
p38 SB203580, SB202190, skepinone-L   
(Ward et al. 1997; Young et al. 1997; Koeberle et 
al. 2012) 
NF-kB 
IKK inhibitor VII, MG0132, Bay11-702 
IkB-alpha (Waelchli et al. 2006; Palombella et al. 1994) 
mTOR Rapamycin, Temsirolimus (Brown et al. 1994; Dudkin et al. 2001) 
that regulate alternative splicing in T cell and networks that are co-regulated by multiple 
signaling pathways. 
 Regarding the biological implications of MKK7 alternative splicing, I showed that 
the MKK7 isoform that lacks exon 2 (MKK7-S) contains an intact docking site for JNK 
and exhibits enhanced downstream signaling relatively to the MKK7-L isoform. However, 
it is of interest whether the MKK7-L isoform that contains an additional 16 amino acid 
peptide in the docking site has any different activities. For example the inclusion of exon 
2 in MKK7 may disrupt the JNK docking site, but make this MAPK docking site have 
greater selectivity for a different substrate. Previous studies have shown that amino acid 
residues surrounding the conserved docking site residues can greatly impact substrate 
selectivity (Bardwell et al. 2009). A plausible hypothesis is that the MKK7-L isoform may 
have distinct or additional substrates such as other kinases or scaffolding proteins. To 
address this possibility one could ectopically express tagged MKK7-L versus MKK7-S in 
T cells and/or other cell types and preform co-immunoprecipitation experiments such as 
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the one presented in Fig 4.3C, but looking for co-association of known MKK7/JNK 
scaffolding proteins, other kinases or subjecting immunoprecipitated complexes to mass 
spectrometric analysis. 
 We show in this thesis that JNK signaling increases CELF2 protein expression 
through an increase in the stability of the CELF2 mRNA. An avenue for further 
investigation is how JNK signaling stabilizes the CELF2 mRNA. It is known that 
elements in the 3’UTR can serve as binding sites for proteins to stabilize or destabilize 
the target mRNA (Reznik and Lykke-Andersen 2010). JNK signaling could alter the 
ability of a stabilizing or destabilizing proteins to interact with the CELF2 3’ UTR. 
Furthermore, our previous study showed that the identity of the CELF2 3’UTR is also 
itself altered in response to T cell activation (Mallory et al. 2015) that could insert or 
eliminate binding sites for proteins that stabilize or destabilize mRNAs and may be 
dependent on JNK signaling. Nevertheless, the regulation of CELF2 mRNA stability is 
likely a process with many layers of complexity. 
 Altogether, the results presented in this thesis identifies novel alternative splicing 
events in response to activation of both a T cell line and primary human T cells. These 
events are enriched for genes that play roles in immune-related functions and cellular 
signaling. Furthermore, I establish that multiple signaling pathways coordinately regulate 
alternative splicing in activated T cells. Finally, I delineate a pathway that relays 
information from the cell surface (TCR), through the cytoplasmic JNK signaling cascade 
to the nuclear splicing factor CELF2 to have pronounced effects on alternative splicing. 
At least one of the regulated splicing events, that of MKK7, has a direct impact on 
immune signaling, including increased activity of the transcription factor c-jun and 
upregulation of immune cytokines. In this positive feedback loop JNK signaling through 
promoting alternative splicing of its upstream kinase MKK7, can amplify its own signaling 
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after the initial induction of the pathway. This mechanism requiring the JNK/CELF2 
signaling arms provides a new type of connectivity between signaling and splicing. 
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CHAPTER 7: MATERIALS AND METHODS 
 
Cell Culture 
The JSL1 clonal population of Jurkat cells were cultured in RPMI supplemented with 5% 
heat-inactivated fetal bovine serum (FBS) (Lynch and Weiss 2000). HEK293 cells were 
cultured in DMEM with 5% heat-inactivated fetal bovine serum (FBS). For stimulations, 
Jurkat T cells were cultured with PMA (20 ng/mL; Sigma-Aldrich) for 48h (RT-PCR), 2h 
(western analysis of phosphoproteins) or indicated time points. CD4+ peripheral blood T 
cells were obtained from the University of Pennsylvania Human Immunology Core (IRB 
protocol #811028) with an average purity of 90%–95%. CD4+ cells were maintained in 
RPMI supplemented with 10% heat-inactivated FBS for unstimulated conditions, or 
additionally stimulated with anti-CD3 (BD Biosciences 555336) and anti-CD28 (BD 
Biosciences 348040) for 48h. For stimulations, plate wells were coated with anti-CD3 at 
2.5 µg/mL and additional soluble anti-CD3 and anti-CD28 were added to a final 
concentration of 2.5 µg/mL. Stimulation of primary CD4+ T cells with PHA was at 
10µg/mL (Sigma L9017) for 60 hours. For inhibition studies, cells were pre-treated with 
inhibitors SP600125 (50µM, Calbiochem, 420119), JNK-IN-8 (3µM, Calbiochem, 
420150), Triciribine (1µM, Calbiochem, 124012), Rapamycin (100nM, LC Laboratories, 
R-5000) or U0126 (20µM, Invitrogen, PHZ1283) for 1 hour or 3 hours (JNK-IN-8) before 
stimulating as described above. Transcription inhibition was achieved by incubation of 
cells with actinomycin D at a final concentration of 5 µg/mL. 
 
Transfections 
Jurkat T cells (10x106) were transfected with 15 nmol of a 5’ splice site blocking 
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antisense morpolino oligo MKK7 AMO (Gene-Tools) 5’-
CGATGATAAAAAGGCTGGTACCTGC-3’, ZC3H14 AMO against the 5’ splice site of 
exon 12 5’-CTTGAAACATTACCAACCTTGACTC-3’, BRD8 AMO against the 5’ splice 
site of exon 21 5’-CCTTGCAGCCATTCAATACTTACAA-3’, EHMT2 AMO against the 3’ 
splice site of exon 10 5’-CACTCCTGACACAGAGACAGAGAGA-3’ or control oligo 
against the 3’ splice site of exon 11 of NGLY1 5’- CAGTTGCCTCTGTAATTCATGTTTT-
3’ by electroporation as previously described (Rothrock et al. 2003). Cells were 
incubated with AMO for 24h after transfection and then stimulated with PMA as 
described above. Knockdown of HuR, SRp20, hnRNPC,, CTCF and hnRNPL was done 
by transfection with translation blocking morpholino oligos (Gene-Tools) hnRNPC 5’- 
ATCGTGTTTGATGGTAAGGTTTCTC -3’, HuR 5’- 
TGTGGTCTTCATAACCATTAGACAT -3’, SRp20 5’- 
AAAATGCGGCGGCTCAAATCCACAC -3’, CTCF 5’-
CTTCGACTGCATCACCTTCCATTTC-3’ and hnRNPL 5’- 
CGCCCGCCGCCGCCATCTTCACCAT-3’ as described above.  
HEK293 cells were transfected  by Lipofectamine 2000 (Invitrogen #11668-019) 
transfection according to manufacturer’s instructions and harvested after 48h. 
Constitutively active JNK1 and JNK2  (pCDNA3 Flag MKK7B2Jnk1a1and pCDNA3 Flag 
MKK7B2Jnk2a2) were a gift from Roger Davis (Addgene plasmid #19726 & 19727). 
HEK293 cells were co-transfected with 2µg of FLAG-CELF2 and 2µg of corresponding 
MKK7 minigenes as above. The CELF2 expression vector pEFnFLAG-CELF2 was 
generated previously (Mallory et al. 2015). Jurkat stable cell lines that were depleted of 
JNK were generated using lentiviral transfection of a short hairpin RNA targeting 
JNK2a2 cDNA (Gen Bank accession number NM_002752.4) corresponding to 
nucleotides 462-480. Similarly, depletion of CELF2 was done by lentivirus encoding 
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hairpins targeting nt 171-189 (A) or 966-990 (B).  
 
Cell Viability 
10 million Jurkat T cells were transfected with indicated AMOs as described above. 
Plated in 10mL of RPMI without phenol red (Promega) and left to recover overnight at 37 
degrees. Subsequently, cells were split back and 100uL of each transfection reaction 
were plated into 96 well plates, one plate for each time point including a time point equal 
to 0h. At the indicated time points 20uL of MTS one solution (Promega) was added to 
each well and incubated for 2h at 37 degress (covered with foil). Absorbance was read 
at 490 nm (subtracting background reference at 600 nm).  
 
Flow cytometry 
Jurkat T cells were transfected and stimulated under indicated conditions. 1 million cells 
per condition were harvested and incubated with anti-CD69 PE antibody (BD 
Pharmingen 560968) or anti-CD25 FITC (BD Pharmingen 560990) for 15 min on ice in 
PBS. Cells were washed and resuspended in PBS (without calcium and magnesium) 
supplemented with 1% FBS and analyzed by flow cytometry in corresponding 
fluorescent channels relative to unstained control.  
 
cDNA Expression Plasmids 
For coimmunoprecipitation experiments, FLAG-MKK7-L (4µg) or FLAG-MKK7-S (1µg) 
were co-transfected with c-myc-JNK1 (1µg) in HEK293 cells as described above. MKK7-
S cDNA was generated by PCR from plasmid pDONR223-MAP2K7 (addgene) with 
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primers containing BamHI/EcoRI and inserted into the pEFnFLAG vector downstream of 
an N-terminal FLAG tag. MKK7-L was generate by RT-PCR from unstimulated Jurkat T 
cell RNA with the same forward primer as MKK7-S and a reverse primer in MKK7 exon 5 
encompassing a natural BspE1 site. The PCR fragment was the inserted in the MKK-S 
plasmid through digestion with BamH1 and BspE1. C-myc-JNK1 was generated by PCR 
from pCDNA3-FLAG-JNK1a1 (addgene) and inserted into a pCDNA3-c-myc plasmid 
using BamH1 and XbaI sites. 
 
Minigenes 
MKK7, BRD8, NGLY1, ZC3H14 minigenes were generated by using PCR with primers 
to isolate the indicated sequences of the endogenous gene and the 5’ and 3’ ends were 
flanked with NdeI and BglI/BAMH1 respectively (see Table 7.2). The genomic fragments 
were then inserted into beta globin constitutive exons 1 and 2 in the SCglo parental 
minigene as previously described (Rothrock et al. 2003). For the MKK7 intron only 
containing construct each intronic seqment was amplified by RT-PCR with primers for 
the endogenous gene containing an NdeI site at the 5’ end and a PstI site and the 3’ end 
for the upstream intron and a PstI at the 5’ end and a BglII site at the 3’ end for the 
downstream intron. These fragments were then inserted into the SCglo parental 
mingene and finally a portion of constitutive CD45 exon 14 dropped in with flanking PstI 
sites (Rothrock et al. 2003).  Primer sequences are listed in Table 7.2. The EHMT2 
minigene was generated by isolating the entire endogenous region encompassing the 
alternative exon and flanking constitutive exons and flanked at the 5’ and 3’ ends with 
KpnI and HindIII and inserted into the SCgloI plasmid. EHMT2 minigenes with 
substituted CTCF and ARS sequence motifs were generated by using nested PCR 
 126 
reactions to swap out the 15 nucleotide CTCF or ARS sequence from the parental 
EHMT2 minigene with a heterologous sequence CAGCATGACTCTCAG (Tong et al. 
2005). This was generated by combining two PCR reactions: the first reaction is 
generated with a forward primer that anneals to the flanking sequences and contain the 
nucleotides to be substituted swCTCF EHMT2-F or swARS EHMT2-F with a reverese 
primer to in beta-globin intron 3 (outsideIVS3-R). The second PCR reaction was 
generated with a Forward primer upstream of the T7 promoter (outside T7 promoter-F) 
and a reverse primer that anneals to the flanking sequences and contain the nucleotides 
to be substituted swCTCF EHMT2-R or swARS EHMT2-R. Then both PCR reaction 
were combined and the full length insert was amplified and cloned into the pcAT7 vector 
using KpnI and HindIII sites. Primers are listed in Table 7.2. Jurkat T cell clones that 
stably express the minigenes described above were created by transfecting 10 million 
cells with 10 ug of minigene plasmid by electroporation and grown under zeocin drug 
selection as previously described (Rothrock et al., 2003).  
 
Coimmunoprecipitation 
HEK293 cells co-transfected with FLAG-MKK7-L or FLAG-MKK7-S and c-myc JNK1 
were resuspended in PBS with protease inhibitor cocktail (Roche). and lysed by three 
freeze-thaw cycles, followed by centrifugation at 13,300 rpm for 10 minutes. 150µg of 
cell lysate and 4µg of anti-c-myc were incubated in 200µL at 4 degrees with rotation for 
1.5h, followed by incubation with 40µL pre-washed protein G Dynabeads for 1h. 
Immunoprecipitated complexes were washed in PBS and eluted from beads in SDS 
sample buffer. 
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RT-PCR 
RNA was isolated using RNABee (Tel-Test, Inc.) according to the manufacturer’s 
protocol. Reverse transcription-PCR (RT-PCR) was performed as previously described 
in detail (Lynch and Weiss 2000; Rothrock et al. 2003; Ip et al. 2007), using sequence-
specific primers for individual genes and low cycle number. Primer sequences for all RT-
PCR events are provided in Table 7.1. Quantification was done by densitometry using a 
Typhoon Phosphor Imager and Image Quant software. Percent spliced in or (PSI) was 
calculated as the density of isoforms including the variable exon over total isoform 
density. Quantification of TNF-alpha, IL-4 and CELF2 gene expression was determined 
by RT-PCR and normalized to B2M for TNF-alpha and actin for IL-4 and CELF2 with 
primer sequences in Table 7.2. A two-tailed Student’s t-test analysis was performed for 
all treatment groups in Jurkat T cells (unpaired) and CD4+ peripheral blood T 
lymphocytes (paired) using Microsoft Excel for at least 3 biological replicates. Conditions 
with a p-value < 0.05 were considered significant. 
 
Western Blots 
Western blots were carried out as previously described (Melton et al. 2007). Briefly,10µg 
of total protein lysates were loaded into 10% 37.5:1 bis-acrylamide SDS-PAGE gels. 
Antibodies used for western blot were as follows: phospho-c-Jun (Ser73) #9164, c-Jun 
(L70B11) #2315, MKK7 #4172, p44/42 MAPK (Erk1/2) (137F5) #4695, phosph-p70 S6 
Kinase (Thr389) (108D2) #9234, phospho-Akt (Ser473) #9271, SAPK/JNK #9252, FLAG 
#2368 and CTCF (D31H2) #3418 from Cell Signaling. Antibody to hnRNPL (ab6106) 
and U2AF35 (ab86305) were from Abcam.  Antibody to c-myc (9E10) was from Roche 
and CELF2 antibody from the University of Florida Hybridoma Lab (HL1889). Antibody to 
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EHMT2 was from Millipore (#09-071). 
 
UV crosslinking 
UV crosslinking assays were preformed as previously described (Mallory et al. 2011). In 
brief, nuclear extract was made from unstimulated or PMA activated from Jurkat T cells.  
MKK7 templates were PCR amplified from the MKK7 minigene using primers containing 
the T7 promoter and gel purified. These MKK7 templates were then in vitro transcribed 
with T7 polymerase (Promega) and body-labeled with 32P alpha-UTP. Nuclear extracts 
were incubated with MKK7 RNAs, UV crosslinked, RNase digested and resolved on an 
SDS-PAGE. For UV crosslinking followed by immunoprecipitation, UV crosslinking 
reactions after RNase digestion were incubated with corresponding primary antibodies at 
4 degrees overnight, followed by incubation with protein G sepharose beads (GE) and 
elution. Antibodies used in immunoprecipiation were as follows: HuR (sc-5261) from 
Santa Cruz, hnRNPC (ab10294) from Abcam, CELF2 provided by UFL Hybridoma Lab, 
SRp20 (33-4200) from Thermo and PSIP1 (A300-847A) from Bethyl Laboratories. 
 
RNA Affinity Purification 
The MKK7 introns construct and Control construct were in vitro transcribed from a T7 
promoter. The 50pmol of RNA were then biotinylated at the 3’ end using RNA ligase 
according to manufacturers protocol (Pierce RNA 3' End Biotinylation Kit). The RNA 
affinity purification was performed as previously described (Rothrock et al. 2005). Briefly, 
biotinylated RNAs were incubated with unstimulated or PMA activated nuclear extract 
from Jurkat T cells at 30 degrees for 30min, the RNA was then coupled to preblocked 
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Streptavidin beads (Pierce) and incubated for 1h at 4 degrees. The pull downs were 
washed 4X and eluted in 2X SDS sample buffer. The samples were ran on a 12% gel for 
0.5cm, stained with colloidal blue and the entire lanes were cut out and trypsin digested. 
Trypsin digests were analyzed by LC-MS/MS on an Q Exactive Plus mass spectrometer. 
Table S1 contains the peptides identified by mass spectrometry with at least 10 spectral 
counts across conditions and is sorted based on the fold increase upon PMA activation. 
 
RNA-Sequencing and Analysis  
Human UniGene sequences (Build #208) and human genomic sequences (Build #36) 
were downloaded from NCBI 
(ftp://ftp.ncbi.nih.gov/repository/UniGene/Homo_sapiens/,ftp://ftp.ncbi.nih.gov/genomes/
H_sapiens/). RefSeq data were downloaded from UCSC 
(http://hgdownload.cse.ucsc.edu/goldenPath/hg18/database/refGene.txt.gz). Cassette 
alternative splicing events (n=27,240) were mined from aligning EST/cDNA sequences 
to genomic sequence essentially as described previously (Pan et al. 2004; 2005; 
Saltzman et al. 2011). 
RNA-seq reads analyzed were 50-mers. For each splice site junction sequence aligned 
to sequence reads, a 90 nucleotide-long sequence was extracted with 45 nucleotides of 
overlap in each upstream and downstream exon. RNA-Seq reads were mapped to exon-
exon junction sequences and the mapped reads were filtered as previously described 
(Pan et al. 2008). Percent exon inclusion values (%In) were calculated by counting the 
number of reads mapping uniquely (i.e. not mapping to another splice junction or 
genomic sequence) to the three junctions formed by alternative splicing of a single 
cassette skipping event. Specifically the ratio of the average count for reads mapping to 
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the two splice junctions formed by exon inclusion (C1:A, A:C2), over the total count for 
reads mapping both to the included exon junctions (C1:A, A:C2) and to the skipped exon 
junction (C1:C2), was determined. Percent exon inclusion values predicted for cassette 
AS events represented by 20 or more reads to at least one of these three junctions were 
shown to have a high correlation (r=0.80) with independent AS microarray measurement 
(Pan et al. 2008), and thus were considered as high-confidence RNA-Seq predictions for 
%In levels. 
 
RNA-seq Ingenuity Pathway Analysis  
Functional and canonical signaling pathway analyses were performed with Ingenuity 
Pathway Analysis software (Ingenuity® Systems, www.ingenuity.com) using the ~11,000 
genes with detectable expression by RNA-seq. A core analysis was performed with this 
dataset as the reference set and the test set as genes with a cutoff of >20 point 
differential in % inclusion. This analysis includes the top 178 genes with an 80% 
validation rate by RT-PCR. Annotations with a  –log (p-value) > 1.5 were selected for 
functional analysis and canonical signaling pathway analysis. 
 
RNA-seq Motif Analysis 
For exons in each of the three categories, sequences of the alternative exons and the 
flanking 200nt of intronic sequence where extracted from the human genome 
(NCBI36/hg18).  These regions were scanned for enriched motifs using MEME v4.7.0 
(Bailey et al. 2009), allowing for any number of repetitions of elicited motifs within the 
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input sequences.  Enriched motifs with an E-value below 5E0 were considered 
significant and shown in Figure 5. 
 
RASL-seq 
RASL-seq was performed as previously described using a set of probes that interrogate 
~5600 specific splicing events (Li et al. 2001; Zhou et al. 2012).  In brief, total RNA was 
harvested from human CD4+ T cells from six independent donors, each of which were 
cultured in RPMI alone (unstimulated), or stimulated with anti-CD3/CD28. Cells from 
three donors were also pre-treated with SP600125 prior to stimulation with anti-
CD3/CD28 or treated with the GSK3 inhibitor SB216763, to determine dependence on 
JNK or sensitivity to GSK3, respectively. All RNA samples were individually hybridized to 
the probe set and selected by oligo-dT. Juxtaposed probes annealed to selected RNAs 
were then ligated and amplified and barcoded by PCR for subsequent multiplexed 
sequencing on a HiSeq2000. On average 2 million reads were obtained for each RNA 
sample. Splicing events were filtered for a minimum of 10 reads average across all 
biologic replicates and conditions and then the percent long isoform (PSI = percent 
spliced in of variable exon) for each event in each sample was calculated by comparing 
number of reads representing the longest isoform to the number of total reads for that 
splicing event. The change in PSI (ΔPSI) was then calculated as the difference in PSI 
comparing CD3/CD28-stimulated cells versus unstimulated cells or versus cells treated 
with SP600125 or SB216763. The ΔPSI method was used as this is a standard criteria 
for large scale splicing analysis (Martinez et al. 2012) and corrects for any possible bias 
in the absolute detection of one isoform to another as it relies on differences in the 
isoform ratio between samples. The validity of this method is confirmed by the high 
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correlation of our RASL-seq and RT-PCR derived ΔPSI values (Fig 4). CD3/CD28-
dependent splicing events were defined as those for which the ΔPSI was significant 
(|ΔPSI|> 10, p< 0.05, paired student t-test) across at least three donors, with consistent 
data amongst all six donors. JNK-dependent splicing events were identified amongst the 
CD3/CD28-dependent splicing events as those for which the addition of the JNK inhibitor 
significantly returned the CD3/CD28-induced PSI back toward the unstimulated pattern 
(i.e. |PSICD3/CD28-SP600125-PSICD3/CD28+SP600125|>10 and in the same direction as PSICD3/CD28-
SP600125-PSIunstim and p< 0.05, paired student t-test across all three donors). GSK3-
sensitive events were calculated in a similar manner. 
 
RASL-seq Gene Ontology 
Gene ontology (GO) and KEGG pathway analysis was performed using DAVID version 
6.7 (http://david.abcc.ncifcrf.gov/). The list of JNK-dependent changes was submitted as 
the gene list (Table S3) with the total queried RASL-seq events w/ >10 reads across 
conditions (Table S2) submitted as the background list. The same background was used 
for the GSK3-sensitive events. We selected significant categories with a p-value < 0.05 
and DAVID enrichment score >1. 
 
RASL-seq AVISPA Motif Enrichment 
Hg19 coordinates for JNK-dependent splicing events (described above) and JNK 
nonresponsive events (|ΔPSI|<3 and p>0.5) were extracted, non-cassette events (e.g. 
alternative 5’ splice sites) were filtered out, leaving 89 and ~950 cassette exons, 
respectively, and these events were run through AVISPA. AVISPA has been described 
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in detail previously (Barash et al. 2013) and has been used to predict known and novel 
regulators of alternative splicing (Gazzara et al. 2014). Briefly, given a cassette exon 
AVISPA extracts a set of over 1,400 features and utilizes an ensemble of splicing code 
models to classify exons as alternative or constitutive, predict their tissue-specific 
splicing patterns, and suggest motifs important to splicing outcome in exon-proximal 
regions (Barash et al. 2013). A hypergeometric test was performed to identify features 
significantly overrepresented in JNK-dependent cassette exons, compared to events not 
responsive to JNK inhibition. CELF2 binding sites were defined by AVISPA as UG-rich 
and CUG-rich motifs (see Barash et al. 2013 for complete description of feature set).  
 
Human Thymocytes 
De-identified human thymus samples were generated as discards from pediatric cardiac 
surgery and obtained through the Co- operative Human Tissue Network in accordance 
with IRB #811028. Single-cell thymocytes suspensions were incubated with RBC lysis 
buffer to deplete for RBCs then stained with anti–CD8-APC (Becton-Dickinson 
#555369), anti– CD4-FITC (Becton-Dickinson #555346), and a mixture of antibodies to 
deplete non-thymocytes (human T-cell depletion antibody mix, Invitrogen #113.44D) that 
were labeled with PE via a secondary antibody (Becton-Dickinson rat anti-mouse PE 
#349073). DN and DP cells were isolated by gating for PE− viable cells, then collecting 
the most intense APC/FITC double stained (DP) or lowest 2–3% staining (DN) a the 
University of Pennsylvania biohazard cell sorting facility.  
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Table 7.1 Primers used for RT-PCR analysis 
Gene Forward Primer Reverse Primer Tm 
SLMAP GACACAGACTGTACTCTCAGAACTG      GCCAGAGCTTCTCCATGAGAGC     65 
FAM36A 
GTGGAGTCGCGGAGTAGTCCTCATGG   CAGCATCCCAAAGTCACCAAGATAAACC
CTCC   
70 
CELF2 
CTGCAGATAGTGAAAAGTCCAACGCTGTG
G 
CCCAGGTGGCAGTGTTGAGCTGCTGC 70 
TRAF3 CACGAAGACACCGACTGTCCCTGC CGAGCGAGTTGCTCCACTCCTTCAGC 70 
BRD8 
GCAAACATCCGAGTCTGGGATCAGTGC CCTCTTCTGTAACTTCCACCTCTGGAACT
GG   
70 
NGLY1 GAAGCAGGGTGAAGTCAGTAAGGCA CACACGCCATTCTCCCATCCAGAAAT 65 
ZC3H14 
GCAGAAGTGGTCCAGGGACAAAGTAGG GACTCTTGGTTTGGTGCCACTACTACTTC
C 
70 
SEC16A GATGGCCTCCTCGCTCTCTCATCCC    GCCAGCTGAGCAGGGTTGTAGAAGG    70 
PPP1R12A CCAAGCACCACATCAACACCAACAG     GCAAGACAATCTAGAAGATCAACACAG    65 
MACF1 
GTCTACTAGATGACTGGGCAAGTAAGGG  GAACCTCCTCCATTCTGTTGAGGATAGC
C   
70 
REPS1 CCAGGTGAGGTAGGTTATTCAGGCTCTCC GCTTGGAGTCATACGAATGGGAACTGG 70 
AKAP9 
CAACCACAGCAGATGACTGCAGTTCAGAG GTCCCATAGGTAACCCTCATTTCTTCCAG
C 
70 
CD45-E6 GGCAAGCCCAACACCTTCCCCCACTG CTGAAACTTTTCAA CCCCTGGTGGCAC 70 
H2AFY GTTGATGTCACTTGGCGATATTCCTG ACTTCCAAGGGCCCGTTCTTTTTCC 70 
TRIM26 GGATTCGCGGCCCGGAGCTCGG GCCACAGTCAATGGTCACAGGGTCC 70 
EHMT2 
CGGGGTACCAGTGGTTCCAGTGGCCGGC
G 
AGATCTAAGCTTCTCTCCGTCCACACTCT
CAGTGG 
65 
DDHD1 GAAGCCAGTTGCCTCACCTTCTGCTACC GGGCAACATCCAAGGATGACCAATAGGC 70 
MAP4K2 
GGGAGATGTCAAACTGGCTGACTTTGGG GCCAGTTTGAGAAAGTGGTGGAAATTCT
GGGTCC 
70 
TIR8 GCCGACCTCTTGGTGAACCTGAGCC    GGTCCTTGTCGTCCTGCAGCTGCG    70 
LUC7L CTGCCTGAGAGAAGTCGTCGCG    CCCATGACATCCTGGCTGGGACG   70 
CD45-E4 GGCAAGCCCAACACCTTCCCCCACTG CTGAAACTTTTCAA CCCCTGGTGGCAC 70 
PIGQ 
GATCCATCTGCTCGTGGACCTCATCAACT
C GTAGGTGTGCACCACGCGGCTGTAGG 
65 
CD45-E5 GGCAAGCCCAACACCTTCCCCCACTG CTGAAACTTTTCAACCCCTGGTGGCAC 70 
MAP2K7 CGACCTCAACCTGGATATCAGCC GGAGCTCTCTGAGGATGGCGAGC 65 
CARD8 
GATACAGTAAAGACATAAATACCACATTTG
ACAAATGG 
GATAGTTGACACTCAGGAACAGCACGG 65 
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Fyn GTCTCTGCTGCCGCCTAGTAGTTCCC CACCACTGCATAGAGCTGGACCAGC 70 
ZNF384 CAGAGTCCAAGTCAGACCAGCTGACC GGAAGAGCTGAGACAATCATGGGAGCC 70 
ERP29 CTTCCTGCTCCTCTCCGCTCCGCATG CGCTGGATGGCTCCAACCTTAACTGC 70 
TRIM65 GAAGAGGGGAGCCACCCTGG GGCCCCGGGACTGACGACAG 65 
CKB CAGCAGCTCATCGACGACCACTTCC GAGGATGTAGCCCAGGTGAGGGTTCC 70 
FAM21C CCAATCCACTGCCGATATCTTTGGTGACG GAGCTTGCCAGGCAGCAGAGACGC 70 
UGCGL1 
CTATCTTGGATTCCCAAGGCAAGACTGCT
GC CATACAGTAACTGCCGTCCAGAAGGGC 
70 
MAP7D1 CATCCAACGGTCAGTGAAGAAGACGTGG GACTCCGAGCAAGGAAGGAGAGAGTGG 70 
FIP1L1 
GAGGTCGAGCGCCTAGTGTCGGAG    GCGATGATGATGAAGATGATGTTCATGTC
AC  
65 
LRRC28 
CTTTGTAAGACGATCTCTGTGGCAAGGC GGAACCACAACTATGTTATTTGAGTGCAG
G 
65 
MYL6 
GTGACTTCACCGAAGACCAGACCGC GTGACAAGAACATGCCGGATTTCAGCAC
C 
70 
CCDC14 GCTGAAACTGTACACGGGCTTGATGG GAGTCTGCACGTGCTCACAGAGGG 70 
GALT CCATGACCCTCTCAACCCTCTGTGTCC CTGCACCCAAGGGTACTGGGCACC 70 
MAP3K7 CTCCCGTGGGAGCAGTGTGGAGAGC GTTACAGTCAAGTCTTGGATGGATCTACG 70 
ATF2 TGTGGAATATGAGTGATGACAAACC TTCATTCTCAAATGGACTCGCCAAC 65 
ARMC10 
GCTATTATTCGTGAATTGGGTGGTATTCCA
ATTGTTGC 
GGCACGGAGAAGTCCTTCTGTCATGG 70 
FAM33A CCAGAAAGCTGAGTCTGATCTGGATTAC GTGAAATTTGAATTGCTCTGCCGCAG 70 
SFRS8 
CATCGTCCAGTAAGACCGTCCCGGACG GACACTGAAAGGACTCTCCTCAATTTTCC
CAGC 
70 
ACTR10 
CGCGTACTTGCTTTGTAAGTGATCTGAAG
CG 
CTGCAAGCAATCTGTGGAGAAATCCTGG
C 
70 
CD3D 
GACCTGGCTTTATCTACTGGATGAGTTCC
G 
CTGATAGACCTGGTCATTCCTCAACAGA
GC 
70 
FoxM1 
CTCCATCCGCCACAACCTTTCCCTGC GGGAGTTCGGTTTTGATGGTCATGTTCC
G 
70 
RNF216 
CAGATGGTCACCATGTTTAGATATTAGCAG
TCCC 
GTCTCATCTTGGCTGGCCAGCAGAC 70 
C2orf33 
CTCTCAGCCAACCACCTCTGAGAGC GAGGGGTTGTAGGAGGTCTTTCTAAATC
CAG 
70 
WDR67 
GCTCTTGCAAAAGAAATGCGAGCAGATGC CTTTATGACATGGATTTTCAGCATGTTCT
ACAGCC 
70 
DGUOK 
CCGAAGGCTCTCCATCGAAGGCAAC CTCTCTCATGAGGTCTTCTTGTTTGGTTA
CTTCC 
70 
ADAT1 GACAAAGGAAGTTGTGTCAATGGGAACAG GGTCTCGTCTAAGTTTCCACACTCC 65 
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G 
PI4KB 
GAAGCGCAGGCGGCCAATGGAACC CAGAAGTGGGCTCAGAAGTTGGCTTCAA
GG 
70 
BAX CTCTGAGCAGATCATGAAGACAGG GAAAACATGTCAGCTGCCACTCG 65 
CAMTA1 GCGAGGAGGAGGAGGATGTGGC CTCATTAGTGTTCCAGCGGTGCC 65 
CCAR1 CACTGGTCTCCTTCGTTGGATGGACC 
GTCTTTGGATCAAGTTTAGACCAATGGGT
AGG 70 
CELF2 
CTGCAGATAGTGAAAAGTCCAACGCTGTG
G CCCAGGTGGCAGTGTTGAGCTGCTGC 70 
FIP1L1 GAGGTCGAGCGCCTAGTGTCGGAG    
GCGATGATGATGAAGATGATGTTCATGTC
AC  65 
LEF1 GAGAGAGAAACTACAGGAATCTGCATCAG CAAGCTTCCATCTCCAGAAGAGGTCC 70 
LUC7L CTG CCT GAG AGA AGT CGT CGC G CGT CCC AGC CAG GAT GTC ATG GG 65 
MKK7 CGACCTCAACCTGGATATCAGCC GGAGCTCTCTGAGGATGGCGAGC 65 
MTF2 AAGATATGAGCATGTTCTGGAGGC GTATATGGGCCAGGTGGACGACC 65 
PRPF3 CTGTTTGAGGCTGTGGAGGAAGGC GGAGCTTAGTCAGCATGCCAGGG 65 
RBM3 GTCAAGGACCGGGAGACTCAGCGG GCAGACTTGCCTGCATGATCCACACGG 70 
RNF34 AGGAGGTCGGCAGTGTGAGGAGC CTGAATGGACCGGTGGCTCCTGC 70 
SMARCA4 CTCGTGGATCATCAAGGACGACG CGCTTCCGTGATGATTTCTTCTGC 65 
TRA2A TGGTTGCCGACTCTTTCCTCTTCC CTACGAGATCCTGACCTGCTCTCC 70 
ZDHHC20 CTTGGGTGATGGTTGCAGTTTTCC CTGAGATTCACTGTCCAACAAGCG 65 
TNF-α CACCATGAGCACTGAAAGCATGATCCG GGCCAGAGGGCTGATTAGAGAGAGG 60 
B2M CTCGCGCTACTCTCTCTTTCTGG ATGGATGAAACCCAGACACATAGC 60 
IL-4 CATGAGAAGGACACTCGCTGCCTGG TTCCAACGTACTCTGGTTGGCTTCC 70 
Actin CCCTGGCATTGCCGACAGG GCCGATCCACACGGAGTACT 60 
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Table 7.2 Primers used for cloning and in vitro transcription  
Gene Primer 5'-3' Ta 
MKK7I1-2 NdeI-F GGAATTCCATATGCCTCCTCCTCGTTTATGATTTGATTTC 65 
MKK7I1-2 PstI-R AAAACTGCAGTAACTGGATGGGGAAAAGGAAGAAA 65 
MKK7I2-3 PstI-F AAAACTGCAGCAGGTACCAGCCTTTTTATCATCGC 70 
MKK7I2-3 Bglll-R GGAAGATCTGGACGCCATTCTGCGGCCGGG 70 
MKK7I1-2 T7-F TAATACGACTCACTATAGGCCTCCTCCTCGTTTATGATTTGATTTC  70 
MKK7I2-3-R GGACGCCATTCTGCGGCCGGG 70 
Beta-globin T7-F TAATACGACTCACTATAGGGACCAATAGAAACTGGGCATATGG 65 
Beta-globin-R CTTCTCTGTCTCCACATGCCCAG 65 
JNK1a1- BamHI-F cgcGGATCCagcagaagcaagcgtgacaaca 65 
JNK1a1-XbaI-R ctagtctagaTCACTGCTGCACCTGTGCTAAAG 65 
MKK7cDNA-BamHI-
F 
CGCGGATCCATGGCGGCGTCCTCCCTGGAAC 65 
MKK7cDNA-EcoR1-
R 
CCGGAATTCCTACCTGAAGAAGGGCAGGTGGGGC 65 
MKK7-LcDNA-R GGTCTTCCGGAAGCGCATCTTCC 65 
swCTCF EHMT2-F GGGACAGCATGACTCTCAGCCTCAGGGCAGGAGGG 50 
swCTCF EHMT2-R GAGGCTGAGAGTCATGCTGTCCCTGTCCCGGCAATTGG 50 
swARS EHMT2-F ACCCAGCATGACTCTCAGGCTGGTAATTGCCAATTGC 50 
swARS EHMT2-R CAGCCTGAGAGTCATGCTGGGTCCCCTCGCTGG 50 
outside T7-F CTAATACGACTCACTATAGGGAGC 50 
Outside GloIVS3-R CCTGATTTGGTCAATATGTGTATCG 50 
mgNGLY1-F GGGAATTCCATATGGTTCTGTTTGTGTGTTTCCACTAGC 70 
mgNGLY1-R CAGAAGATCTTATTCTGGTTGGCGATTACATGGG 70 
mgBRD8NdeI-F CGGGAATTCCATATGCTTAGAATGATGGTGGTTTGCACCC 70 
mgBRD8RBamHI-R CGCGAGATCTGACAAGAGAAAAACTATTTGCTGAGTACTGCC 70 
mgZC3H14NdeI-F CGGGAATTCCATATGGCCATGCTTATTGTGCAGTTGGC 70 
mgZC3H14BAMH1-
R 
CGGGAATTCCATATGGCCATGCTTATTGTGCAGTTGGC 70 
mgMKK7-F GGAATTCCATATGCTCTCCTGACCTGAGTCAGCGTGG 70 
mgMKK7-R GAAGATCTGGAATGTGCTCCTTGTCCAGTGGG 70 
mgMKK7210-F GGAATTCCATATGCCGAGGAGTCCCCTCCAGGCGTC 70 
mgMKK7220-R AGAAGATCTGTCCAAAGTGGAGCTGGGAGTAAGG 70 
mgEHMT2-F CGGGGTACCAGTGGTTCCAGTGGCCGGCG 70 
mgEHMT2-R AGATCTAAGCTTCTCTCCGTCCACACTCTCAGTGG 70 
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  Table A1.1.  Prediction of Alternative Splicing by RNA-Seq. 
Gene name Chromosome Strand A coordinates
JSL1 (-PMA) 
%inclusion
JSL1 (+PMA) 
%inclusion
dela PSI         
(rest-stim)
SLMAP 3 + 57886612'57886701 80.65 6.67 74
PPP1R12A 12 - 78723503-78723679 68.12 9.28 59
FAM136A 2 - 70382158-70382239 12.12 64.71 53
UGCGL1 2 + 128630436-128630459 62.16 15.56 47
FAM36A 1 + 243071869-243071983 90.91 48.39 43
BRD8 5 - 137523143-137523187 70.79 28.74 42
FIP1L1 4 + 53939997-53940041 71.43 30.77 41
LUC7L 16 - 218333-218402 48.48 88.57 40
ZNF384 12 - 6658090-6658137 46.67 86.67 40
GALT 9 + 34637489-34637564 53.85 93.10 39
HYOU1 11 - 118432941-118433035 57.52 18.31 39
DDHD1 14 - 52588312-52588395 54.84 15.79 39
ARHGEF7 13 + 110655637-110655721 61.11 100.00 39
SEC16A 9 - 138459325-138459384 53.33 17.33 36
TIR8 11 - 396843-396993 55.56 91.49 36
PLSCR3 17 - 7237644-7237879 50.00 85.71 36
BTBD10 11 - 13423147-13423304 68.89 33.33 36
RABL5 7 - 100748125-100748214 65.08 100.00 35
NGLY1 3 - 25748814-25748978 94.34 59.42 35
PUS1 12 + 130989671-130989773 66.67 100.00 33
PPA2 4 - 106597287-106597351 94.39 61.24 33
FAM21C 10 + 51529744-51529830 78.38 46.43 32
AKAP9 7 + 91459408-91459461 72.41 40.54 32
BTF3L4 1 + 52298095-52298161 92.00 60.87 31
POLQ 3 - 122661587-122661771 59.26 28.21 31
H2AFY 5 - 134714412-134714502 83.13 52.33 31
EHMT2 6 - 31964725-31964826 56.32 87.10 31
ZMIZ2 7 + 44766275-44766352 24.24 54.93 31
BPTF 17 + 63302134-63302322 82.46 52.00 30
NTAN1 16 - 15049355-15049457 80.39 50.00 30
RBM23 14 - 22447382-22447429 100.00 70.00 30
BPTF 17 + 63302134-63302322 75.34 45.45 30
C11orf57 11 + 111450821-111450850 68.18 38.46 30
C2orf33 2 + 227925474-227925533 80.95 51.52 29
SENP7 3 - 102702604-102702653 58.33 87.65 29
MACF1 1 + 39616720-39616782 41.33 12.08 29
MVK 12 + 108501990-108502134 93.75 64.71 29
CUGBP2 10 + 11348567-11348646 92.31 63.33 29
ZC3H14 14 + 88132831-88132905 55.29 84.21 29
 140 
  
WDR67 8 + 124215535-124215627 93.75 64.86 29
MED15 22 + 19259400-19259519 25.42 54.29 29
FAM33A 17 - 54551462-54551638 90.48 61.64 29
RPL41 12 + 54797240-54797262 66.67 95.35 29
LRRC40 1 - 70427363-70427544 72.00 100.00 28
TRPM2 21 + 44671321-44671422 72.22 100.00 28
PIGQ 16 + 572249-572310 66.67 94.44 28
COL4A3BP 5 - 74730891-74730968 33.33 5.66 28
FAM122B 23 - 133751276-133751332 55.29 27.66 28
ZNF346 5 + 176403996-176404140 65.71 93.33 28
PSD4 2 + 113672788-113672932 64.63 92.20 28
RPS2 16 - 1954278-1954367 58.70 86.21 28
PTPRC-E6 1 + 196938139-196938282 79.87 52.42 27
CCDC88A 2 - 55383709-55383792 65.31 92.45 27
TNRC6C 17 + 73605421-73605537 68.12 95.12 27
SFRS12 5 + 65490393-65490516 61.70 34.78 27
MAP3K7 6 - 91310992-91311072 34.55 7.69 27
WASF1 6 - 110588531-110588628 45.00 18.18 27
LRMP 12 + 25110566-25110713 97.50 70.73 27
CARD8 19 - 53433452-53433601 84.62 58.14 26
C10orf84 10 - 120091229-120091429 77.14 51.02 26
VPS11 11 + 118447516-118447763 100.00 73.91 26
PLEKHM2 1 + 15920411-15920470 59.14 33.33 26
ARPP-21 3 + 35704235-35704379 100.00 74.19 26
TMEM69 1 + 45929233-45929369 88.24 62.50 26
NRM 6 - 30765032-30765208 84.76 59.09 26
ERP29 12 + 110941943-110942081 49.34 74.76 25
AP1GBP1 17 - 33011591-33011824 45.83 20.43 25
MAP4K2 11 - 64324948-64325079 64.71 90.00 25
PARP6 15 - 70330240-70330349 61.22 86.44 25
DPP8 15 - 63533654-63533806 69.23 94.44 25
PTPRC-E4 1 + 196932464-196932661 33.18 7.97 25
C1orf85 1 - 154531174-154531431 52.63 77.78 25
PTPRC-E5 1 + 196935316-196935456 94.02 68.87 25
ABCD3 1 + 94696751-94696787 75.00 100.00 25
EDEM2 20 - 33189344-33189469 75.00 100.00 25
UBE2V1 20 - 48134073-48134198 75.00 100.00 25
MTRR 5 + 7939728-7939816 95.35 70.37 25
HISPPD1 5 + 102540467-102540510 34.69 9.76 25
RFXANK 19 + 19168995-19169060 46.15 71.05 25
TMC6 17 - 73632565-73632661 60.98 85.59 25
MYEF2 15 - 46230589-46230660 48.39 23.81 25
LTBP4 19 + 45814635-45814766 11.11 35.48 24
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  MAPK11 22 - 49048125-49048183 68.42 92.77 24
BAT2D1 1 + 169825131-169825367 4.55 28.89 24
NFYA 6 + 41156528-41156614 17.46 41.79 24
TBC1D13 9 + 130592835-130592875 69.23 93.55 24
HDAC10 22 - 49028248-49028332 94.12 69.81 24
ZNF289 11 - 47150837-47150878 24.14 0.00 24
C19orf2 19 + 35153940-35153974 46.09 70.21 24
MAN1B1 9 + 139117829-139117951 67.57 91.67 24
FYN 6 - 112128000-112128164 100.00 76.00 24
DLG1 3 - 198372908-198373006 32.14 8.20 24
UNC84B 22 - 37480593-37480657 62.50 86.36 24
BAT5 6 - 31777830-31777886 53.33 77.14 24
DMPK 19 - 50965481-50965738 76.47 100.00 24
ARHGAP17 16 - 24858186-24858419 35.00 11.54 23
PPP1R12A 12 - 78724077-78724244 68.00 91.40 23
TOR2A 9 - 129534664-129534791 63.33 86.67 23
VAPB 20 + 56443064-56443167 76.67 100.00 23
SRRM1 1 + 24846157-24846286 40.54 17.24 23
ATF2 2 - 175694488-175694514 44.44 67.74 23
MFN2 1 + 11964614-11964758 100.00 76.74 23
ZDHHC20 13 - 20893200-20893303 100.00 76.74 23
TRIM65 17 - 71399489-71399554 76.81 100.00 23
SGSM3 22 + 39127543-39127625 90.77 67.74 23
HDAC10 22 - 49029659-49029724 71.43 94.44 23
HDAC10 22 - 49029387-49029415 70.59 93.55 23
C22orf13 22 - 23280917-23281104 40.74 17.81 23
RBCK1 20 + 349524-349675 43.80 66.67 23
TPCN2 11 + 68578765-68578841 77.14 100.00 23
NOL8 9 - 94113249-94113362 77.14 100.00 23
ICMT 1 - 6216121-6216290 88.64 65.79 23
PMS2 7 - 5995957-5996112 69.49 46.67 23
DPY19L4 8 + 95816034-95816158 84.21 61.54 23
HISPPD1 5 + 102549920-102550039 53.49 30.86 23
FAM122B 23 - 133733839-133733979 55.00 32.56 22
MAP2K7 19 + 7876693-7876740 61.29 38.89 22
C11orf79 11 + 60962052-60962161 60.00 82.35 22
C1orf103 1 - 111295433-111296960 28.77 51.11 22
NCOR2 12 - 123507605-123507661 73.33 95.65 22
STX16 20 + 56677753-56677915 48.42 70.68 22
KIAA1191 5 - 175719420-175719527 38.89 61.11 22
AP1G2 14 - 23105611-23105735 59.29 81.48 22
RHOT1 17 + 27562248-27562370 39.13 16.98 22
RUNX3 1 - 25106337-25106495 72.41 94.52 22
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ZNF496 1 - 245552623-245552730 1.82 23.81 22
COX4NB 16 - 84371486-84371580 90.21 68.25 22
LOC647696 17 - 42602282-42602407 68.75 90.70 22
FBXW8 12 + 115871806-115871894 93.22 71.43 22
WSB1 17 + 22658897-22659072 61.67 83.45 22
PCMTD1 8 - 52914560-52914751 29.41 7.69 22
VPS29 12 - 109421645-109421734 53.33 75.00 22
IVNS1ABP 1 - 183542240-183542380 36.62 14.95 22
ATXN2 12 - 110438341-110438550 100.00 78.38 22
COQ5 12 - 119444400-119444549 65.71 87.23 22
RBM23 14 - 22450377-22450452 100.00 78.57 21
EIF4A2 3 + 187985445-187985584 62.57 83.89 21
TSR1 17 - 2186081-2186184 73.47 94.74 21
CD97 19 + 14368889-14369035 42.03 63.27 21
B3GALNT2 1 - 233719096-233719196 71.22 92.45 21
RLTPR 16 + 66236944-66237035 70.27 91.49 21
DSCR3 21 - 37534667-37534810 69.70 90.91 21
MGC4172 17 + 32030213-32030305 60.61 81.82 21
P2RX4 12 + 120139320-120139467 93.94 72.73 21
ARHGEF12 11 + 119785313-119785369 44.00 22.86 21
KIAA0746 4 - 25458014-25458584 78.95 100.00 21
LYPLA2 1 + 23992085-23992116 100.00 78.95 21
PPP2R5C 14 + 101453921-101454037 19.35 40.35 21
IWS1 2 - 127997787-127997837 74.36 95.35 21
PPP5C 19 + 51578508-51578573 75.90 96.77 21
ODF2 9 + 130259298-130259537 37.50 16.67 21
CDK5RAP2 9 - 122209111-122209347 73.33 52.54 21
MBD1 18 - 46054554-46054721 60.00 80.65 21
MYCBP2 13 - 76705292-76705399 76.47 55.84 21
SLAIN2 4 + 48091350-48091427 51.81 31.20 21
CMAH 6 - 25214566-25214701 95.00 74.47 21
ZNF33B 10 - 42447749-42447893 79.49 100.00 21
ARMC10 7 + 102520160-102520336 88.89 68.42 20
C18orf19 18 - 13661861-13661972 79.59 100.00 20
CKB 14 - 103056559-103056682 65.71 86.11 20
DUSP22 6 + 280114-280163 75.86 55.56 20
ARFGAP3 22 - 41637971-41638107 82.76 62.50 20
LRRC28 15 + 97634304-97634344 73.53 93.75 20
GOLGA4 3 + 37290031-37290096 74.07 94.29 20
NT5C2 10 - 104889153-104889226 75.38 95.45 20
SIP1 14 + 38672616-38672674 100.00 80.00 20
TOR1B 9 + 131611005-131611132 80.00 100.00 20
LARP4 12 + 49092455-49092503 30.43 10.53 20
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SEC22C 3 - 42580261-42580384 28.57 8.70 20
TRIM26 6 - 30280412-30280521 77.27 97.14 20
TRAF3 14 + 102425650-102425724 97.85 78.05 20
KIAA0182 16 + 84225021-84225239 62.58 82.35 20
CCDC14 3 - 125157380-125157502 94.74 75.00 20
ALKBH3 11 + 43870167-43870255 74.58 94.29 20
SEC16A 9 - 138459918-138459992 71.43 91.11 20
MYL6 12 + 54839674-54839781 73.14 92.71 20
REPS1 6 - 139289231-139289311 94.55 75.00 20
MAP7D1 1 + 36413086-36413196 64.71 84.21 20
Table A1.1.  Prediction of Alternative Splicing by RNA-Seq.  Complete data from the RNA-Seq 
alternative splicing analysis pipeline, comprising all ~ 11,000 exons for which greater than 10 exon-
junction reads were obtained. Gene names highlighted in bold indicate those AS events which have 
been validated by RT-PCR.  Gene names highlighted in grey indicate those AS events which were 
analyzed by RT-PCR and found to be inconsistent with the RNA-Seq prediction.
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Table A1.2: Non-Signal-Responsive Exons in JSL1 Cells Predicted by RNA-Seq
Gene % Inc - PMA         
RT-PCR
StDv % inc +PMA       
RT-PCR
StDv RT-PCR       
Differential
% Inc - PMA  
Solexa 
% Inc + PMA  
Solexa 
Solexa 
Differential
PMS1 86 2 85 2 -1 100 100 0
WDR67 75 3 73 6 -2 80 80 0
FoxM1 67 1 79 3 12 71 71 0
SFRS8 55 3 52 1 -3 86 87 1
ACTR10 98 1 99 0 1 62 63 1
DGUOK 9 2 9 1 0 66 67 1
PI4KB 6 1 4 1 -2 23 24 1
RNF216 0 0 0 0 0 54 53 -1
MAX 55 4 57 3 2 43 41 -2
C2orf33 14 3 14 1 0 73 76 3
ADAT1 14 1 18 2 4 77 80 3
CD3D 19 3 16 1 -3 78 74 -4
Table A1.2. RT-PCR analysis of exons predicted NOT to change in inclusion value between 
resting and stimulated JSL1 cells. (n> 3 for all data)
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Table A1.3. Ingenuity Pathway Analysis results. Complete genes and statistics above 
threshold of p>0.03 for (A) Functional analysis. 
Category  p-value Molecules
Nervous System 
Development and Function
1.16E-03-4.69E-02 RUNX3,WASF1,NTAN1,FYN,ATF2,SIGIRR
Organ Morphology 1.16E-03-3.42E-02 WASF1,FYN,FBXW8,ATF2,TRPM2
Cell Cycle 3.41E-03-3.42E-02 NCOR2,IVNS1ABP,PPP5C,MFN2,AKAP9,FYN,TOR2A,MAP2K7,ATF2
Cell-To-Cell Signaling and 
Interaction
3.41E-03-4.37E-02 NCOR2,CMAH,PTPRC,FYN,TRAF3,HYOU1,ATF2,DLG1,MAP3K7
Connective Tissue 
Development and Function
3.41E-03-3.42E-02 IVNS1ABP,PPP5C,LTBP4,FYN,TOR2A,MAP2K7,ARHGEF7,MAP3K7
Hematological System 
Development and Function
3.41E-03-4.37E-02 NCOR2,RUNX3,CMAH,NFYA,PTPRC,FYN,TRAF3,HYOU1,DLG1,MAP3
K7
Hematopoiesis 3.41E-03-3.42E-02 RUNX3,NFYA,PTPRC,FYN,MAP3K7
Immune Cell Trafficking 3.41E-03-4.37E-02 NCOR2,RUNX3,CMAH,PTPRC,FYN,TRAF3,HYOU1,DLG1,MAP3K7
Inflammatory Response 3.41E-03-4.37E-02 NCOR2,RUNX3,CMAH,PTPRC,FYN,TRAF3,HYOU1,DLG1,MAP3K7
Cancer 6.67E-03-4.37E-02 NCOR2,RUNX3,CCDC88A,FYN,TRAF3,MAP2K7,HYOU1,ATF2,ARMC1
Cellular Growth and 
Proliferation
6.67E-03-3.42E-02 RUNX3,PTPRC,FYN,MAP2K7,ATF2,ARMC10
Hematological Disease 6.67E-03-3.42E-02 LYPLA2,TRAF3,MAP2K7,ATF2
Immunological Disease 6.67E-03-3.42E-02 LYPLA2,TRAF3,MAP2K7,RFXANK
Skeletal and Muscular 
System Development and 
Function
6.67E-03-4.69E-02 ICMT,LUC7L,MFN2,SLMAP,TOR2A,MAP2K7,DLG1,ARHGEF7,MAP3K7,
MYL6,P2RX4,COL4A3BP
Tissue Development 6.67E-03-4.69E-02 ICMT,LUC7L,RUNX3,CMAH,PTPRC,FYN,MAP2K7,DLG1,ARHGEF7,MY
L6,MAP3K7
Cellular Development 8.17E-03-3.42E-02 RUNX3,NFYA,PTPRC,FYN,ATF2,ARMC10,MAP3K7
Gene Expression 1.09E-02-4.22E-02 IVNS1ABP,C1orf85,ZMIZ2,MAPK11,HDAC10,ARHGEF7,PPP2R5C,BPTF
,ARHGEF12,RUNX3,BRD8,ATF2,MAP3K7,EHMT2,NFYA,FYN,PUS1,MB
D1,MAP2K7,ZNF496,DUSP22,MYCBP2,ZNF384,NCOR2,PPP5C,C19orf
2,MACF1,RFXANK,MED15
Post-Translational 
Modification
1.21E-02-3.42E-02 EDEM2,ERP29,LTBP4,UGGT1,FYN,MAN1B1
Protein Folding 1.21E-02-1.21E-02 EDEM2,ERP29,LTBP4,UGGT1,MAN1B1
Cell Signaling 1.29E-02-3.61E-02 ICMT,MFN2,UBE2V1,CARD8,PTPRC,RBCK1,FYN,MAP4K2,MAPK11,PP
P5C,NT5C2,RFXANK,MAP3K7
Tissue Morphology 1.42E-02-3.42E-02 LTBP4,RUNX3,SLMAP,PTPRC,FYN,ATF2,MYL6,P2RX4,COL4A3BP
Cell Death 1.58E-02-3.42E-02 RUNX3,PTPRC,TRAF3,MAP3K7
Cellular Assembly and 
Organization
1.59E-02-3.42E-02 ABCD3,CCDC88A,CKB,LRMP,WASF1,FYN,MAP4K2,ARHGEF7,DLG1,A
P1G2,MAP3K7
Cellular Function and 
Maintenance
1.8E-02-3.42E-02 MFN2,CCDC88A,CKB,WASF1,FYN,DLG1,ARHGEF7,SIGIRR,MAP3K7
Behavior 2.18E-02-4.69E-02 NTAN1,FYN,SIGIRR
Carbohydrate Metabolism 2.18E-02-3.42E-02 CMAH,GALT,B3GALNT2,LYPLA2,MAN1B1,MTRR
Reproductive System 
Disease
2.18E-02-2.18E-02 EHMT2,FBXW8
Cell-mediated Immune 
Response
2.84E-02-3.42E-02 FYN,DLG1
Molecular Transport 2.84E-02-4.69E-02 ABCD3,SRRM1,NT5C2,ATXN2,GALT,LYPLA2,DMPK,FYN,TRAF3,DLG1,
P2RX4
RNA Trafficking 2.84E-02-2.84E-02 SRRM1,ATXN2
© 2000-2011 Ingenuity Systems, Inc. All rights reserved.
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Table A1.3. Ingenuity Pathway Analysis results. Complete genes and statistics above 
threshold of p>0.03 for (B) Canonical Signaling analysis.
Ingenuity Canonical 
Pathways
 -log(p-value) Molecules
Phospholipase C Signaling 2.22E00 PPP1R12A,ARHGEF12,RHOT1,FYN,ATF2,HDAC10,ARHGEF7,MYL6
Cardiomyocyte 
Differentiation via BMP 
Receptors
2.18E00 ATF2,MAP3K7
Production of Nitric Oxide 
and Reactive Oxygen 
Species in Macrophages
1.87E00 PPP1R12A,RHOT1,MAPK11,MAP2K7,PPP2R5C,MAP3K7
Regulation of Actin-based 
Motility by Rho
1.8E00 PPP1R12A,WASF1,RHOT1,MYL6
CD40 Signaling 1.74E00 MAPK11,TRAF3,MAP2K7,MAP3K7
April Mediated Signaling 1.73E00 MAPK11,TRAF3,MAP2K7
B Cell Activating Factor 
Signaling
1.66E00 MAPK11,TRAF3,MAP2K7
NF-κB Signaling 1.64E00 UBE2V1,TRAF3,MAP2K7,SIGIRR,MAP3K7
SAPK/JNK Signaling 1.56E00 MAP4K2,ATF2,MAP2K7,MAP3K7
Role of PKR in Interferon 
Induction and Antiviral 
Response
1.54E00 TRAF3,ATF2,MAP3K7
Role of MAPK Signaling in 
the Pathogenesis of 
Influenza
1.54E00 MAPK11,ATF2,MAP2K7
RhoA Signaling 1.52E00 PPP1R12A,ARHGEF12,WASF1,MYL6
© 2000-2011 Ingenuity Systems, Inc. All rights reserved.
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Table A1.4  Ingenuity Pathway Analysis: Functional Categories. 
Transcripts Up-regulated upon Stimulation
Functional Categories p-value Molecules
Inflammatory Response 1.18E-21-3.65E-03 SELL,CD40LG,MBP,CTSW,LTB,TGFBR2,CD28,IFITM2,CD226,KRT1,
CD84,GZMA,STAT5A,IL4R,PTPRE,HSH2D,SAMSN1,ITGA6,IER3,LGA
LS9B,APOBEC3G,IL18BP,SELP,PNP,RARRES3,ITGA1,GPR68,RXRA,
TFPI,ADCYAP1 (includes 
EG:11516),LCP2,TMEM173,TNFSF10,TNFAIP3,LGALS9,ARRB1,TIMP
1,GBP2 (includes 
EG:14469),SEMA4A,HPGDS,SLA2,EPAS1,FLT1,RELB,EGR1,CD69,A
LOX5AP,CD58,SLIT2,IL16,CCR4,RETN,GATA3,LGALS1
Cellular Movement 5.7E-14-2.8E-03 CD40LG,SELL,TNFAIP3,LTB,TNFSF10,LGALS9,TGFBR2,CD28,ARR
B1,TIMP1,CD226,STAT5A,PIK3C2B,TP53INP1,IL4R,EPAS1,FGFR1,P
OU4F1,EGR1,RELB,CD69,FLT1,SH2D3C,ITGA6,CD58,ALOX5AP,TRP
C6,IER3,SLIT2,IL18BP,IL16,RETN,SELP,CCR4,TGFA,ITGA1,CD82,HH
EX,ADCYAP1 (includes 
EG:11516),TFPI,RXRA,GATA3,LCP2,LGALS1,ETV5
Immune Cell Trafficking 5.7E-14-3.65E-03 CD40LG,SELL,MBP,TNFSF10,LTB,TNFAIP3,LGALS9,TGFBR2,CD28,
ARRB1,TIMP1,CD226,SEMA4A,CD84,SLA2,GZMA,STAT5A,PTPRE,IL
4R,HSH2D,EPAS1,SAMSN1,RELB,EGR1,FLT1,CD69,SH2D3C,ITGA6,
ALOX5AP,CD58,IER3,SLIT2,IL16,IL18BP,CCR4,RETN,SELP,ITGA1,G
ATA3,ADCYAP1 (includes EG:11516),RXRA,LCP2,LGALS1
Hematological System 
Development and 
Function
1.65E-13-3.65E-03 CD40LG,SELL,MBP,ZFP36L1,LTB,HES1 (includes 
EG:15205),TGFBR2,CD28,CD226,CD84,GZMA,STAT5A,PTPRE,IL4R,
TP53INP1,HSH2D,SAMSN1,SH2D3C,ITGA6,IER3,LGALS9B,IL18BP,L
ST1,SELP,PNP,ITGA1,HHEX,TFPI,RXRA,ADCYAP1 (includes 
EG:11516),LCP2,TNFSF10,TNFAIP3,LGALS9,CD52,ARRB1,TIMP1,LY
L1,SEMA4A,HPGDS,SLA2,EPAS1,FLT1,CD69,EGR1,RELB,CD58,AL
OX5AP,SLIT2,IL16,ZFPM2,CCR4,RETN,HLA-E,CD82,GATA3,LGALS1
Cardiovascular System 
Development and 
Function
7.36E-12-3.29E-03 CD40LG,SELL,MB,ZFP36L1,TNFSF10,TNFAIP3,SPRY4,TGFBR2,CD
28,TIMP1,CASP10,STAT5A,TUBB3,IL4R,EPAS1,ADAMTS1,SPRY1,F
GFR1,FLT1,TUBA4A,TRPC6,SLIT2,PLXND1,IL18BP,ZFPM2,SELP,TG
FA,ITGA1,HHEX,TFPI,GATA3,LGALS1
Organismal Development 7.36E-12-2.8E-03 MB,ZFP36L1,TNFAIP3,TNFSF10,LTB,HES1 (includes 
EG:15205),SPRY4,TGFBR2,CD28,TIMP1,FOXB1,KRT1,STAT5A,IL4R,
EPAS1,ADAMTS1,SPRY1,POU4F1,RELB,FLT1,FGFR1,EGR1,ITGA6,
SLIT2,PLXND1,IL18BP,ZFPM2,SELP,TGFA,ITGA1,HHEX,TFPI,GATA3
,ADCYAP1 (includes EG:11516),RXRA,LCP2,LGALS1
Cell-To-Cell Signaling and 
Interaction
7.64E-12-3.65E-03 CD40LG,SELL,MBP,LTB,HES1 (includes 
EG:15205),TGFBR2,CD28,CD226,CD84,CASP10,GZMA,STAT5A,IL4R
,PTPRE,HSH2D,SAMSN1,FGFR1,ITGA6,SELP,PNP,RARRES3,ITGA1
,RXRA,ADCYAP1 (includes 
EG:11516),TFPI,PARVG,LCP2,TNFAIP3,TNFSF10,LGALS9,CD52,TIM
P1,FOXB1,SEMA4A,SLA2,SPRY1,CD69,RELB,FLT1,EGR1,CD58,SLI
T2,PLXND1,IL16,RETN,CCR4,TGFA,CD82,GATA3,SIGLEC6,LGALS1
Cellular Growth and 
Proliferation
6.01E-11-3.65E-03 CD40LG,SGK1,MBP,ZFP36L1,LTB,HES1 (includes 
EG:15205),TGFBR2,CD28,CD84,STAT5A,TUBB3,IL4R,TP53INP1,PTP
RE,HSH2D,ADAMTS1,SAMSN1,POU4F1,FGFR1,SH2D3C,ITGA6,TR
PC6,IER3,LST1,SELP,PNP,RARRES3,NEIL1,ITGA1,HHEX,ADCYAP1 
(includes 
EG:11516),RXRA,TFPI,LCP2,ETV5,DUSP6,TNFSF10,TNFAIP3,LGAL
S9,CD52,COL6A1,TIMP1,HPGD,GBP2 (includes 
EG:14469),HPGDS,EPAS1,SPRY1,EGR1,CD69,RELB,FLT1,CD58,SLI
T2,IL16,RETN,HLA-E,TGFA,CD82,GATA3,LGALS1
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Table A1.4  Ingenuity Pathway Analysis: Functional Categories. 
Transcripts Up-regulated upon Stimulation
Tissue Morphology 7.91E-11-3.31E-03 SELL,CD40LG,SGK1,TNFAIP3,TNFSF10,LTB,HES1 (includes 
EG:15205),TGFBR2,CD28,TIMP1,HPGDS,STAT5A,TUBB3,IL4R,EPAS
1,ADAMTS1,SAMSN1,POU4F1,FLT1,CD69,EGR1,RELB,FGFR1,SH2
D3C,ITGA6,LGALS9B,IL18BP,SELP,CCR4,PNP,TGFA,RARRES3,ITG
A1,GATA3,ADCYAP1 (includes EG:11516),RXRA,LCP2
Cellular Development 1.46E-09-3.35E-03 CD40LG,MBP,LTB,HES1 (includes 
EG:15205),SPRY4,TGFBR2,CD28,IFITM2,STAT5A,TP53INP1,IL4R,TU
BB3,ADAMTS1,FGFR1,POU4F1,ITGA6,TRPC6,IER3,SELP,PNP,RAR
RES3,ITGA1,HHEX,TFPI,ADCYAP1 (includes 
EG:11516),RXRA,LCP2,ETV5,MB,NID2,TNFSF10,TNFAIP3,LGALS9,C
D52,TIMP1,LYL1,HPGD,SEMA4A,EPAS1,SPRY1,FLT1,CD69,EGR1,R
ELB,SLIT2,ZFPM2,RETN,TGFA,CD82,GATA3,LGALS1
Dermatological Diseases 
and Conditions
2.06E-09-3.4E-03 SELL,LAPTM5,SGK1,MBP,LTB,TNFAIP3,TNFSF10,TMC6,CLEC2B,TG
FBR2,CD28,CD52,TIMP1,IFITM2,FAR2,GBP2 (includes 
EG:14469),KRT1,TMC8,TUBB3,IL4R,IER2,RELB,FGFR1,FLT1,EGR1,
TUBA4A,ITGA6,ALOX5AP,PLXND1,IL16,SELP,CCR4,HLA-
E,TGFA,ITGA1,GATA3,RXRA,LCP2,LGALS1
Inflammatory Disease 2.06E-09-3.4E-03 SELL,CD40LG,SCML1,SGK1,MBP,LTB,TGFBR2,CD28,IFITM2,CD226,
KRT1,FAM101B,CASP10,GZMA,TP53INP1,AMPD3,IL4R,TUBB3,ADA
MTS1,POU4F1,FGFR1,ITGA6,IL18BP,LST1,SELP,ITGA1,RXRA,LCP2,
LAPTM5,TMEM173,TNFAIP3,TNFSF10,CLEC2B,CD52,COL6A1,SLFN
5,ARRB1,TIMP1,HPGD,GBP2 (includes 
EG:14469),SEMA4A,EPAS1,RELB,CD69,FLT1,EGR1,TUBA4A,ALOX5
AP,CD58,NMT2,SLIT2,PLXND1,IL16,RETN,CCR4,HLA-
E,TGFA,GATA3,LGALS1
Hematopoiesis 1.21E-08-2.59E-03 CD40LG,MBP,TNFAIP3,TNFSF10,LTB,HES1 (includes 
EG:15205),TGFBR2,CD28,CD52,TIMP1,LYL1,SEMA4A,STAT5A,IL4R,
TP53INP1,EPAS1,FLT1,RELB,EGR1,CD69,ZFPM2,SELP,PNP,RARRE
S3,ITGA1,HHEX,RXRA,ADCYAP1 (includes 
EG:11516),GATA3,LCP2,LGALS1
Renal and Urological 
Disease
1.87E-08-3.4E-03 TUBB3,CD40LG,EPAS1,SGK1,SAMSN1,FLT1,FGFR1,TUBA4A,ITGA6
,TNFSF10,TNFAIP3,TRPC6,IL16,CD28,COL6A1,SELP,TIMP1,TGFA,IT
GA1,CPXM1
Cardiovascular Disease 2.53E-08-9.39E-04 CD40LG,KIAA1462,TNFSF10,TNFAIP3,TGFBR2,CD28,CD52,TIMP1,T
OX2,DPF3,STAT5A,PTPRE,TUBB3,EPAS1,MAST4,FLT1,EGR1,TUBA
4A,ALOX5AP,HIVEP3,RCBTB2,ZFPM2,SELP,TGFA,RXRA,TFPI,GATA
3
Immunological Disease 2.72E-08-3.4E-03 CD40LG,SELL,SCML1,MBP,LTB,TGFBR2,CD28,IFITM2,CD226,KRT1,
FAM101B,CASP10,GZMA,TUBB3,AMPD3,IL4R,HSH2D,MAST4,FGFR
1,ITGA6,PREX2,IL18BP,LST1,SELP,PNP,ITGA1,RXRA,LCP2,ETV5,LA
PTM5,TMEM173,TNFAIP3,TNFSF10,PLCH1,CLEC2B,CD52,SLFN5,A
RRB1,TIMP1,SEMA4A,GBP2 (includes 
EG:14469),HPGDS,DPF3,EPAS1,CD69,TUBA4A,NMT2,SLIT2,PLXND
1,IL16,TMEM2,CCR4,HLA-E,TGFA,GATA3,LGALS1
Cancer 2.73E-08-3.58E-03 SELL,CD40LG,SGK1,MBP,LTB,HES1 (includes 
EG:15205),TGFBR2,CD28,IFITM2,KRT1,CASP10,GZMA,STAT5A,IL4
R,PTPRE,TP53INP1,TUBB3,ADAMTS1,SAMSN1,IER2,FGFR1,ITGA6,
TRPC6,IER3,APOBEC3G,IL18BP,SELP,PNP,ITGA1,RXRA,TFPI,ETV5,
DUSP6,TNFSF10,TNFAIP3,PLCH1,CD52,COL6A1,ARRB1,TIMP1,HP
GD,ANTXR2,HPGDS,GBP2 (includes 
EG:14469),EPAS1,RELB,FLT1,CD69,EGR1,TUBA4A,CD58,SLIT2,KLH
L6,IL16,ZFPM2,LPCAT2,RETN,CCR4,HLA-
E,TGFA,LIMD2,CD82,GATA3,LGALS1
Cell-mediated Immune 
Response
5.47E-08-2.59E-03 CD40LG,SELL,MBP,TNFSF10,LTB,TNFAIP3,TGFBR2,CD28,CD52,CD
226,SEMA4A,STAT5A,IL4R,CD69,RELB,EGR1,FLT1,ITGA6,IL18BP,IL
16,CCR4,SELP,PNP,GATA3,ADCYAP1 (includes 
EG:11516),LCP2,LGALS1
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Table A1.4  Ingenuity Pathway Analysis: Functional Categories. 
Transcripts Up-regulated upon Stimulation
Cellular Function and 
Maintenance
5.47E-08-2.59E-03 CD40LG,SGK1,MBP,LTB,TNFAIP3,TNFSF10,HES1 (includes 
EG:15205),TGFBR2,CD28,CD52,SEMA4A,GZMA,SLA2,STAT5A,PIK3
C2B,IL4R,RELB,EGR1,CD69,FLT1,TRPC6,RETN,CCR4,PNP,ADCYAP
1 (includes EG:11516),GATA3,LCP2,LGALS1
Lymphoid Tissue 
Structure and 
Development
5.47E-08-2.59E-03 CD40LG,MBP,LTB,TNFAIP3,TNFSF10,HES1 (includes 
EG:15205),TGFBR2,CD28,CD52,TIMP1,SEMA4A,STAT5A,IL4R,FLT1,
EGR1,RELB,CD69,SH2D3C,KLHL6,SELP,PNP,ITGA1,TFPI,ADCYAP1 
(includes EG:11516),GATA3,LCP2,LGALS1
Neurological Disease 8.72E-08-2.72E-03 SELL,CD40LG,MBP,EGR1,CD58,TNFSF10,IL18BP,CD28,CD52,ARRB
1,TIMP1,SEMA4A,LCP2,LGALS1
Hematological Disease 9.44E-08-3.51E-03 SELL,CD40LG,SGK1,LTB,TNFAIP3,TNFSF10,TGFBR2,CD28,CD52,H
PGDS,CASP10,STAT5A,TUBB3,CD69,FLT1,FGFR1,EGR1,TUBA4A,IT
GA6,CD58,IER3,KLHL6,IL16,PNP,ITGA1,RXRA
Connective Tissue 
Disorders
1.11E-07-2.32E-03 SCML1,CD40LG,TMEM173,TNFSF10,LTB,TNFAIP3,CLEC2B,CD28,C
OL6A1,SLFN5,TIMP1,CD226,GBP2 (includes 
EG:14469),FAM101B,CASP10,GZMA,IL4R,AMPD3,TUBB3,EPAS1,AD
AMTS1,POU4F1,CD69,FLT1,FGFR1,TUBA4A,ALOX5AP,NMT2,SLIT2,
PLXND1,IL16,IL18BP,LST1,CCR4,SELP,RETN,HLA-E,RXRA,LGALS1
Skeletal and Muscular 
Disorders
1.11E-07-2.32E-03 SCML1,CD40LG,TMEM173,TNFSF10,LTB,TNFAIP3,CLEC2B,CD28,C
OL6A1,SLFN5,TIMP1,IFITM2,CD226,GBP2 (includes 
EG:14469),FAM101B,CASP10,GZMA,IL4R,AMPD3,TUBB3,EPAS1,AD
AMTS1,POU4F1,CD69,FLT1,FGFR1,TUBA4A,ALOX5AP,NMT2,SLIT2,
PLXND1,IL16,IL18BP,LST1,CCR4,SELP,RETN,HLA-E,RXRA,LGALS1
Cell Death 2.06E-07-3.4E-03 CD40LG,SGK1,MBP,LTB,HES1 (includes 
EG:15205),TGFBR2,CD28,MICAL1,UBA7,CD226,CASP10,GZMA,STA
T5A,IL4R,TP53INP1,TUBB3,PTPRE,HSH2D,POU4F1,FGFR1,ITGA6,I
ER3,PNP,RARRES3,ITGA1,HHEX,ADCYAP1 (includes 
EG:11516),RXRA,MB,DUSP6,TMEM173,TNFSF10,TNFAIP3,LGALS9,
ARRB1,TIMP1,ANTXR2,FOXB1,HPGDS,HCST,EPAS1,CD69,EGR1,FL
T1,RELB,SLIT2,PPP1R16B,HLA-
E,TGFA,CD82,GATA3,LGALS1,FAIM3
Tissue Development 2.66E-07-3.6E-03 SELL,CD40LG,SGK1,MBP,ZFP36L1,LTB,HES1 (includes 
EG:15205),TGFBR2,CD28,CD226,KRT1,STAT5A,IL4R,PTPRE,ADAM
TS1,FGFR1,POU4F1,ITGA6,TRPC6,IER3,IL18BP,LST1,SELP,ITGA1,
HHEX,PARVG,RXRA,ADCYAP1 (includes 
EG:11516),TFPI,LCP2,MB,CHST7,NID2,TNFSF10,LGALS9,TIMP1,AN
TXR2,FOXB1,SHANK3,EPAS1,SPRY1,FLT1,RELB,EGR1,CD69,HIVE
P3,CD58,SLIT2,PLXND1,ZFPM2,CCR4,TGFA,CD82,GATA3,LGALS1
Genetic Disorder 3.34E-07-1.51E-03 CD40LG,SGK1,DUSP6,MBP,TNFSF10,TNFAIP3,HES1 (includes 
EG:15205),TMC6,CLEC2B,TGFBR2,CD28,CD52,COL6A1,TIMP1,ANT
XR2,FAR2,HPGD,GBP2 (includes 
EG:14469),KRT1,TMC8,CASP10,GZMA,TP53INP1,TUBB3,IL4R,EPAS
1,ADAMTS1,IER2,RELB,FGFR1,FLT1,EGR1,ITGA6,TUBA4A,ALOX5A
P,IER3,SLIT2,IL16,CCR4,SELP,TGFA,CD82,ITGA1,GATA3,RXRA,LCP
2,ETV5,LGALS1
Antigen Presentation 9.91E-07-3.4E-03 CD40LG,SELL,LTB,TNFAIP3,TNFSF10,CD28,ARRB1,TIMP1,CD226,K
RT1,GZMA,IL4R,PTPRE,EPAS1,RELB,CD69,FLT1,ITGA6,CD58,SLIT2
,IL16,RETN,ITGA1,LCP2,LGALS1
Gastrointestinal Disease 1.71E-06-3.58E-03 CD40LG,SGK1,DUSP6,LTB,TNFSF10,LGALS9,TGFBR2,COL6A1,TIM
P1,IFITM2,HPGD,CASP10,STAT5A,TP53INP1,TUBB3,IL4R,EPAS1,A
DAMTS1,RELB,EGR1,CD69,FGFR1,FLT1,TUBA4A,ITGA6,CD58,SLIT
2,LPCAT2,RETN,HLA-
E,TGFA,ITGA1,CD82,TFPI,RXRA,PCBP3,LGALS1,ETV5
Hepatic System Disease 1.71E-06-1.57E-03 CD40LG,TUBB3,IL4R,EPAS1,EGR1,FGFR1,FLT1,TUBA4A,ITGA6,LTB
,TNFSF10,LGALS9,TGFBR2,TIMP1,TGFA,RXRA,PCBP3
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Table A1.4  Ingenuity Pathway Analysis: Functional Categories. 
Transcripts Up-regulated upon Stimulation
Lipid Metabolism 3.42E-06-3.4E-03 CD40LG,SGK1,HCAR1,MBP,TNFSF10,GBP5,CD28,TIMP1,HPGD,FA
R2,HPGDS,STAT5A,PIK3C2B,IL4R,EGR1,FLT1,ITGA6,ALOX5AP,SLC
O2A1,IL16,IL18BP,LPCAT2,RETN,TGFA,CD82,ADCYAP1 (includes 
EG:11516),RXRA,TFPI,LGALS1
Small Molecule 
Biochemistry
3.42E-06-3.4E-03 CD40LG,MB,SGK1,HCAR1,MBP,TNFSF10,TNFAIP3,GBP5,CD28,ARR
B1,TIMP1,HPGD,FAR2,HPGDS,PIK3C2B,STAT5A,IL4R,FLT1,EGR1,IT
GA6,ALOX5AP,SLCO2A1,IL16,IL18BP,LPCAT2,RETN,TGFA,CD82,TF
PI,RXRA,ADCYAP1 (includes EG:11516),GPR68,LGALS1
Humoral Immune 
Response
3.82E-06-2.96E-03 STAT5A,CD40LG,TP53INP1,IL4R,HSH2D,SAMSN1,RELB,FLT1,CD69,
EGR1,SH2D3C,LTB,KLHL6,TGFBR2,CD28,LYL1,PNP,HHEX,KRT1,LG
ALS1
Molecular Transport 7.55E-06-3.04E-03 SELL,CD40LG,SGK1,HCAR1,MBP,TNFSF10,GBP5,CD28,ARRB1,TIM
P1,HPGD,HPGDS,SLA2,PIK3C2B,IL4R,EGR1,ALOX5AP,TRPC6,IL16,
IL18BP,RETN,SELP,CCR4,TGFA,GPR68,ADCYAP1 (includes 
EG:11516),RXRA,TFPI,LCP2,LGALS1
Skeletal and Muscular 
System Development and 
Function
1.09E-05-2.22E-03 TGFBR2,RETN,TIMP1,FLT1,FGFR1,ITGA6,TNFSF10,TNFAIP3,TRPC
6,RXRA,TFPI
Respiratory Disease 1.23E-05-6.66E-04 SELL,TUBB3,EPAS1,EGR1,DUSP6,FLT1,FGFR1,TUBA4A,HES1 
(includes 
EG:15205),SLIT2,TGFBR2,IL16,SELP,TIMP1,TGFA,HPGD,ITGA1,RX
RA,CASP10
Organismal Injury and 
Abnormalities
1.86E-05-1.81E-03 SELL,IL4R,CD40LG,EPAS1,MB,FLT1,FGFR1,EGR1,TNFAIP3,LTB,TN
FSF10,TGFBR2,SELP,TIMP1,TGFA,LCP2
Reproductive System 
Disease
3.5E-05-3.4E-03 CD40LG,SELL,SGK1,MBP,TGFBR2,CD52,COL6A1,TIMP1,IFITM2,AN
TXR2,GBP2 (includes 
EG:14469),KRT1,CASP10,GZMA,TP53INP1,TUBB3,PTPRE,IER2,FGF
R1,FLT1,RELB,EGR1,CD69,ITGA6,TUBA4A,IER3,SLIT2,APOBEC3G,
ZFPM2,LPCAT2,CCR4,TGFA,ITGA1,CD82,RXRA,GATA3,ETV5
Reproductive System 
Development and 
Function
4.16E-05-1.41E-03 TGFBR2,STAT5A,TIMP1,FLT1,EGR1,HPGD,TGFA,FOXB1,HES1 
(includes EG:15205),ADCYAP1 (includes EG:11516)
Gene Expression 9.82E-05-3.65E-03 CD40LG,IL4R,EPAS1,RELB,EGR1,TNFAIP3,IER3,CD28,TGFA,GBP2 
(includes EG:14469),ADCYAP1 (includes 
EG:11516),RXRA,GATA3,LCP2,LGALS1
Drug Metabolism 1.4E-04-3.8E-04 IL18BP,CD40LG,TGFA,HPGD,TNFSF10,SLCO2A1,HPGDS
Infectious Disease 1.85E-04-2.32E-03 CD40LG,SGK1,CTSW,TNFSF10,TNFAIP3,TMC6,CLEC2B,CD28,UBA
7,IFITM2,HPGD,ANTXR2,TMC8,GZMA,EPAS1,FGFR1,RELB,CD58,B
ZRAP1,ALOX5AP,APOBEC3G,IL16,RETN,RARRES3,RXRA
Embryonic Development 2.1E-04-2.22E-03 MB,LTB,HES1 (includes 
EG:15205),TGFBR2,TIMP1,FOXB1,KRT1,STAT5A,EPAS1,ADAMTS1,
SPRY1,POU4F1,RELB,FLT1,FGFR1,EGR1,ITGA6,SLIT2,IL18BP,ZFP
M2,SELP,TGFA,ITGA1,HHEX,GATA3,ADCYAP1 (includes 
EG:11516),RXRA,LCP2
Organ Development 2.1E-04-2.59E-03 MB,LTB,HES1 (includes 
EG:15205),TGFBR2,TIMP1,FOXB1,SEMA4A,KRT1,STAT5A,EPAS1,A
DAMTS1,SPRY1,RELB,FLT1,FGFR1,EGR1,ITGA6,SLIT2,IL18BP,ZFP
M2,SELP,TGFA,ITGA1,HHEX,GATA3,ADCYAP1 (includes 
EG:11516),RXRA,LCP2
Cell Signaling 2.19E-04-3.35E-03 SLA2,PIK3C2B,CD40LG,SELL,MB,SAMSN1,FGFR1,MBP,ITGA6,TNF
SF10,TNFAIP3,TRPC6,IL16,CD28,SELP,CCR4,TGFA,ADCYAP1 
(includes EG:11516),LCP2,LGALS1
Vitamin and Mineral 
Metabolism
2.19E-04-1.12E-03 SLA2,PIK3C2B,SELL,MBP,TRPC6,IL16,CD28,SELP,CCR4,TGFA,ADC
YAP1 (includes EG:11516),LCP2,LGALS1
Carbohydrate Metabolism 2.42E-04-2.8E-03 CD28,CD40LG,ARRB1,LPCAT2,FLT1,TGFA,GPR68,ADCYAP1 
(includes EG:11516),LGALS1
Cell Cycle 3.8E-04-3.65E-03 STAT5A,CD28,CD40LG,IL4R,TNFSF10,LGALS1
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Table A1.4  Ingenuity Pathway Analysis: Functional Categories. 
Transcripts Up-regulated upon Stimulation
Cell Morphology 3.8E-04-3.29E-03 PTPRE,CD40LG,FLT1,EGR1,ITGA6,TNFSF10,TGFBR2,CD28,TGFA,
RARRES3,CD82,RXRA,GATA3,LCP2
Energy Production 3.8E-04-3.8E-04 HPGD,SLCO2A1
Hair and Skin 
Development and 
Function
3.8E-04-2.8E-03 TGFBR2,PIK3C2B,SELL,MB,TIMP1,SH2D3C,TGFA,ITGA1,SEMA4A
Nervous System 
Development and 
Function
3.8E-04-3.31E-03 PTPRE,MBP,POU4F1,FGFR1,EGR1,ITGA6,SLIT2,HES1 (includes 
EG:15205),ARRB1,CCR4,TGFA,FOXB1,ADCYAP1 (includes 
EG:11516),GATA3
Tumor Morphology 4.39E-04-2.8E-03 SELL,FLT1,FGFR1,ITGA6,SLIT2,TGFBR2,IL18BP,TIMP1,TGFA,ITGA1
,ADCYAP1 (includes EG:11516),TFPI,LGALS1
Cellular Compromise 5.64E-04-2.8E-03 CD28,SELL,CD40LG,SLIT2,TFPI,ADCYAP1 (includes EG:11516)
Free Radical Scavenging 6.83E-04-2.28E-03 GZMA,CD28,CD40LG,CD52,EPAS1,SELP,TGFA,ITGA1,ADCYAP1 
(includes EG:11516),LCP2
Hepatic System 
Development and 
Function
9.67E-04-2.22E-03 TGFBR2,TIMP1,FLT1,TGFA,LTB,HHEX,LGALS1
Developmental Disorder 1.12E-03-1.12E-03 TGFA,KRT1
Endocrine System 
Development and 
Function
1.12E-03-1.12E-03 EGR1,HES1 (includes EG:15205)
Hypersensitivity 
Response
1.12E-03-2.28E-03 IL16,PTPRE,SELL,SELP,CD226,LCP2
Organismal Survival 1.63E-03-1.63E-03 STAT5A,IL4R,CD40LG,FLT1,POU4F1,PNP,ANTXR2,TNFSF10,ITGA1,
ADCYAP1 (includes EG:11516),TFPI,LGALS1
Renal and Urological 
System Development and 
Function
1.81E-03-2.03E-03 CD28,ADAMTS1,TIMP1,SPRY1,FGFR1,SLIT2,GATA3,PLXND1
Cellular Assembly and 
Organization
2.22E-03-2.22E-03 PTPRE,MBP
Digestive System 
Development and 
Function
2.22E-03-2.22E-03 FGFR1,ITGA6
Organ Morphology 2.22E-03-2.55E-03 TGFBR2,TIMP1,FGFR1,ITGA6,PNP,TGFA,ALOX5AP
Protein Synthesis 2.22E-03-2.22E-03 CD28,CD40LG
Post-Translational 
Modification
3.35E-03-3.35E-03 CD28,SELL,SAMSN1,FGFR1,ITGA6,LGALS1
Metabolic Disease 3.37E-03-3.37E-03 SELL,CD40LG,TNFSF10,HES1 (includes 
EG:15205),CLEC2B,PLCH1,TGFBR2,CD28,CD52,TIMP1,GBP2 
(includes 
EG:14469),HPGDS,CASP10,DPF3,PTPRE,TUBB3,EPAS1,HSH2D,MA
ST4,SAMSN1,CD69,FGFR1,TUBA4A,BZRAP1,HIVEP3,PREX2,NMT2,
LST1,TMEM2,SELP,RETN,TGFA,ADCYAP1 (includes 
EG:11516),PCBP3
© 2000-2011 Ingenuity Systems, Inc. All rights reserved.
Table A1.4. Ingenuity Pathway Analysis results for targets of regulated gene expression. 
Complete list of genes and statistics above threshold of p<0.03 for (A) Functional analysis of genes 
up-regulated. (B) Functional analysis of genes down-regulated. (C) Canonical Signaling pathway 
analysis of genes up-regulated. (D) Canonical Signaling pathway analysis of genes down-
regulated.
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Table A1.4B:  Ingenuity Pathway Analysis: Functional Categories. 
Transcripts Down-regulated upon Stimulation
Functional 
Categories
p-value Molecules
Nervous System 
Development and 
Function
6.74E-07-1.09E-02 GAB2,SLIT1,SLC6A9 (includes 
EG:116509),EPHB2,ATF5,POU3F2,SH3GL2,IRX5,PDGFC,EIF4EBP1,
VEGFA,MYC,SLC23A1,GFRA1,MAL,PHGDH,NOTCH3,CXCR4,HERP
UD1,S1PR3,ARHGEF10,CBS,GNAO1,RAG1,ARPP21,SYNGR1
Cellular Development 1.72E-06-1.09E-02 TEAD4,GAB2,DDIT3,SLIT1,EPHB2,ATF5,POU3F2,IRX5,PDGFC,EIF4
EBP1,CD1D,VEGFA,MYC,GFRA1,RAG2,MAL,LONP1,RIPK4,NOTCH
3,CXCR4,TRIB3,S1PR3,GNAO1,TSHR,RAG1,ARPP21
Inflammatory Response 2.18E-06-1.09E-02 GAB2,CXCR4,ASS1,EPHX2,CD1B,ULBP1,DNTT,CD1E,PDGFC,TUB,
EIF4EBP1,CD1D,VEGFA,S1PR3,MYC,CBS,RAG2,GNAO1,ANXA3,TS
HR,RAG1,CST7
Cellular Movement 4.94E-06-1.09E-02 GAB2,SLIT1,EPHB2,CXCR4,POU3F2,HSPA5,CD1D,VEGFA,MYC,S1
PR3,LGMN,PTPRU,GFRA1,ANXA3,GNAO1,TSHR,RAG1
Tissue Development 7.87E-06-1.09E-02 GAS2 (includes 
EG:14453),TEAD4,GAB2,SLIT1,EPHB2,POU3F2,IRX5,PDGFC,CD1D,
EIF4EBP1,MYC,VEGFA,SLC23A1,GFRA1,MAL,RAG2,PHGDH,RIPK4,
NOTCH3,CXCR4,TRIB3,S1PR3,ARHGEF10,CBS,KHDRBS3,TSHR,R
AG1,AARS
Cardiovascular Disease 1.18E-05-1.09E-02 GAB2,RASL10B,DDIT3,CXCR4,EPHX2,SNTB1,SH3GL2,PDGFC,TUB,
EIF4EBP1,MYC,VEGFA,PTPRU,MGAT4A,LGMN,CBS,GFRA1,GNAO1
,RAG2,PHGDH,RAG1,KIAA0226L,PMEPA1
Hematopoiesis 1.2E-05-1.09E-02 MYC,VEGFA,GAB2,CXCR4,RAG2,TSHR,RAG1,LONP1,CD1D
Organismal Injury and 
Abnormalities
1.2E-05-1.09E-02 MYC,VEGFA,SLC7A11,SLC23A1,DDIT3,CBS,EPHX2,RAG2,MAL,GNA
O1,TSHR,RAG1
Cell Death 2.63E-05-1.09E-02 GAS2 (includes 
EG:14453),GAB2,SLC7A11,DDIT3,EPHB2,ATF5,SH3GL2,HSPA5,CD1
D,EIF4EBP1,MYC,VEGFA,LGMN,GFRA1,MAL,RAG2,EEF1E1,CXCR4
,ULBP1,HERPUD1,TRIB3,TUB,S1PR3,MZB1,GNAO1,RAG1,AARS,P
MEPA1
Cell-mediated Immune 
Response
4.22E-05-1.09E-02 CXCR4,RAG2,RAG1,LONP1,CD1D
Cellular Function and 
Maintenance
4.22E-05-1.09E-02 GAB2,NOTCH3,DDIT3,EPHB2,CXCR4,HERPUD1,TRIB3,HSPA5,TUB,
CD1D,GLRB,VEGFA,S1PR3,MYC,ANXA3,RAG2,RAG1,AARS,LONP1
Hematological System 
Development and 
Function
4.22E-05-1.09E-02 GAB2,NOTCH3,DDIT3,CXCR4,ULBP1,HSPA5,PDGFC,CD1D,S1PR3,
VEGFA,MYC,CBS,GNAO1,RAG2,TSHR,RAG1,LONP1
Lymphoid Tissue 
Structure and 
Development
4.22E-05-1.09E-02 MYC,VEGFA,GAB2,EPHB2,CXCR4,RAG2,RAG1,LONP1
Embryonic Development 6.15E-05-1.09E-02 RIPK4,NOTCH3,SLIT1,EPHB2,CXCR4,POU3F2,IRX5,PDGFC,MYC,S
1PR3,VEGFA,SLC23A1,CBS,GFRA1,RAG2,KHDRBS3,PHGDH,RAG1
,AARS
Organ Development 6.15E-05-1.09E-02 RIPK4,NOTCH3,SLIT1,EPHB2,CXCR4,POU3F2,IRX5,PDGFC,MYC,S
1PR3,VEGFA,SLC23A1,CBS,GFRA1,RAG2,KHDRBS3,PHGDH,RAG1
,AARS
Organismal Development 6.15E-05-1.09E-02 TEAD4,RIPK4,NOTCH3,SLIT1,CXCR4,EPHB2,EPHX2,POU3F2,IRX5,
PDGFC,VEGFA,S1PR3,MYC,LGMN,SLC23A1,CBS,GFRA1,KHDRBS
3,ANXA3,RAG2,TSHR,PHGDH,RAG1,AARS
Hair and Skin 
Development and 
Function
8.11E-05-1.09E-02 RIPK4,VEGFA,MYC,SLC7A11,GFRA1,POU3F2,AARS
Cardiovascular System 
Development and 
Function
9.98E-05-1.09E-02 TEAD4,MYC,S1PR3,VEGFA,NOTCH3,CBS,SLIT1,EPHB2,CXCR4,EP
HX2,ANXA3,PDGFC
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Table A1.4B:  Ingenuity Pathway Analysis: Functional Categories. 
Transcripts Down-regulated upon Stimulation
Cell Morphology 9.98E-05-1.09E-02 GAB2,SLIT1,DDIT3,SLC6A9 (includes 
EG:116509),CXCR4,EPHB2,TRIB3,EIF4EBP1,VEGFA,S1PR3,MYC,C
BS,GFRA1,MAL
Cellular Growth and 
Proliferation
1.17E-04-1.09E-02 TEAD4,GAB2,SLC7A11,DDIT3,EPHB2,EPHX2,POU3F2,HSPA5,IRX5,
PDGFC,EIF4EBP1,CD1D,MYC,VEGFA,LGMN,STC2,GFRA1,RAG2,E
EF1E1,NOTCH3,CXCR4,ULBP1,S1PR3,PTPRU,GNAO1,RNF187,TS
HR,RAG1
Connective Tissue 
Disorders
1.17E-04-1.09E-02 VEGFA,GAB2,RAG2,RAG1
DNA Replication, 
Recombination, and 
Repair
1.17E-04-1.09E-02 MYC,RAG2,RAG1
Genetic Disorder 1.17E-04-1.09E-02 GAB2,SLC7A11,DDIT3,EPHB2,ASS1,EPHX2,HSPA5,EIF4EBP1,GLRB
,VEGFA,MYC,LGMN,GFRA1,MAL,RAG2,PHGDH,PSAT1,NOTCH3,CX
CR4,HERPUD1,DAAM2,GPT2 (includes 
EG:108682),TUB,ARHGEF10,GNAO1,TSHR,RAG1,ARPP21,SYNGR1
Hematological Disease 1.17E-04-1.09E-02 MYC,VEGFA,CXCR4,ANXA3,RAG2,RAG1,HSPA5
Immunological Disease 1.17E-04-1.09E-02 VEGFA,MYC,GAB2,LGMN,CXCR4,ANXA3,RAG2,PHGDH,RAG1,HSP
A5,CD1D
Infectious Disease 1.17E-04-1.09E-02 VEGFA,CXCR4,RAG2,RAG1,CD1D,EIF4EBP1
Inflammatory Disease 1.17E-04-1.09E-02 VEGFA,LGMN,CXCR4,RAG2,PHGDH,RAG1,CD1D
Skeletal and Muscular 
Disorders
1.17E-04-1.09E-02 PSAT1,GAB2,DDIT3,EPHB2,EPHX2,DAAM2,HERPUD1,SH3GL2,CD1
E,C16orf74,HSPA5,S1PR3,GLRB,VEGFA,ARHGEF10,RAG2,GNAO1,
RAG1,ARPP21
Skeletal and Muscular 
System Development and 
Function
1.17E-04-1.09E-02 MYC,TEAD4,VEGFA,GAB2,LGMN,CBS,CXCR4,TSHR,TRIB3,PDGFC
Tissue Morphology 1.39E-04-1.09E-02 GAB2,NOTCH3,DDIT3,EPHB2,CXCR4,EPHX2,PDGFC,CD1D,EIF4EB
P1,MYC,VEGFA,S1PR3,LGMN,CBS,GFRA1,RAG2,GNAO1,MTHFD2,
RAG1
Amino Acid Metabolism 2.19E-04-1.09E-02 SLC7A11,CBS,SLC6A9 (includes 
EG:116509),ASS1,PHGDH,MTHFD2,PYCR1
Small Molecule 
Biochemistry
2.19E-04-1.09E-02 SLC7A11,SLC6A9 (includes 
EG:116509),CXCR4,ASS1,EPHX2,CD1B,TRIB3,CD1D,MYC,S1PR3,V
EGFA,CBS,RAG2,MZB1,TSHR,MTHFD2,PHGDH,PYCR1
Humoral Immune 
Response
2.5E-04-1.09E-02 S1PR3,VEGFA,MYC,CXCR4,RAG2,TSHR,RAG1
Cancer 2.55E-04-1.09E-02 TEAD4,MYO7B,SLC7A11,DDIT3,ATF5,EPHB2,ASS1,HSPA5,PDGFC,
EIF4EBP1,CD1D,MYC,VEGFA,NEIL3,GFRA1,RAG2,MAL,MTHFD2,P
HGDH,EEF1E1,TFDP2,LONP1,PSAT1,NOTCH3,CXCR4,MFAP4,SDF
2L1,ANXA3,RNF187,KHDRBS3,TSHR,RAG1,CST7,CEP70,SYNGR1
Cell Signaling 5.15E-04-1.05E-02 GAB2,EPHB2,CXCR4,ASS1,HERPUD1,HSPA5,VEGFA,S1PR3,MYC,
GFRA1,GNAO1,MZB1,RAG2,TSHR
Connective Tissue 
Development and 
Function
6E-04-1.09E-02 MYC,VEGFA,TEAD4,GAB2,LGMN,CBS,CXCR4,TSHR,TRIB3,PDGFC
Immune Cell Trafficking 6.29E-04-1.09E-02 MYC,VEGFA,S1PR3,GAB2,CBS,CXCR4,GNAO1,ULBP1,TSHR,CD1D
Cell Cycle 6.93E-04-1.09E-02 VEGFA,MYC,DDIT3,ATF5
Cellular Assembly and 
Organization
6.93E-04-1.09E-02 MYC,VEGFA,SLIT1,CXCR4,EPHB2,GFRA1,GNAO1,POU3F2,SYNGR
1,HSPA5,EIF4EBP1
Lipid Metabolism 6.93E-04-1.09E-02 MYC,S1PR3,VEGFA,CBS,EPHX2,CD1B,TRIB3,CD1D
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Table A1.4B:  Ingenuity Pathway Analysis: Functional Categories. 
Transcripts Down-regulated upon Stimulation
Neurological Disease 6.93E-04-1.09E-02 GAB2,SLC7A11,DDIT3,EPHB2,EPHX2,SH3GL2,CD1E,HSPA5,PDGF
C,EIF4EBP1,CD1D,MYC,VEGFA,GLRB,GFRA1,RAG2,MAL,PHGDH,P
SAT1,CXCR4,HERPUD1,DAAM2,C16orf74,S1PR3,OGN,ARHGEF10,
CBS,KHDRBS3,GNAO1,RAG1,ARPP21,SYNGR1
Tumor Morphology 6.93E-04-1.09E-02 MYC,VEGFA,CXCR4,GFRA1,ANXA3,POU3F2,EIF4EBP1
Cellular Compromise 9.03E-04-1.09E-02 VEGFA,MYC,DDIT3,HSPA5,EIF4EBP1
Molecular Transport 1.04E-03-1.09E-02 GAB2,SLC7A11,DDIT3,SLC6A9 (includes 
EG:116509),EPHB2,CXCR4,HERPUD1,HSPA5,VEGFA,S1PR3,MYC,C
BS,GNAO1,TSHR
Vitamin and Mineral 
Metabolism
1.04E-03-8.44E-03 MYC,S1PR3,VEGFA,GAB2,CXCR4,EPHB2,GNAO1,TSHR,HERPUD1,
HSPA5
Hepatic System 
Development and 
Function
1.15E-03-1.09E-02 MYC,VEGFA,CBS,MTHFD2
Visual System 
Development and 
Function
1.15E-03-1.09E-02 VEGFA,PDGFC
Organismal Survival 1.62E-03-1.62E-03 SLC6A9 (includes 
EG:116509),EPHB2,CXCR4,PDGFC,MYC,VEGFA,S1PR3,CBS,MAL,R
AG2,TSHR,PHGDH,MTHFD2,EEF1E1,RAG1
Cell-To-Cell Signaling and 
Interaction
1.71E-03-1.09E-02 GAS2 (includes 
EG:14453),MYC,VEGFA,GAB2,CXCR4,GFRA1,ULBP1,TSHR,PDGFC,
CD1D
Nucleic Acid Metabolism 2.06E-03-1.09E-02 CBS,CXCR4,MZB1,TSHR
Antigen Presentation 2.38E-03-1.09E-02 VEGFA,CBS,ULBP1,TSHR,CD1D
Respiratory Disease 2.41E-03-1.09E-02 VEGFA,CXCR4,CD1D
Post-Translational 
Modification
3.02E-03-1.09E-02 MYC,VEGFA,DDIT3,HERPUD1
Dermatological Diseases 
and Conditions
3.15E-03-1.09E-02 MYC,VEGFA,LGMN,CXCR4,PHGDH,RAG1,CD1D,EIF4EBP1
Developmental Disorder 3.15E-03-1.09E-02 VEGFA,GFRA1,ASS1,PHGDH,TSHR,EIF4EBP1
Reproductive System 
Disease
3.15E-03-1.09E-02 VEGFA,LGMN,NOTCH3,MTHFD2,PMEPA1
Nutritional Disease 3.17E-03-3.17E-03 MYC,VEGFA,GPT2 (includes EG:108682),TUB,EIF4EBP1
Endocrine System 
Disorders
4.09E-03-1.09E-02 MYC,DDIT3,TSHR,TRIB3
Metabolic Disease 4.09E-03-1.09E-02 RIPK4,SLC7A11,DDIT3,EPHB2,ASS1,SNTB1,TRIB3,SH3TC1,SH3GL
2,PDGFC,TUB,CD1D,EIF4EBP1,MYC,VEGFA,LGMN,MZB1,RAG2,KH
DRBS3,TSHR,PHGDH,KIAA0226L
Organ Morphology 4.49E-03-1.09E-02 VEGFA,MYC,NOTCH3,GFRA1,MZB1,GNAO1,RAG1,IRX5
Gene Expression 6.05E-03-6.05E-03 DDIT3,TRIB3
Protein Synthesis 6.24E-03-6.24E-03 MYC,VEGFA,CBS,CXCR4,RAG2,HSPA5,EIF4EBP1
Gastrointestinal Disease 6.46E-03-1.09E-02 TEAD4,MYO7B,SLC7A11,ATF5,EPHB2,CXCR4,HSPA5,PDGFC,VEGF
A,MYC,SDF2L1,NEIL3,GFRA1,MAL,PHGDH,RAG1,TFDP2
Hepatic System Disease 6.46E-03-1.09E-02 MYC,VEGFA,NEIL3,ATF5,PHGDH,RAG1,HSPA5,PDGFC
Psychological Disorders 8.06E-03-8.06E-03 GLRB,SLC7A11,ARHGEF10,GFRA1,MAL,DAAM2,SYNGR1
Endocrine System 
Development and 
Function
8.46E-03-1.09E-02 MYC,CXCR4,POU3F2
Behavior 1.06E-02-1.09E-02 GLRB,VEGFA,EPHB2,GFRA1,GNAO1,RAG1
Antimicrobial Response 1.09E-02-1.09E-02 CD1D
Auditory and Vestibular 
System Development and 
Function
1.09E-02-1.09E-02 VEGFA,EPHB2
Carbohydrate Metabolism 1.09E-02-1.09E-02 CD1D
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Digestive System 
Development and 
Function
1.09E-02-1.09E-02 MYC,GFRA1
Drug Metabolism 1.09E-02-1.09E-02 CBS
Ophthalmic Disease 1.09E-02-1.09E-02 VEGFA
Organismal Functions 1.09E-02-1.09E-02 MYC,VEGFA
Protein Folding 1.09E-02-1.09E-02 VEGFA
Protein Trafficking 1.09E-02-1.09E-02 DDIT3
Renal and Urological 
Disease
1.09E-02-1.09E-02 MYC,VEGFA
Reproductive System 
Development and 
Function
1.09E-02-1.09E-02 MYC,TSHR,POU3F2
Respiratory System 
Development and 
Function
1.09E-02-1.09E-02 VEGFA,NOTCH3
© 2000-2011 Ingenuity Systems, Inc. All rights reserved.
Table A1.4. Ingenuity Pathway Analysis results for targets of regulated gene expression. 
Complete list of genes and statistics above threshold of p<0.03 for (A) Functional analysis of genes 
up-regulated. (B) Functional analysis of genes down-regulated. (C) Canonical Signaling pathway 
analysis of genes up-regulated. (D) Canonical Signaling pathway analysis of genes down-
regulated.
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Table A1.4C:  Ingenuity Pathway Analysis: Canonical Signaling Pathways
Transcripts  Up-regulated upon Stimulation
Ingenuity Canonical 
Pathways
 -log(p-value) Molecules
Crosstalk between 
Dendritic Cells and Natural 
Killer Cells
5.99E+00 CD28,CD40LG,HLA-E,CD69,CD226,LTB,TNFSF10
Hepatic Fibrosis / Hepatic 
Stellate Cell Activation
5.31E+00 TGFBR2,CD40LG,IL4R,TIMP1,FLT1,FGFR1,TGFA
T Helper Cell 
Differentiation
4.86E+00 TGFBR2,CD28,CD40LG,IL4R,GATA3
Altered T Cell and B Cell 
Signaling in Rheumatoid 
Arthritis
4.06E+00 CD28,CD40LG,RELB,LTB
NF-κB Signaling 3.52E+00 TGFBR2,PIK3C2B,CD40LG,FLT1,FGFR1,RELB,TGFA,TNFAIP3
Allograft Rejection 
Signaling
2.85E+00 CD28,CD40LG,HLA-E
Autoimmune Thyroid 
Disease Signaling
2.85E+00 CD28,CD40LG,HLA-E
Communication between 
Innate and Adaptive 
Immune Cells
2.85E+00 CD28,CD40LG,HLA-E
Dendritic Cell Maturation 2.21E+00 PIK3C2B,CD40LG,RELB,LTB,CD58
Role of Tissue Factor in 
Cancer
2.15E+00 PIK3C2B,STAT5A,ARRB1,EGR1,ITGA6
G-Protein Coupled 
Receptor Signaling
1.87E+00 PIK3C2B,LPAR6,CCR4,GPR84,HCAR1,DUSP6,GPR68
Graft-versus-Host Disease 
Signaling
1.81E+00 CD28,HLA-E
Extrinsic Prothrombin 
Activation Pathway 1.71E+00
TFPI
Eicosanoid Signaling 1.66E+00 ALOX5AP,HPGDS
Role of JAK1 and JAK3 in 
γc Cytokine Signaling 1.66E+00
PIK3C2B,STAT5A,IL4R
© 2000-2011 Ingenuity Systems, Inc. All rights reserved.
Table A1.4. Ingenuity Pathway Analysis results for targets of regulated gene expression. 
Complete list of genes and statistics above threshold of p<0.03 for (A) Functional analysis of genes 
up-regulated. (B) Functional analysis of genes down-regulated. (C) Canonical Signaling pathway 
analysis of genes up-regulated. (D) Canonical Signaling pathway analysis of genes down-regulated.
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Table A1.4D:  Ingenuity Pathway Analysis: Canonical Signaling Pathways
Transcripts Down-regulated upon Stimulation
Ingenuity Canonical 
Pathways
 -log(p-value) Molecules
B Cell Development 4.61E+00 RAG2,DNTT,RAG1
Alanine and Aspartate 
Metabolism
2.78E+00 ASS1,AARS,GPT2 (includes EG:108682)
Bladder Cancer Signaling 2.67E+00 VEGFA,MYC,PDGFC
Ephrin Receptor Signaling 2.44E+00 VEGFA,EPHB2,CXCR4,GNAO1,PDGFC
Glycine, Serine and 
Threonine Metabolism
2.20E+00 PSAT1,CBS,PHGDH
Lipid Antigen Presentation 
by CD1
2.01E+00 CD1B,CD1D
Axonal Guidance Signaling 1.93E+00 VEGFA,SLIT1,EPHB2,CXCR4,GNAO1,PDGFC
Atherosclerosis Signaling 1.80E+00 CXCR4,PDGFC
Clathrin-mediated 
Endocytosis Signaling
1.72E+00 VEGFA,EPHB2,SH3GL2,PDGFC
Urea Cycle and 
Metabolism of Amino 
Groups
1.71E+00 ASS1,PYCR1
Primary Immunodeficiency 
Signaling
1.67E+00 RAG2,RAG1
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Table A1.4. Ingenuity Pathway Analysis results for targets of regulated gene expression. 
Complete list of genes and statistics above threshold of p<0.03 for (A) Functional analysis of genes 
up-regulated. (B) Functional analysis of genes down-regulated. (C) Canonical Signaling pathway 
analysis of genes up-regulated. (D) Canonical Signaling pathway analysis of genes down-regulated.
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Table&A2.1&Proteins&bound&to&MKK7&introns&identified&by&RNA&purification&followed&by&mass&spec
Tested&binding Gene&ID Molecular&Weight
Peptide&Count&
Unstimulated&
Peptide&Count&
Stimulated Fold&Stim/Unstim
Total&Peptide&
Counts
+ sp|O95319*3|CELF2_HUMAN;sp|O95319|CELF2_HUMAN;sp|O95319*5|CELF2_HUMAN;sp|O95319*4|CELF2_HUMAN55754;54285;52054;54365 3 18 6.00 21
– sp|Q14980*2|NUMA1_HUMAN;sp|Q14980|NUMA1_HUMAN236513;238257 3 16 5.33 19
– sp|P08670|VIME_HUMAN53652 14 39 2.79 53
sp|Q92922|SMRC1_HUMAN;tr|Q58EY4|Q58EY4_HUMAN;tr|Q05CR1|Q05CR1_HUMAN122867;122911;91756 4 8 2.00 12
– sp|P43243|MATR3_HUMAN94623 14 26 1.86 40
sp|P55265*2|DSRAD_HUMAN;tr|E7ENU4|E7ENU4_HUMAN;sp|P55265*4|DSRAD_HUMAN;sp|P55265*3|DSRAD_HUMAN133274;140828;140838;13117010 18 1.80 28
– sp|P31483*2|TIA1_HUMAN;tr|C9JTN7|C9JTN7_HUMAN41801;31625 4 7 1.75 11
– sp|Q01085*2|TIAR_HUMAN;sp|Q01085|TIAR_HUMAN43449;41591 6 9 1.50 15
– sp|P52272*2|HNRPM_HUMAN;sp|P52272|HNRPM_HUMAN73621;77516 13 19 1.46 32
– sp|Q8WXF1|PSPC1_HUMAN58744 5 7 1.40 12
– sp|P14866|HNRPL_HUMAN64133 15 20 1.33 35
sp|P23246|SFPQ_HUMAN76150 20 25 1.25 45
– sp|Q96I24|FUBP3_HUMAN61640 15 18 1.20 33
sp|Q92841*2|DDX17_HUMAN;tr|Q59F66|Q59F66_HUMAN;tr|C9JMU5|C9JMU5_HUMAN;sp|Q92841*3|DDX17_HUMAN72542;81068;72576;72557 10 12 1.20 22
tr|Q53GL6|Q53GL6_HUMAN32550 16 19 1.19 35
sp|Q15365|PCBP1_HUMAN37498 17 20 1.18 37
– sp|Q15233|NONO_HUMAN54232 19 22 1.16 41
sp|Q9NXV6|CARF_HUMAN61125 13 15 1.15 28
sp|P51991|ROA3_HUMAN39595 20 22 1.10 42
P00761 24409 314 337 1.07 651
Streptavidin 16622 586 622 1.06 1208
sp|P09651*2|ROA1_HUMAN;tr|F8W6I7|F8W6I7_HUMAN;sp|P09651*3|ROA1_HUMAN34196;33155;29386 41 41 1.00 82
sp|O75533|SF3B1_HUMAN145830 17 17 1.00 34
sp|Q15393|SF3B3_HUMAN135577 12 12 1.00 24
sp|P17844|DDX5_HUMAN;tr|B5BUE6|B5BUE6_HUMAN69148;69121 12 12 1.00 24
sp|Q15459|SF3A1_HUMAN88886 8 8 1.00 16
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sp|P38159*2|RBMX_HUMAN;tr|H3BT71|H3BT71_HUMAN;tr|H0Y6E7|H0Y6E7_HUMAN40846;3219 ;31859 8 8 1.00 16
– sp|Q9UHX1*2|PUF60_HUMAN;sp|Q9UHX1|PUF60_HUMAN;sp|Q9UHX1*6|PUF60_HUMAN;sp|Q9UHX1*5|PUF60_HUMAN58172;59876;55400;57103 6 6 1.00 12
sp|P62805|H4_HUMAN 11367 5 5 1.00 10
– sp|Q96PK6|RBM14_HUMAN69492 5 5 1.00 10
sp|P35579|MYH9_HUMAN226530 5 5 1.00 10
+ sp|P84103|SRSF3_HUMAN;tr|B4E241|B4E241_HUMAN19330;14203 5 5 1.00 10
sp|Q9Y230|RUVB2_HUMAN;tr|B3KNL2|B3KNL2_HUMAN51157;47404 5 5 1.00 10
sp|Q08554*2|DSC1_HUMAN;sp|Q08554|DSC1_HUMAN93835;99987 5 5 1.00 10
sp|P22626|ROA2_HUMAN37430 37 36 0.97 73
– sp|P26599*2|PTBP1_HUMAN;sp|P26599|PTBP1_HUMAN;sp|P26599*3|PTBP1_HUMAN59037;57221;59633 42 40 0.95 82
+ sp|Q15717|ELAV1_HUMAN36092 33 31 0.94 64
sp|Q99729*3|ROAA_HUMAN30588 12 11 0.92 23
sp|O00148|DX39A_HUMAN49130 12 11 0.92 23
sp|P68871|HBB_HUMAN;tr|C8C504|C8C504_HUMAN15998;15997 11 10 0.91 21
sp|Q13838*2|DX39B_HUMAN;tr|F8VQ10|F8VQ10_HUMAN50679;50745 14 12 0.86 26
sp|Q14103*3|HNRPD_HUMAN;sp|Q14103|HNRPD_HUMAN32835;3843 24 20 0.83 44
sp|P38919|IF4A3_HUMAN46871 6 5 0.83 11
sp|P09661|RU2A_HUMAN;tr|Q53G61|Q53G61_HUMAN;tr|H0YMA0|H0YMA0_HUMAN28416;28402;1 839 6 5 0.83 11
sp|Q9Y265|RUVB1_HUMAN;tr|B5BUB1|B5BUB1_HUMAN50228; 0216 6 5 0.83 11
sp|Q15366*2|PCBP2_HUMAN;sp|Q15366|PCBP2_HUMAN;sp|Q15366*6|PCBP2_HUMAN;sp|Q15366*3|PCBP2_HUMAN38651;38580;38151;38222 29 24 0.83 53
– sp|P61978*2|HNRPK_HUMAN;sp|P61978|HNRPK_HUMAN51028;50976 40 33 0.83 73
+ sp|P07910*2|HNRPC_HUMAN;sp|P07910|HNRPC_HUMAN32338;336 0 47 38 0.81 85
sp|Q9H0D6|XRN2_HUMAN108583 10 8 0.80 18
sp|P21333*2|FLNA_HUMAN;tr|Q5HY54|Q5HY54_HUMAN280016;276 8 49 39 0.80 88
ENSEMBL:ENSBTAP00000016242;sp|P68363|TBA1B_HUMAN50180;50152 32 25 0.78 57
sp|P09874|PARP1_HUMAN113084 13 10 0.77 23
sp|P31943|HNRH1_HUMAN;tr|G8JLB6|G8JLB6_HUMAN49229;51230 13 10 0.77 23
tr|B4DTA2|B4DTA2_HUMAN30214 12 9 0.75 21
sp|P01857|IGHG1_HUMAN;tr|Q6PYX1|Q6PYX1_HUMAN;tr|Q6GMX6|Q6GMX6_HUMAN36106;38162;51083 8 6 0.75 14
sp|P63104|1433Z_HUMAN27745 11 8 0.73 19
sp|P25311|ZA2G_HUMAN34259 7 5 0.71 12
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sp|P02774|VTDB_HUMAN52964 7 5 0.71 12
sp|Q92499|DDX1_HUMAN82432 7 5 0.71 12
sp|P26368*2|U2AF2_HUMAN;tr|B5BU25|B5BU25_HUMAN;sp|P26368|U2AF2_HUMAN53121;53137; 3501 7 5 0.71 12
sp|P01011|AACT_HUMAN47651 35 24 0.69 59
sp|Q92945|FUBP2_HUMAN73115 66 44 0.67 110
sp|Q00839*2|HNRPU_HUMAN;sp|Q00839|HNRPU_HUMAN88980;90585 9 6 0.67 15
sp|Q09028*2|RBBP4_HUMAN;sp|Q09028|RBBP4_HUMAN;sp|Q09028*3|RBBP4_HUMAN47585;47656;46158 6 4 0.67 10
sp|P61088|UBE2N_HUMAN17138 8 5 0.63 13
– sp|P52597|HNRPF_HUMAN45672 7 4 0.57 11
sp|Q13263*2|TIF1B_HUMAN;sp|Q13263|TIF1B_HUMAN79474;88550 9 5 0.56 14
sp|P01008|ANT3_HUMAN52602 35 19 0.54 54
sp|Q96AE4|FUBP1_HUMAN67560 39 21 0.54 60
sp|P51610*4|HCFC1_HUMAN;tr|A6NEM2|A6NEM2_HUMAN;sp|P51610|HCFC1_HUMAN213403;213474;208730 13 7 0.54 20
sp|P07437|TBB5_HUMAN49671 35 18 0.51 53
sp|P68371|TBB4B_HUMAN;tr|Q8N6N5|Q8N6N5_HUMAN;tr|Q8IWP6|Q8IWP6_HUMAN49831;49808;49753 28 14 0.50 42
sp|P67809|YBOX1_HUMAN35924 12 6 0.50 18
sp|P68104|EF1A1_HUMAN;tr|Q6IPT9|Q6IPT9_HUMAN;tr|Q53HR5|Q53HR5_HUMAN;sp|Q5VTE0|EF1A3_HUMAN50141;50185;50125;50185 27 13 0.48 40
sp|P11021|GRP78_HUMAN72333 13 6 0.46 19
sp|P07737|PROF1_HUMAN15054 9 4 0.44 13
sp|O43143|DHX15_HUMAN90933 7 3 0.43 10
sp|Q14141*4|SEPT6_HUMAN;tr|Q8NFH9|Q8NFH9_HUMAN;tr|Q6NT82|Q6NT82_HUMAN;tr|Q6B514|Q6B514_HUMAN;tr|F5H1J5|F5H1J5_HUMAN;tr|B1AMS2|B1AMS2_HUMAN49167;63143;48847;50204;52250;493037 3 0.43 0
sp|P07900|HS90A_HUMAN;tr|Q2VPJ6|Q2VPJ6_HUMAN84660;68372 15 6 0.40 21
tr|D3DUZ3|D3DUZ3_HUMAN82423 18 7 0.39 25
sp|Q13085*2|ACACA_HUMAN;sp|Q13085|ACACA_HUMAN259684;265551 21 8 0.38 29
sp|P13796|PLSL_HUMAN70289 22 8 0.36 30
sp|P31946|1433B_HUMAN28082 14 5 0.36 19
sp|P27348|1433T_HUMAN27764 12 4 0.33 16
sp|P31146|COR1A_HUMAN51026 12 4 0.33 16
– sp|Q9UKA9*2|PTBP2_HUMAN;sp|Q9UKA9|PTBP2_HUMAN57647;57491 12 4 0.33 16
sp|Q04917|1433F_HUMAN28219 9 3 0.33 12
sp|P42166|LAP2A_HUMAN75492 9 3 0.33 12
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sp|P14625|ENPL_HUMAN;tr|Q5CAQ5|Q5CAQ5_HUMAN92469;92340 9 3 0.33 12
tr|B4DMA2|B4DMA2_HUMAN79195 22 7 0.32 29
sp|P62258|1433E_HUMAN;tr|G9K389|G9K389_HUMAN;tr|G9K388|G9K388_HUMAN29174;412 6;41224 16 5 0.31 21
sp|P61981|1433G_HUMAN28303 10 3 0.30 13
sp|P62826|RAN_HUMAN;tr|J3KQE5|J3KQE5_HUMAN24423;26816 10 3 0.30 13
sp|P04406|G3P_HUMAN 36053 41 11 0.27 52
sp|P13639|EF2_HUMAN 95338 12 3 0.25 15
sp|P60842|IF4A1_HUMAN46154 8 2 0.25 10
sp|Q9P258|RCC2_HUMAN56085 9 2 0.22 11
sp|P07237|PDIA1_HUMAN57116 9 2 0.22 11
sp|Q16181*2|SEPT7_HUMAN;tr|Q3LIE9|Q3LIE9_HUMAN;tr|E7ES33|E7ES33_HUMAN50581;48774;50609 9 2 0.22 11
sp|P26641|EF1G_HUMAN50119 15 3 0.20 18
sp|P10809|CH60_HUMAN;tr|B3GQS7|B3GQS7_HUMAN61055;60680 33 6 0.18 39
sp|P07195|LDHB_HUMAN36639 11 2 0.18 13
sp|P00558|PGK1_HUMAN44615 17 3 0.18 20
sp|P62937|PPIA_HUMAN;tr|A8K486|A8K486_HUMAN18012;1 013 20 3 0.15 23
sp|P13489|RINI_HUMAN 49974 16 2 0.13 18
sp|P11142|HSP7C_HUMAN70898 28 3 0.11 31
sp|P09429|HMGB1_HUMAN;tr|Q5T7C6|Q5T7C6_HUMAN;tr|Q59GW1|Q59GW1_HUMAN24894;18808;20164 11 1 0.09 12
sp|P30101|PDIA3_HUMAN;tr|G5EA52|G5EA52_HUMAN56782;54964 13 1 0.08 14
sp|P29401*2|TKT_HUMAN;tr|Q53EM5|Q53EM5_HUMAN;sp|P29401|TKT_HUMAN68814;67906;67878 13 1 0.08 14
sp|P06733|ENOA_HUMAN47169 14 1 0.07 15
sp|P15311|EZRI_HUMAN 69413 15 1 0.07 16
sp|P26038|MOES_HUMAN67820 17 1 0.06 18
sp|P50395|GDIB_HUMAN50663 11 0 0.00 11
sp|P27797|CALR_HUMAN;tr|Q53G71|Q53G71_HUMAN48142;469 9 10 0 0.00 10
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Event ID and Gene 
Name
anti-
CD3/CD28 GSK3i effect JNKi    effect
2173TRA2A -50.90 -79.2
532FBXO38 -47.30 -77.9
2948SFRS3 -49.80 -76.2
1080LEF1 -59.20 -74.3
2565LUC7L -85.50 -72.8
2063SFRS7 -45.30 -64.5
288PPIL5 -51.80 -63.6
3549RBM3 -29.70 -23.5 -54.6
2934NT5C3 -41.20 -47.3
5599FIP1L1 -13.80 -15.2 -44.9
1849IPO9 -27.50 -44.3
1634ZDHHC20 -28.70 -43.9
25EZH2 -46.10 -21.4 -42.7
1213BAX -42.00 -42.7
1483LRRFIP2 -29.90 -42.0
2830TIMM8B -46.30 -55.2 -41.4
1451EYA3 -27.70 -40.1
6116CXorf45 -46.50 -37.7
6384RAD51C -23.70 -34.9
2349MTF2 -30.00 -34.2
2577BPTF -31.20 -33.5
5202LETMD1 -30.00 -33.2
196ZNF207 -24.20 -18.8 -32.6
5681SWAP70 -21.80 -31.9
1034SNX14 -18.50 -30.0
5419TFAM -19.20 -29.5
772FHL1 -27.80 -28.0
6460TROVE2 -47.20 -45.0 -25.8
1095PRPF3 -25.70 -24.5
2385DNM1L -22.10 -24.3
5759AK311167 -35.60 -28.2 -23.9
2183KIAA0515 -20.90 -29.7 -22.8
5411OGDH -25.20 -22.4
684CD74 -19.80 -21.4
3462RPGR -15.20 -20.0
2972CCNL2 -28.10 -19.8
901SMARCA4 -13.30 -19.3
120SHC1 -16.20 -16.8
3251TMEM183A -14.10 -14.8
3464RNF167 -16.00 -14.7
6587PRUNE -19.70 -14.3
687MRE11A -10.50 -14.1
Table A2.2: Delta PSI values for significant anti-CD3/CD28 responsive splicing events in primary 
human CD4+ cells.  (detailed description at end of table)
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1835ERC1 -13.00 -13.8
6609PRMT2 -17.60 -13.6
3612MAZ -33.80 -34.8 -11.1
293HNRNPK -10.10 -10.8
6631MTHFD2L -29.90 -26.8 -10.5
6605ERCC2 -12.50 -10.1
1154MADD -13.40 -9.8
2403FNBP1 13.00 9.5
3026RIF1 10.00 11.5
5364ZNF271 25.80 11.6
5485CREM 22.60 28.4 12.1
3397IMAA 15.10 12.2
1699ACTL6A 12.80 12.7
1220NUP98 37.20 35.0 13.2
1225STK4 13.70 14.1
6393PCNP 11.00 14.4
5457PPP6R3 10.20 9.8 14.7
5868C20orf72 15.40 14.7
5664STARD3NL 16.50 16.2
1567NCOR1 24.30 16.3
3223GIT1 16.70 16.8
975BCLAF1 14.00 17.7
3598CAMTA1 20.70 14.3 18.0
5517PPP2R2D 14.50 12.2 18.6
1788GTF2I 22.80 19.3
5964SGK3 15.00 19.5
6482SNHG3-RCC1 15.60 21.1
80DTNB 23.80 21.1
433FLJ00353 20.30 22.7
377ECT2 10.80 35.0 24.1
6550CCDC7 40.50 18.8 24.8
6851KTN1 21.00 25.6
6578C10orf28 31.80 26.4
5865CDKN2AIP 23.00 26.5
33TBRG4 14.10 27.3
5659RNF34 14.70 28.6
3668CUGBP2 36.60 23.8 29.0
902PTS 37.40 30.7
767RP5-1022P6.2 15.00 32.8
6023DDR1 30.00 36.1
473FOXRED1 33.40 36.6
886C2orf4 12.90 10.3 37
915CSNK1D 12.10 10.0 37.1
5989EIF3EIP 31.30 37.3
569KIF21B 36.40 37.7
1065EIF4A2 42.30 18.9 38.4
2456EIF4A2 42.30 18.9 38.4
699EXOC7 36.90 39.7
1678FUBP3 41.50 40.2
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59PPP5C 44.80 40.6
2263FUS 16.00 40.9
876EIF4H 39.70 41.5
5214WHSC1L1 23.20 23.8 43.3
736FGFR1OP2 33.30 43.3
6316CCAR1 47.60 44.5
1767CD97 29.30 49.9
1314DAZAP1 20.00 59.8
785CHTF8 -57.30 -54.2
2793CHTF8 -57.30 -54.2
2758HDC -43.20 -51.4
5526KIAA1219 -43.30 -48.1
1690POMT1 -27.80 -46.4
2640CAMKK2 -45.20 -44.5
3665SNRNP70 -76.40 -44.2
1905ABLIM1 -35.90 -44.2
2084ASCC2 -45.30 -42.6
6132THAP9 -41.60 -42.2
187BPTF -30.90 -41.8
5585OFD1 -44.00 -40.5
6659PILRB -17.70 -39.8
369BRE -48.30 -39.7
472EP400 -23.20 -37.4
3551HRAS -37.30 -35.5
959C12orf30 -34.30 -35.2
592ACIN1 -33.70 -34.4
6475IRAK4 -46.90 -32.4
1260USP15 -29.10 -32.1
1740TXNRD1 -28.00 -31.6
6186GEMIN7 -33.70 -31.4
2704ZDHHC13 -41.10 -30.9
3015C2orf33 -25.10 -30.7
2107MAPKAP1 -27.40 -30.5
2TPP2 -33.30 -30.0
6877MRRF -25.50 -29.0
480EIF4G1 -13.10 -28.9
1613SYNCRIP -25.20 -28.7
1348PAN3 -32.10 -28.5
3705OS9 -25.50 -28.5
64ZMIZ1 -17.70 -28.1
5133PILRB -24.50 -27.6
5746DKFZp667H0616 -30.70 -27.5
6590PIP5K1A -29.70 -27.4
184L3MBTL3 -21.90 -25.0
1783BANP -27.20 -24.9
6781C20orf199 -20.40 -24.1
2998ANXA7 -20.20 -23.9
2467SF1 -25.10 -23.8
3374MBNL1 -22.80 -23.7
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1242UBTF -28.50 -23.2
1645MFN2 -26.10 -23.2
2585OSBPL9 -16.20 -22.5
2671RBMS1 -11.10 -22.1
2795SMAD2 -20.90 -21.8
6883ANKHD1-EIF4EBP3 -17.50 -21.3
2713PCBP2 -22.70 -21.2
357EHMT1 -35.40 -20.9
860DKFZp434I0612 -18.90 -20.8
3329DIAPH1 -23.20 -19.6
5558M-RIP -24.60 -19.3
833CD47 -18.10 -18.2
3083PXN -16.40 -18.0
6798PSMD13 -23.40 -16.9
6462AKT2 -19.90 -16.9
6855SMARCD1 -31.10 -16.7
278HISPPD2A -14.70 -16.4
2526PDK1 -14.90 -15.3
5714ESNA1 -11.40 -15.3
6641GNPAT -25.50 -15.0
3603SENP6 -26.90 -14.1
2379RICTOR -14.20 -14.1
2402FAM135A -22.50 -13.6
2753bim-alpha1 -19.10 -12.8
1425PAPOLA -12.90 -12.8
6326CSNK1G2 -11.80 -12.1
6568ZNF146 -22.10 -11.8
708CDC16 -30.20 -11.5
2687C1orf9 -22.20 -11.5
6693RABGAP1L -13.50 -11.3
1060PI4KB -12.60 -11.3
6134NGFRAP1 -11.20 -10.9
6820TMEM106C -18.30 -10.7
6745ZFYVE27 -17.10 -10.6
1200MBD1 13.00 9.7
3095MADD 10.70 9.9
2055GTPBP10 14.50 10.2
779DKFZp762G052 16.70 10.5
1600KIAA0494 11.80 10.7
2436FIP1L1 11.40 11.3
492PACSIN2 24.80 11.9
3326BIN1 11.60 12.0
6674SS18L1 18.40 12.0
597COL4A3BP 24.30 12.0
700RAPGEF1 10.00 12.3
5853BC037884 10.50 12.6
6873LTBP4 15.80 12.8
296IFNAR2 11.90 13.0
3218SFRS15 14.80 13.2
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6476KIAA0391 12.90 13.5
521CDCA7L 10.10 14.4
3575RBM4 18.20 14.9
1438OSBPL9 14.90 15.4
6582NEDD1 18.90 15.7
2868ATRX 27.20 15.7
1755STAG2 19.70 16.3
2319CCNL1 14.30 17.0
86CARD16 15.40 17.0
2620FLJ00246 15.50 17.1
6035DKFZp434N2030 27.10 17.5
1010SLMAP 18.70 18.2
3513ARID5B 18.40 18.6
2164AKAP9 17.10 18.9
6280SMA4 23.50 19.7
6727dJ1198O21.1 29.70 19.9
1032CNBP 17.90 20.0
934PTPN4 15.70 20.8
5906LYRM1 24.60 20.9
5392XPR1 25.00 21.0
5843SCLY 13.80 21.6
2227AP1GBP1 29.10 21.8
5726TACC1 20.10 23.4
1705HMGN3 25.20 23.4
3584KIAA1565 18.20 24.0
483FIS1 17.80 25.0
6096ZNF789 30.00 25.6
5683INF2 27.30 27.9
5153LOC221442 31.60 28.1
5341FBXO38 14.60 28.2
6325NUP214 32.30 29.8
3041UCHL5 29.20 31.2
2009BBX 33.00 31.2
1947SLMAP 34.90 32.7
5278VAP-B 33.00 32.8
2886mccb 32.40 33.4
6541AKR1A1 25.60 33.8
5579BRPF1 36.60 33.9
6066UGCGL1 44.40 34.6
2473CAMKK2 21.50 35.1
6572TFE3 25.00 35.2
825NAE1 35.70 35.4
3268MFF 42.50 35.7
122CBFB 35.30 35.9
2434CLSTN1 32.10 37.5
1375KCTD13 35.60 38.3
1435SKP2 29.50 39.7
5290LYRM1 48.60 42.1
1623AK125149 49.00 47.6
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247PCM1 50.20 47.7
93CEP57 22.70 49.1
1872MFF 53.40 61.5
1890ST7 -16.10
6184LYPLAL1 -18.40
5991DKFZp566I1024 -12.50
827PLAUR -61.80
175ABCC1 -54.70
594ABCC1 -54.70
1181DNAJC7 -52.20
2683GOLGA2 -51.00
5952DENND3 -48.10
54FAM120A -46.20
2759FAM120A -46.20
2781CDK5RAP2 -44.80
506TRPC1 -44.10
5871ARHGEF10 -42.30
5151NUB1 -39.20
6185DBF4B -37.70
1135KIAA1782 -36.60
1317GGCT -36.50
1268RAD51L3 -36.00
5931TNFRSF14 -35.70
6263SRRM2 -35.30
778CAMTA1 -35.00
2649ZFAND3 -33.10
758DEDD2 -33.10
5940TBC1D22A -31.90
6231PCM1 -31.50
922TRAF3 -31.50
5813DAP3 -31.00
125OSBPL8 -28.40
5179PIGT -28.20
972WBP1 -28.10
5398AFG3L1 -27.30
6555HN1L -26.30
3515TLK2 -25.60
3005ZNF195 -23.90
855ORMDL2 -23.70
367CHURC1 -23.40
5371EHMT1 -23.00
1515PXMP3 -22.30
3370BCL11A -22.30
2896KIAA0723 -21.60
1205MAP4K1 -21.40
5490AACS -21.10
385ZDHHC16 -21.10
6729MATR3 -20.50
3719MAP3K7 -20.30
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896S100PBP -19.90
2802CAMK2D -19.80
2666IVNS1ABP -19.60
6738UPF3 -19.40
605SFRS10 -19.00
5751RNF216L -18.10
2935KIF23 -17.80
1959RBM27 -17.60
6650RAB3IP -17.20
3724RAD51L3 -17.10
2437GPR137 -16.90
5918FAM120B -16.40
382C11orf80 -16.30
1367C11orf80 -16.30
2669MTMR3 -16.10
1180SRPK2 -16.00
1234FAM48A -15.90
968RABEP1 -15.20
3688BTRC -15.20
5995PMS1 -14.50
1537E2F6 -14.40
6376IKBKB -14.30
3350EIF5 -14.20
1257MPHOSPH9 -14.10
2938CBWD2 -13.80
2315SFRS12 -13.80
921RBBP6 -13.40
5668MAST2 -13.20
3624POLDIP3 -13.00
1707MBNL2 -12.90
248MTA1 -12.80
6675EEFSEC -12.50
2866BCLAF1 -12.20
6385PAN3 -12.20
2381RPAIN -12.00
2924PRNPIP -11.90
1599SFRS10 -11.80
6166METT5D1 -11.80
5738GPBP1 -11.60
1903C2orf33 -11.50
6901RWDD3 -11.50
6055NDUFB5 -11.40
1254BAT2D1 -11.30
961MAP3K3 -11.30
5675C1orf124 -11.30
2908TPM2 -11.20
6866LIN52 -10.90
3389USF2 -10.70
2923ARMC8 -10.20
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728TCERG1 10.10
595GPBP1 10.20
5731THRA 10.20
1958TCF12 10.40
2297UTX 10.40
2386TRIP12 10.40
6089LRRC28 10.50
5706ARFIP1 10.70
5900ARFIP1 10.70
2643FBXO25 11.40
2114LSM5 11.50
2074ATP11C 11.60
1138IL15 11.60
6554UPF3 11.60
662MTMR10 11.70
5648SDHC 11.90
6417hMLH1 12.00
691ANK3 12.00
6183RNF13 12.00
6146TLK2 12.10
3531ZMYND11 12.30
471EXOSC1 12.40
843EHBP1 12.50
1606NASP 12.90
3271HIPK2 13.10
2159C13orf23 13.30
3213NUMB 13.30
1876MYO9A 13.60
2857ARHGAP17 13.60
5602XPA 13.70
828FMNL3 14.10
2242C2orf37 14.30
6340ZNF257 14.50
1415SR140 15.10
1655MINK1 15.40
6392C14orf159 15.50
2646PBX3 16.50
2484MAPKAP1 17.40
5346LYRM1 17.80
2169TMPO 17.90
31LSR 18.00
1551SETD5 18.10
2564MARK2 18.50
2869DLST 18.70
1753RNF115 18.80
72APP 18.90
2555KIAA0920 19.00
1145PKM2 19.80
2465SMARCA2 19.90
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1464XPO6 20.30
677CLIP1 20.50
3494CCM2 20.90
2049TTLL5 21.00
1747NDUFV3 22.10
6774ZNF673 22.70
2757ARHGEF1 22.90
3028NAT15 23.10
943ATXN2 23.30
1487RBM5 23.60
6003CRKRS 23.90
1586TCF7L2 24.10
6757SNED1 24.40
227PPHLN1 24.80
2054SH3KBP1 25.20
6315IL9R 25.70
1969CAMK2G 25.80
3591ATF2 26.50
1687ZNF529 26.60
3650ZC3H18 27.00
5325C14orf135 27.60
172MTRR 28.60
1373MTRR 28.60
1392PATZ1 29.80
5755DKFZp666E123 30.20
2813NAPB 31.10
6898SC4MOL 32.00
5513USP3 32.60
5147DKFZp762G094 33.70
438IKZF1 34.50
6426NR4A3 34.60
1526RAPH1 52.50
1251MBNL2 53.80
2461COL6A3 64.60
6625NRF1 69.20
Table A2.2: DeltaPSI for anti-CD3/CD28 calculated as PSI(anti-CD3/CD28)-PSI(unstimulated). 
DeltaPSI for GSK3i effect calculated as PSI(GSK3i)-PSI(unstimulated) since SB216763 inhibitor 
mimics CD3/CD28-inhibition of GSK3. DeltaPSI for JNKi effect calculated as PSI(anti-CD3/CD28)-
PSI(anti-CD3/CD28+JNKi pretreatment) as SP600125 blocks CD3/CD28-activation of JNK. All 
values shown are the average of at least 3 donors with p<0.05, paired student t-test.  Color scale as 
shown in Fig 4B.
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RNA binding
GENE NAME Related Genes Species
CDKN2A interacting protein RG Homo sapiens
DAZ associated protein 1 RG Homo sapiens
DEAD (Asp-Glu-Ala-Asp) box polypeptide 50RG Homo sapiens
FIP1 like 1 (S. cerevisiae) RG Homo sapiens
RNA binding motif (RNP1, RRM) protein 3 RG Homo sapiens
eukaryotic translation initiation factor 4H RG Homo sapiens
far upstream element (FUSE) binding protein 3RG Homo sapiens
heterogeneous nuclear ribonucleoprotein K; similar to heterogeneous nuclear ribonucleoprotein KRG Homo sapiens
similar to eukaryotic translation initiation factor 4A2; eukaryotic translation initiation factor 4A, isoform 2RG Homo sapiens
splicing factor, arginine/serine-rich 3 RG Homo sapiens
splicing factor, arginine/serine-rich 7, 35kDaRG Homo sapiens
transformer 2 alpha homolog (Drosophila) RG Homo sapiens
Organelle
GENE NAME Related Genes Species
CDKN2A interacting protein RG Homo sapiens
DAZ associated protein 1 RG Homo sapiens
DEAD (Asp-Glu-Ala-Asp) box polypeptide 50RG Homo sapiens
MRE11 meiotic recombination 11 homolog A (S. cerevisiae)RG Homo sapiens
PRP3 pre-mRNA processing factor 3 homolog (S. cerevisiae)RG Homo sapiens
RPA interacting protein RG Homo sapiens
Wolf-Hirschhorn syndrome candidate 1-like 1RG Homo sapiens
actin-like 6A RG Homo sapiens
cAMP responsive element modulator RG Homo sapiens
cyclin L2; chemokine (C-C motif) receptor 6RG Homo sapiens
heterogeneous nuclear ribonucleoprotein K; similar to heterogeneous nuclear ribonucleoprotein KRG Homo sapiens
lymphoid enhancer-binding factor 1 RG Homo sapiens
nuclear receptor co-repressor 1 RG Homo sapiens
oxoglutarate (alpha-ketoglutarate) dehydrogenase (lipoamide)RG Homo sapiens
ring finger protein 34 RG Homo sapiens
similar to translocase of inner mitochondrial membrane 8 homolog B; translocase of inner mitochondrial membrane 8 homolog B (yeast)RG Homo sapiens
transcription factor A, mitochondrial RG Homo sapiens
zinc finger protein 207 RG Homo sapiens
Chromatin
GENE NAME Related Genes Species
Table A2.3: Specific genes that comprise the enriched GO-
categories presented in Fig 5.9D.
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MRE11 meiotic recombination 11 homolog A (S. cerevisiae)RG Homo sapiens
RAD51 homolog C (S. cerevisiae) RG Homo sapiens
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4RG Homo sapiens
Wolf-Hirschhorn syndrome candidate 1-like 1RG Homo sapiens
actin-like 6A RG Homo sapiens
bromodomain PHD finger transcription factorRG Homo sapiens
nuclear autoantigenic sperm protein (histone-binding)RG Homo sapiens
nuclear receptor co-repressor 1 RG Homo sapiens
Metal ion binding
GENE NAME Related Genes Species
5'-nucleotidase, cytosolic III RG Homo sapiens
6-pyruvoyltetrahydropterin synthase RG Homo sapiens
CD97 molecule RG Homo sapiens
G protein-coupled receptor kinase interacting ArfGAP 1RG Homo sapiens
LUC7-like (S. cerevisiae) RG Homo sapiens
MRE11 meiotic recombination 11 homolog A (S. cerevisiae)RG Homo sapiens
RPA interacting protein RG Homo sapiens
Wolf-Hirschhorn syndrome candidate 1-like 1RG Homo sapiens
additional sex combs like 1 (Drosophila) RG Homo sapiens
bromodomain PHD finger transcription factorRG Homo sapiens
dystrobrevin, beta RG Homo sapiens
four and a half LIM domains 1 RG Homo sapiens
metal response element binding transcription factor 2RG Homo sapiens
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2-likeRG Homo sapiens
prune homolog (Drosophila) RG Homo sapiens
ring finger protein 167 RG Homo sapiens
ring finger protein 34 RG Homo sapiens
serine/threonine kinase 4 RG Homo sapiens
similar to translocase of inner mitochondrial membrane 8 homolog B; translocase of inner mitochondrial membrane 8 homolog B (yeast)RG Homo sapiens
splicing factor, arginine/serine-rich 7, 35kDaRG Homo sapiens
zinc finger protein 207 RG Homo sapiens
zinc finger, DHHC-type containing 20 RG Homo sapiens
Protein localization
GENE NAME Related Genes Species
BCL2-associated X protein RG Homo sapiens
CD74 molecule, major histocompatibility complex, class II invariant chainRG Homo sapie s
ELKS/RAB6-interacting/CAST family member 1RG Homo sapiens
RPA interacting protein RG Homo sapiens
exocyst complex component 7 RG Homo sapiens
importin 9 RG Homo sapiens
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nuclear autoantigenic sperm protein (histone-binding)RG Homo sapiens
retinitis pigmentosa GTPase regulator RG Homo sapiens
similar to translocase of inner mitochondrial membrane 8 homolog B; translocase of inner mitochondrial membrane 8 homolog B (yeast)RG Homo sapiens
sorting nexin 14 RG Homo sapiens
Transcription
GENE NAME Related Genes Species
ELKS/RAB6-interacting/CAST family member 1RG Homo sapiens
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4RG Homo sapiens
Wolf-Hirschhorn syndrome candidate 1-like 1RG Homo sapiens
actin-like 6A RG Homo sapiens
additional sex combs like 1 (Drosophila) RG Homo sapiens
bromodomain PHD finger transcription factorRG Homo sapiens
cAMP responsive element modulator RG Homo sapiens
calmodulin binding transcription activator 1 RG Homo sapiens
cell division cycle and apoptosis regulator 1RG Homo sapiens
cyclin L2; chemokine (C-C motif) receptor 6RG Homo sapiens
far upstream element (FUSE) binding protein 3RG Homo sapiens
general transcription factor II, i; general transcription factor II, i, pseudogeneRG Homo sapiens
lymphoid enhancer-binding factor 1 RG Homo sapiens
nuclear receptor co-repressor 1 RG Homo sapiens
similar to Bcl-2-associated transcription factor 1 (Btf); BCL2-associated transcription factor 1RG Homo sapiens
transcription factor A, mitochondrial RG Homo sapiens
zinc finger protein 207 RG Homo sapiens
Kegg Pathway
Spliceosome
GENE NAME Related Genes Species
PRP3 pre-mRNA processing factor 3 homolog (S. cerevisiae)RG Homo sapiens
heterogeneous nuclear ribonucleoprotein K; similar to heterogeneous nuclear ribonucleoprotein KRG Homo sapiens
splicing factor, arginine/serine-rich 3 RG Homo sapiens
splicing factor, arginine/serine-rich 7, 35kDaRG Homo sapiens
transformer 2 alpha homolog (Drosophila) RG Homo sapiens
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  Table A2.4A:  DAVID analysis of JNK-dependent genes in primary human CD4+ T Cells
Annotation Cluster 1 Enrichment Score: 3.51 Count P_Value
SP_PIR_KEYWORDS ubl conjugation 14 3.20E-06
SP_PIR_KEYWORDS isopeptide bond 8 1.30E-03
UP_SEQ_FEATURE cross-link:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin) 6 7.40E-03
Annotation Cluster 2 Enrichment Score: 2.37 Count P_Value
KEGG_PATHWAY Spliceosome 5 4.30E-07
GOTERM_BP_FAT RNA splicing, via transesterification reactions 6 1.90E-04
GOTERM_BP_FAT RNA splicing, via transesterification reactions with bulged adenosine as nucleophile 6 1.90E-04
GOTERM_BP_FAT nuclear mRNA splicing, via spliceosome 6 1.90E-04
GOTERM_MF_FAT RNA binding 12 2.80E-03
SP_PIR_KEYWORDS rna-binding 11 3.40E-03
GOTERM_BP_FAT mRNA processing 7 1.70E-02
GOTERM_BP_FAT RNA processing 8 1.80E-02
SP_PIR_KEYWORDS mrna splicing 5 1.90E-02
UP_SEQ_FEATURE domain:RRM 5 1.90E-02
GOTERM_BP_FAT mRNA metabolic process 7 2.40E-02
GOTERM_BP_FAT RNA splicing 6 2.50E-02
SP_PIR_KEYWORDS mrna processing 6 3.10E-02
INTERPRO RNA recognition motif, RNP-1 6 4.70E-02
INTERPRO Nucleotide-binding, alpha-beta plait 6 4.80E-02
SMART RRM 6 7.90E-02
Annotation Cluster 3 Enrichment Score: 2.18 Count P_Value
GOTERM_CC_FAT membrane-enclosed lumen 18 1.40E-04
GOTERM_CC_FAT intracellular organelle lumen 17 3.10E-04
GOTERM_CC_FAT organelle lumen 17 3.60E-04
GOTERM_CC_FAT nuclear lumen 15 9.30E-04
GOTERM_CC_FAT nucleolus 8 1.80E-03
GOTERM_CC_FAT nucleoplasm 11 6.80E-03
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GOTERM_CC_FAT nucleoplasm part 8 3.00E-02
GOTERM_CC_FAT nuclear body 4 5.30E-02
GOTERM_CC_FAT nuclear speck 3 1.00E-01
GOTERM_CC_FAT non-membrane-bounded organelle 16 1.80E-01
GOTERM_CC_FAT intracellular non-membrane-bounded organelle 16 1.80E-01
Annotation Cluster 4 Enrichment Score: 1.51 Count P_Value
GOTERM_BP_FAT chromatin remodeling 4 3.60E-03
BIOCARTA Control of Gene Expression by Vitamin D Receptor 3 1.40E-02
GOTERM_BP_FAT chromosome organization 8 1.80E-02
GOTERM_BP_FAT chromatin modification 6 2.70E-02
SP_PIR_KEYWORDS chromatin regulator 5 4.10E-02
GOTERM_BP_FAT chromatin organization 6 5.90E-02
GOTERM_CC_FAT chromatin remodeling complex 3 7.50E-02
GOTERM_BP_FAT covalent chromatin modification 3 2.10E-01
Annotation Cluster 5 Enrichment Score: 1.28 Count P_Value
UP_SEQ_FEATURE zinc finger region:PHD-type 2 3 1.80E-02
UP_SEQ_FEATURE zinc finger region:PHD-type 1 3 1.80E-02
INTERPRO Zinc finger, PHD-finger 3 9.90E-02
INTERPRO Zinc finger, PHD-type 3 1.00E-01
SMART PHD 3 1.30E-01
Annotation Cluster 6 Enrichment Score: 1.26 Count P_Value
SP_PIR_KEYWORDS zinc-finger 14 3.20E-03
SP_PIR_KEYWORDS zinc 16 2.30E-02
SP_PIR_KEYWORDS metal-binding 19 3.60E-02
GOTERM_MF_FAT zinc ion binding 16 5.70E-02
GOTERM_MF_FAT transition metal ion binding 18 7.50E-02
GOTERM_MF_FAT metal ion binding 22 1.80E-01
GOTERM_MF_FAT cation binding 22 1.90E-01
GOTERM_MF_FAT ion binding 22 2.10E-01
Annotation Cluster 7 Enrichment Score: 1.12 Count
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GOTERM_BP_FAT protein localization 10 1.90E-02
GOTERM_BP_FAT protein transport 9 2.40E-02
GOTERM_BP_FAT establishment of protein localization 9 2.60E-02
SP_PIR_KEYWORDS protein transport 6 5.10E-02
GOTERM_BP_FAT cellular protein localization 6 5.80E-02
GOTERM_BP_FAT cellular macromolecule localization 6 6.10E-02
GOTERM_BP_FAT intracellular transport 7 6.40E-02
GOTERM_BP_FAT protein import 3 1.00E-01
GOTERM_BP_FAT intracellular protein transport 5 1.30E-01
GOTERM_BP_FAT protein localization in organelle 3 1.40E-01
GOTERM_BP_FAT protein targeting 3 2.20E-01
SP_PIR_KEYWORDS transport 6 7.30E-01
Annotation Cluster 8 Enrichment Score: 1.11 Count P_Value
GOTERM_BP_FAT negative regulation of gene expression 7 2.70E-02
GOTERM_BP_FAT limb morphogenesis 3 7.00E-02
GOTERM_BP_FAT limb development 3 7.20E-02
GOTERM_BP_FAT negative regulation of macromolecule metabolic process 7 7.80E-02
GOTERM_BP_FAT appendage morphogenesis 3 8.00E-02
GOTERM_BP_FAT appendage development 3 8.40E-02
GOTERM_BP_FAT forebrain development 3 2.40E-01
Annotation Cluster 9 Enrichment Score: 1.06 Count P_Value
GOTERM_BP_FAT transcription 15 7.40E-03
SP_PIR_KEYWORDS transcription regulation 15 1.30E-02
SP_PIR_KEYWORDS Transcription 15 1.60E-02
GOTERM_BP_FAT regulation of transcription 17 4.90E-02
SP_PIR_KEYWORDS dna-binding 12 7.90E-02
GOTERM_MF_FAT DNA binding 15 9.20E-02
GOTERM_MF_FAT transcription regulator activity 11 1.00E-01
SP_PIR_KEYWORDS activator 6 1.10E-01
GOTERM_MF_FAT transcription activator activity 4 2.30E-01
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Annotation Cluster 1 Enrichment Score: 3.62 Count P_Value
KEGG_PATHWAY Neurotrophin signaling pathway 6 1.00E-06
KEGG_PATHWAY Focal adhesion 5 1.10E-04
KEGG_PATHWAY Renal cell carcinoma 3 3.30E-03
KEGG_PATHWAY Insulin signaling pathway 3 9.20E-03
Annotation Cluster 2 Enrichment Score: 3.55 Count P_Value
KEGG_PATHWAY Neurotrophin signaling pathway 6 1.00E-06
KEGG_PATHWAY Fc epsilon RI signaling pathway 3 2.80E-03
KEGG_PATHWAY T cell receptor signaling pathway 3 8.00E-03
Annotation Cluster 3 Enrichment Score: 2.88 Count P_Value
GOTERM_CC_FAT nucleolus 12 3.50E-04
GOTERM_CC_FAT membrane-enclosed lumen 25 5.80E-04
GOTERM_CC_FAT intracellular organelle lumen 24 8.10E-04
GOTERM_CC_FAT nuclear lumen 22 9.80E-04
GOTERM_CC_FAT organelle lumen 24 9.90E-04
GOTERM_CC_FAT nucleoplasm 14 3.50E-02
Annotation Cluster 4 Enrichment Score: 2.8 Count P_Value
KEGG_PATHWAY Focal adhesion 5 1.10E-04
KEGG_PATHWAY VEGF signaling pathway 3 3.30E-03
KEGG_PATHWAY Chemokine signaling pathway 3 1.10E-02
Annotation Cluster 5 Enrichment Score: 2.19 Count P_Value
KEGG_PATHWAY Focal adhesion 5 1.10E-04
BIOCARTA Integrin Signaling Pathway 3 4.60E-02
BIOCARTA Signaling of Hepatocyte Growth Factor Receptor 3 5.60E-02
Annotation Cluster 6 Enrichment Score: 2.17 Count P_Value
SP_PIR_KEYWORDS chromatin regulator 10 2.60E-04
GOTERM_BP_FAT chromatin modification 10 3.50E-03
GOTERM_BP_FAT chromatin organization 10 1.40E-02
Table A2.4B:  DAVID analysis of GSK3-sensitive genes in primary human CD4+ T Cells
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GOTERM_BP_FAT histone modification 6 1.50E-02
GOTERM_BP_FAT covalent chromatin modification 6 1.90E-02
GOTERM_BP_FAT chromosome organization 11 2.50E-02
Annotation Cluster 7 Enrichment Score: 1.88 Count P_Value
GOTERM_BP_FAT cellular macromolecular complex subunit organization 10 8.00E-04
KEGG_PATHWAY Regulation of actin cytoskeleton 4 1.50E-03
GOTERM_BP_FAT cellular macromolecular complex assembly 8 4.80E-03
GOTERM_BP_FAT macromolecular complex subunit organization 11 1.60E-02
BIOCARTA Erk and PI-3 Kinase Are Necessary for Collagen Binding in Corneal Epithelia 3 2.30E-02
GOTERM_BP_FAT macromolecular complex assembly 10 2.40E-02
GOTERM_BP_FAT cellular protein complex assembly 5 2.40E-02
GOTERM_BP_FAT protein complex assembly 7 1.00E-01
GOTERM_BP_FAT protein complex biogenesis 7 1.00E-01
Annotation Cluster 8 Enrichment Score: 1.75 Count P_Value
GOTERM_MF_FAT RNA binding 17 7.30E-04
SP_PIR_KEYWORDS rna-binding 16 8.20E-04
GOTERM_BP_FAT RNA processing 14 1.20E-03
GOTERM_BP_FAT RNA splicing, via transesterification reactions 6 2.80E-03
GOTERM_BP_FAT RNA splicing, via transesterification reactions with bulged adenosine as nucleophile 6 2.80E-03
GOTERM_BP_FAT nuclear mRNA splicing, via spliceosome 6 2.80E-03
GOTERM_BP_FAT mRNA metabolic process 11 7.10E-03
GOTERM_BP_FAT mRNA processing 10 1.30E-02
GOTERM_BP_FAT RNA splicing 8 3.00E-02
SP_PIR_KEYWORDS mrna processing 7 6.40E-02
GOTERM_BP_FAT ribonucleoprotein complex assembly 3 8.70E-02
GOTERM_CC_FAT spliceosome 4 9.80E-02
SP_PIR_KEYWORDS Spliceosome 3 1.50E-01
GOTERM_BP_FAT ribonucleoprotein complex biogenesis 4 1.70E-01
SP_PIR_KEYWORDS mrna splicing 4 2.30E-01
GOTERM_CC_FAT ribonucleoprotein complex 7 6.20E-01
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Annotation Cluster 9 Enrichment Score: 1.64 Count P_Value
SP_PIR_KEYWORDS ubl conjugation 12 5.10E-03
SP_PIR_KEYWORDS isopeptide bond 8 1.70E-02
UP_SEQ_FEATURE cross-link:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin) 5 1.30E-01
Annotation Cluster 10 Enrichment Score: 1.62 Count P_Value
GOTERM_CC_FAT centrosome 8 2.70E-03
GOTERM_CC_FAT microtubule organizing center 8 4.20E-03
SP_PIR_KEYWORDS cytoskeleton 12 4.90E-03
GOTERM_CC_FAT pericentriolar material 3 1.10E-02
GOTERM_CC_FAT microtubule cytoskeleton 10 3.30E-02
GOTERM_CC_FAT microtubule organizing center part 3 7.00E-02
GOTERM_CC_FAT cytoskeleton 15 2.10E-01
GOTERM_CC_FAT cytoskeletal part 9 3.70E-01
Annotation Cluster 11 Enrichment Score: 1.53 Count P_Value
GOTERM_MF_FAT GTPase binding 5 7.70E-03
GOTERM_MF_FAT Ras GTPase binding 4 2.10E-02
GOTERM_MF_FAT small GTPase binding 4 2.70E-02
GOTERM_MF_FAT Rho GTPase binding 3 4.40E-02
GOTERM_MF_FAT enzyme binding 7 1.10E-01
Annotation Cluster 12 Enrichment Score: 1.39 Count P_Value
GOTERM_CC_FAT eukaryotic translation initiation factor 4F complex 3 6.50E-03
GOTERM_BP_FAT posttranscriptional regulation of gene expression 6 1.70E-02
GOTERM_BP_FAT regulation of translational initiation 3 1.90E-02
GOTERM_BP_FAT regulation of cellular protein metabolic process 6 2.30E-01
GOTERM_BP_FAT regulation of translation 3 2.40E-01
Annotation Cluster 13 Enrichment Score: 1.3 Count P_Value
GOTERM_BP_FAT ubiquitin-dependent protein catabolic process 6 3.50E-02
GOTERM_BP_FAT proteasomal ubiquitin-dependent protein catabolic process 3 5.90E-02
GOTERM_BP_FAT proteasomal protein catabolic process 3 5.90E-02
Annotation Cluster 14 Enrichment Score: 1.28 Count P_Value
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GOTERM_CC_FAT intracellular non-membrane-bounded organelle 31 2.70E-02
GOTERM_CC_FAT non-membrane-bounded organelle 31 2.70E-02
GOTERM_CC_FAT cytoskeleton 15 2.10E-01
Annotation Cluster 15 Enrichment Score: 1.24 Count P_Value
GOTERM_BP_FAT transcription 24 2.80E-03
SP_PIR_KEYWORDS Transcription 23 4.30E-03
SP_PIR_KEYWORDS transcription regulation 22 6.90E-03
GOTERM_MF_FAT transcription factor binding 9 7.90E-03
GOTERM_BP_FAT positive regulation of macromolecule metabolic process 15 1.00E-02
GOTERM_BP_FAT regulation of transcription 30 1.00E-02
GOTERM_MF_FAT DNA binding 24 2.20E-02
GOTERM_MF_FAT transcription cofactor activity 6 3.10E-02
GOTERM_BP_FAT positive regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process 11 4.60E-02
GOTERM_BP_FAT positive regulation of macromolecule biosynthetic process 11 4.70E-02
GOTERM_BP_FAT positive regulation of nitrogen compound metabolic process 11 5.10E-02
GOTERM_BP_FAT positive regulation of cellular biosynthetic process 11 5.40E-02
GOTERM_BP_FAT positive regulation of biosynthetic process 11 5.90E-02
GOTERM_MF_FAT transcription regulator activity 16 6.70E-02
GOTERM_BP_FAT regulation of RNA metabolic process 20 6.90E-02
GOTERM_MF_FAT transcription coactivator activity 4 8.20E-02
GOTERM_MF_FAT transcription activator activity 6 1.10E-01
GOTERM_BP_FAT positive regulation of transcription 9 1.10E-01
GOTERM_BP_FAT positive regulation of gene expression 9 1.30E-01
GOTERM_BP_FAT positive regulation of gene-specific transcription 3 1.50E-01
GOTERM_BP_FAT regulation of transcription from RNA polymerase II promoter 9 2.00E-01
GOTERM_BP_FAT regulation of transcription, DNA-dependent 17 2.20E-01
GOTERM_BP_FAT positive regulation of transcription, DNA-dependent 7 2.40E-01
GOTERM_BP_FAT positive regulation of RNA metabolic process 7 2.40E-01
GOTERM_BP_FAT regulation of gene-specific transcription 3 2.90E-01
GOTERM_BP_FAT positive regulation of transcription from RNA polymerase II promoter 5 4.60E-01
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GOTERM_MF_FAT transcription factor activity 7 6.40E-01
Annotation Cluster 16 Enrichment Score: 1.14 Count P_Value
INTERPRO Zinc finger, CCHC-type 3 6.30E-02
SP_PIR_KEYWORDS repressor 7 6.70E-02
SMART ZnF_C2HC 3 9.00E-02
Annotation Cluster 17 Enrichment Score: 1.01 Count P_Value
GOTERM_BP_FAT histone modification 6 1.50E-02
GOTERM_BP_FAT covalent chromatin modification 6 1.90E-02
GOTERM_BP_FAT one-carbon metabolic process 5 5.30E-02
GOTERM_BP_FAT histone methylation 3 5.70E-02
GOTERM_BP_FAT biopolymer methylation 4 5.90E-02
GOTERM_BP_FAT methylation 4 7.50E-02
GOTERM_MF_FAT protein-lysine N-methyltransferase activity 3 8.90E-02
GOTERM_MF_FAT lysine N-methyltransferase activity 3 8.90E-02
GOTERM_MF_FAT histone-lysine N-methyltransferase activity 3 8.90E-02
GOTERM_BP_FAT protein amino acid alkylation 3 1.20E-01
GOTERM_BP_FAT protein amino acid methylation 3 1.20E-01
UP_SEQ_FEATURE domain:SET 3 1.20E-01
GOTERM_MF_FAT histone methyltransferase activity 3 1.30E-01
INTERPRO SET 3 1.40E-01
GOTERM_MF_FAT N-methyltransferase activity 3 1.40E-01
SMART SET 3 1.90E-01
GOTERM_MF_FAT protein methyltransferase activity 3 3.10E-01
SP_PIR_KEYWORDS methyltransferase 3 7.90E-01
Annotation Cluster 18 Enrichment Score: 1.01 Count P_Value
GOTERM_BP_FAT ubiquitin-dependent protein catabolic process 6 3.50E-02
GOTERM_BP_FAT modification-dependent protein catabolic process 9 6.80E-02
GOTERM_BP_FAT modification-dependent macromolecule catabolic process 9 6.90E-02
GOTERM_BP_FAT proteolysis involved in cellular protein catabolic process 9 8.80E-02
GOTERM_BP_FAT cellular protein catabolic process 9 9.00E-02
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APPENDIX 3: ALTERNATIVE SPLICING DURING THYMOCYTE 
DEVELOPMENT 
 
Introduction 
In addition to widespread alternative splicing in response to mature T-cell activation, our 
lab had evidence suggesting that alternative splicing may regulate gene expression as 
consequence of pre-TCR signaling during thymocyte development. Early thymic 
progenitors are uncommitted cells that must pass through a series of signaling and 
transcriptional checkpoints in the thymus (Bell and Bhandoola 2008; Carpenter and 
Bosselut 2010). T cell development in the thymus involves a number of differentiation 
and proliferation steps. This process is necessary for the generation of mature T cells 
that carry out effector functions in immune response. During the DN stage, T cells must 
undergo a checkpoint known as β-selection in which thymocytes signal through their pre-
TCR. Although there are no known ligands that mediate this process, it is thought to 
involve receptor oligomerization and intracellular molecules similar to those triggered by 
TCR signaling in mature T cells (Yamasaki et al. 2006). Although pre-TCR signal is less 
understood, there seems to be parallels between pre-TCR and mature TCR signaling. 
After β-selection, thymocytes proceed to become double positive (DP) thymocytes, 
characterized by the expression of CD4 and CD8 before they ultimately undergo lineage 
commitment and become single positives.  
 The Lynch laboratory demonstrated that at least one gene, the transcription 
factor LEF1 is alternatively alternatively spliced in response to both activation of Jurkat T 
cells with PMA and during pre-TCR signaling (chapter 1). That change in spliced 
isoforms of LEF1 in the DN to DP stage is directly correlated correlated with increased 
TCR-α expression, an important LEF1 target gene. Futhermore, Michael Mallory showed 
that the expression of CELF2, the splicing factor regulating LEF1 and MKK7 pre-mRNA 
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splicing, increases during the transition from DN to DP in thymocytes. Given, that an 
increase in CELF2 protein is sufficient to explain the differential splicing of MKK7 (See 
chapter 5), we hypothesized that the increase in CELF2 protein during the DN to DP 
transition of thymocyte development may regulate the alternative splicing of additional 
genes and that alternative splicing may serve as a broad mechanism to control gene 
expression during pre-TCR signaling.  
 
Results 
 
Splicing is regulated during thymocyte development 
 To first identify additional changes in splicing during T cell development, I FACS-
isolated DN and DP cell populations from single cell suspensions that I generated from 
human thymus (Fig A3.1). I extracted RNA from DN and DP thymocytes that and 
submitted the RNA to our collaborators in the Fu Lab who performed RASL-Seq 
(described in Chapter 5). Given limited thymic material available and inherent donor 
variability, the RASL-Seq analysis only identified 14 high confidence exons that display 
>10% PSI changes that are statistically significant across the three donors surveyed 
(Fig. A3.2B).  
Alternative splicing events in thymocytes are enriched for known CELF2 target genes  
Despite the minimal information drawn from the RASL-seq we found that 4 of the 
 185 
dentified 14 events (29%) are among the 72 CELF2-dependent activation-responsive 
exons identified in the Jurkat cells ((Mallory et al. 2015) and Fig. A3.2B) (P < 0.00036, 
two-tailed Fisher’s exact test). An additional CELF2-dependent event (CTTN) was also 
observed to change dramatically in the DN vs. DP cells, although with a modest P value 
(0.09). Matthew Gazzara in the lab validated the dependence of four of these genes on 
CELF2 in Jurkat T cells that express the CELF2 shRNA described in chapter 5. He 
further confirmed the change in alternative splicing between DN and DP stages for 
SRPK2 (Fig. A3.2C,D). Matthew was unable to obtain RT-PCR data on PIP5K5A given 
the presence of highly homologous intronless genes. We had minimal amounts of 
Figure A3.1 Isolation of double negative (CD4–CD8–, DN) and double positive (CD4+CD8+, DP) 
thymocytes from single cell thymocyte suspensions. Representative FACS plots of gating to isolate DP 
and DN thymocytes with anti–CD8-APC, anti–CD4-FITC. For isolating the DN population, cells were stained 
with anti–CD8-APC, anti–CD4-FITC, and a cocktail of antibodies to deplete non-thymocytes that were labeled 
with PE. For isolation of the DP   population cells were stained with anti–CD8-APC, anti–CD4-FITC.  Cells 
were first gated for PE− (Upper Left), then by forward scatter/side scatter for live cells (Lower Left), and finally 
DN and DP cells were collected based on the gates shown (Bottom Right). Typical yields were ∼ 2 × 106 DP 
and 5 × 105 DN cells.  
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thymocyte RNA from the DN and DP populations and were not able to detect sufficient 
amounts of CTTN, OPA1, or MPRL42 for quantification by RT-PCR, depletion of CELF2 
in the Jurkat T cells altered the splicing pattern of these genes in the direction opposite 
to that observed upon the transition from DN to DP (Fig. A3.2C), supporting that 
increased CELF2 expression in DP cells contributes to the observed alternative splicing 
of these genes during pre-TCR signaling. For one of the genes SRPK2, which is 
expressed at higher levels, Matthew validated the RASL-seq identified change in splicing 
from DN to DP stages in thymocytes, as well as the sensitivity to CELF2 knockdown in 
Jurkat T cells (Fig A3.2D).  
  
Discussion 
 We acknowledge that the RASL-seq identified developmentally regulated 
changes in alternative splicing of thymocytes is likely an underestimation of the scope of 
this mechanism of gene regulation, due to technical reasons such as inherent donor 
variability and limited quantity of material from the very minor fraction that the DN 
population represents of total human thymus. Nevertheless, the profiling of alternative 
splicing during thymocyte development presented in this appendix proposes that 
alternative splicing may regulate a larger set of genes than previously appreciated during 
the developmental process of pre-TCR signaling in a manner analogous to TCR 
signaling during activation of mature T cells.  
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 We found that a 1/3 of the developmentally regulated splicing events in 
thymocytes are also sensitive to CELF2 depletion in Jurkat T cells, suggesting that 
CELF2 may regulate a fraction of DN to DP splicing events. Moreover, the increase in 
CELF2 expression during the transition from DN to DP is reminiscent of the increase in 
CELF2 mRNA and protein observed upon activation of Jurkat T cells. In chapters 4 and 
5 I described the mechanism leading to increased CELF2 expression in T cells. 
Specifically, we established that an increase in CELF2 mRNA, is driven by a JNK 
signaling-induced increase in message stability that results in increased CELF2 protein. 
Thus, JNK signaling through driving increased expression of CELF2 is a plausible 
mechanism by which alternative splicing is controlled during thymocyte pre-TCR 
signaling, underscoring the biological significance of the JNK/CELF2 signaling pathway. 
Figure A3.2  Differential alternative splicing in DP relative to DN thymocytes. (A) Table of significant 
(p-value < 0.05) differences in percent inclusion (PSI) between DN and DP stages of thymocyte 
development identified by RASL-seq. (B) Representative RT-PCR gel of the validation of sensitivity to 
CELF2 knockdown, of genes overlapping in the thymocytes and CELF2 knockdown (Mallory 2015) RASL-
seq experiments, in Jurkat T cells that have been depleted of CELF2 with an shRNA as in Fig 5.5D. 
Average percent inclusion of at least three independent experiments is shown below. (C) Same as B, but 
including also showing percent inclusion values from DN and DP thymocytes. RNA from FACS purified 
DN and DP thymocytes. Average percent inclusion for the thymocytes is the average of at least three 
independent donors.  
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 APPENDIX 4: EXPERIMENTAL PROTOCOLS 
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In vitro Transcription of Cold RNA  
 
1. Transcription reaction: 
 4µL of linearized plasmid DNA (or more from PCR template and adjust water) 
 10µL  TINOCO buffer 
 4µL  each NTP (from 100mM stock) 
 16µL  PEG 
 60µL  water 
 2µL  RNasin  
 4µL  T7 RNA polymerase 
2. Incubate reaction at 37 degrees for 3h. 
3. Add 5µL of DNase and incubate at 37 degrees for 15 min. 
4. PCA extract/EtOH precipitate and freeze for 15 min. 
5. Re-suspend in 10µL of formamide and run on 5-10% PAGE. 
6. Examine in UV light. 
7. Cut-out bands . 
8. Crush gel in 500µL TE buffer plus 0.1% SDS. 
9. Incubate overnight with rotation at room temperature. 
10. Spin down at max speed for 5 min. 
11. Take top phase and PCA extract/EtOH precipitate freeze for 15 min. 
12. Re-suspend in 11µL water. 
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In vitro Transcription of Hot RNA 
 
1. Make 10X ACG mix 
   Final Conc.  Volume 
 100mM ATP 8mM  16µL 
 100mM CTP 8mM  16µL 
 100mM GTP 8mM  16µL 
 H2O    152µL 
 
2. Transcription Reaction 
 PCR template (~50ng/uL) 6.25µL 
 10X ACG   5µL 
 10mM UTP   2.5µL 
 100mM DTT   0.25µL 
 P-32 alpha-UTP  5µL 
 RNasin   1µL 
 T7 RNA polymerase  2.5µL 
 
3. Incubate at 37 degrees for 1-3h. 
4. Add 2µL RQ1 DNase and incubate at 37 degrees for 15 min. 
5. Add water to make 200µL . 
6. PCA extract/EtOH precipitate and freeze for 15 min. 
7. Re-suspend in 8µL of formamide and run on 5-10% PAGE. 
8. Expose to film for 1 min with glow in the dark stickers. 
13. Align film to gel and cut-out band.  
14. Crush gel in 500µL TE buffer plus 0.1% SDS. 
15. Elute overnight with rotation at room temperature. 
16. Spin down max speed for 5 min. 
17. Collect supernatant and PCA extract/EtOH precipitate. 
18. Re-suspend in 11µL water. 
19. Spot 1µL in whatman paper and soak in 2mL scintillation fluid. 
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Biotinylation of in vitro Transcribed RNA 
 
Using Thermo 3’ end biotinylation kit 
 
1. Thaw kit components on ice 
 Warm PEG (30%) at 37 degrees for 5 min. 
2. Adjust heating block to 85 degrees. 
3. Transfer 20-50 pmol of RNA in a maximum of 8µL volume or adjust volume with 
water to a tube. Heat RNA for 3 min at 85 degrees. Place on ice immediately. 
4. Labeling reaction 
 20-50 pmol RNA  8µL 
 10X RNA ligation buffer  3µL 
 RNase inhibitor   1µL 
 Biotinylated cytidine   1µL 
 T4 RNA ligase   2µL 
 30% PEG    15µL 
5. Incubate at 16 degrees overnight (PCR block). 
6. Bring volume to 100µL. 
7. Add 100µL PCA, vortex and spin 3 min max speed. 
8. Take top phase add 300µL of EtOH, 10µL NaCl (5M) and 1µL glycogen. Vortex 
and freeze for 1h at 20 degrees. 
9. Spin ma speed 15 min at 4 degrees. 
10. Wash with 300µL 70% EtOH. 
11. Air dry and re-suspend pellet in 20µL nuclease free water. 
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RNA Affinity Purification 
 
Part A- Binding Reaction 
 
1. Prepare binding reaction: 
25µL  BC400 
66.25µL  BC100  
25µL 13% PVA 
10µL 80mM MgCL2 
10µL 25mM ATP 
10µL creatine phosphate 
25µL 0.25ug/uL tRNA/BC100 
10µL 2.5pmol/uL RNA (or if at other concentration adjust water) 
58.8µL water 
10µL nuclear extract 
 
2. Incubate binding reactions in 30 degree water bath for 30 min. 
 
Part B- Block Beads 
 
1. Pool 30µL of Streptavidin beads (Pierce) per reaction. 
2. Wash 3X in 1mL of GFB100. 
3. Spin 2,500 x g for 1 min. 
4. Block beads in: (per reaction) 
 10uL Heparin 50µg/µL 
 1mL GFB100 
5. Incubate with rotation at 4 degrees for 30 min. 
6. Wash 1X with GFB100. 
 
Part-C Couple RNA to Beads 
 
 193 
7. After last wash re-suspend Beads in (per reaction): 
 5µL  Heparin 
 10µL  80mM MgCl2 
 48.5µL  BC400 
 197µL   water 
 
8. Add 250µL of bead mix from above to each binding reaction. 
9. Incubated for 1h at 4 degrees. 
10. Washed 4X in GFB100 + 4mM MgCl2. 
11. Re-suspended in 20µL SDS sample buffer, boiled for 5 min. 
12. Run 10µL in SDS-PAGE for silver stain and save other 10µL for western blot or 
mass spec. 
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UV Crosslinking Followed by Immunoprecipitation 
 
1. Binding reaction: 
 4µL  of nuclear extract (or ~20ug) 
 1µL  BC400 
 1µL  13% PVA 
 1µL  tRNA/BSA/BC100 (0.25ug/uL tRNA+0.2ug/uL BSA in BC100) 
 0.4µL  80mM MgCl2 
 0.4µL  25mM ATP 
 0.4µL  creatine phosphate 
 1µL  of H2O 
 1µL  radiolabeled RNA 
 
2. Make master mix. 
3. Incubate at 30 degrees for 20 min. 
4. Pipet into 96-well plate (round bottom) on ice. 
5. Place UV lamp (254nm) on top of plate without lid. 
6. UV crosslink for 20 min. 
7. Place reactions in new tubes with 20U RNase T1 + 20µg RNase A. 
8. Digest at 37 degrees for 20 min. 
9. Add 10µL SDS sample buffer (+BME). 
10. Boil 5 min and run on 12.5% SDS-PAGE. 
 
For IP step: 
 
1. Pool binding UV crosslinking reactions for each IP after step 8 (RNase digestion). 
2. Add 5-10µL of antibody depending on concentration. 
3. Bring volume to 400µL with 1X RIPA buffer (150mM NaCl, 1% NP-40, 0.5% 
sodium deoxycholate, 50mM Tris pH 8, 0.1% SDS) plus protease inhibitor 
cocktail. 
4. Incubate overnight at 4 degrees with rotation. 
5. Pre-wash 40µL of protein G Dynabeads (or protein G sepharose) per reaction 
with RIPA buffer. 
6. Add IP reactions to beads. 
7. Incubate with beads for 1h at 4 degrees. 
8. Place on magnet and wash 3X with RIPA buffer. 
9. Re-suspend beads in 20µL 2X SDS sample buffer (+BME) and boil for 5 min. 
10. Run on 12.5% SDS-PAGE gels. 
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RT-PCR 
 
1. RT-step 
  Master mix (per reaction): 
 1µL 5X Hyb buffer 
 1µL reverse primer (1ng/uL) 
 
 Add 2µL of master mix to each tube of a PCR strip  
 Then add 2µL of each RNA(50-500ng/µL). 
 Run RT program on PCR machine. 
 
2. Make master mix (per reaction):  
 19.5µL 1.25X RT mix (pre-warm at 43 degrees for ~10min) 
 0.5µL  MMLV (add enzyme prior to adding to tubes with cDNA) 
  
 Keep RT program running while adding 20µL of master mix to each tube. Pipet to 
 mix. 
 Run RT-Pol program on PCR machine. 
 
3. PCR step 
 Master mix per reaction: 
 1µL 5ng/µL reverse primer 
 1µL 2.5ng/µL forward primer 
 1µL 2.5ng/µL P-32 labeled forward primer 
 1.5µL RT-PCR buffer 
 10.3µL water 
 0.2µL Taq (5U/µL) 
 
 Pipet 15 µL of master mix to new PCR tubes and add 5µL of cDNA from RT-step. 
 Add a drop of mineral oil. 
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 Run PCR program: 
 94 degrees for 2 min 
 loop X cycle # 
 94 degrees for 1 min 
 65-70 degrees for 1 min 
 72 degrees for 1.5 min 
 final extension 72 degrees for 5-10 min 
 
 Add 15µL of formamide buffer. Boil samples. 
 
 Run on 5% acrylamide gel. 
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Thymocyte Sorting  
 
Part A- Single Cell Suspensions 
 
1. Disinfect everything with bleach and follow precautions for handling human 
tissue. Prepare work area in hood with diaper, beaker with bleach, tweezers, 
razor, well plates and microscope slides. 
2. Cut-up thymus into chunks ½” to 1”. 
3. Place in well plates that accommodates thymus and ~10mL PBS. 
4. Take 2 microscope slides and use the rough surface to grind thymus to make 
single cell suspension. Discard tissue that doesn’t break up. 
5. Filter cell suspension through a glass Pasteur pipette that has a piece of cotton 
inserted at the top (from sterile plastic pipettes) to remove clumps. 
6. Collect flowthrough in 50mL conical tube. Spin at 1,200 rpm for 5 min at 4 
degrees. 
7. If pellet is red, resuspend in 10mL of red blood cell lysis buffer. Incubate at room 
temperature for 10 min. and spin down at 1,200 rpm for 5 min at 4 degrees. 
8. Repeat step 7 if pellet is still red. 
9. Re-suspend in PBS without Ca2+/Mg2+, 0.1% FBS, 2mM EDTA. Count cells and 
adjust concentration for sorting. 
 
Part B- Double Negative Sorting 
 
CD4 Depletion by Magnetic Sorting 
 
1. Started w/ 6x108 total cells 
2. Re-suspended in 60mL of Magnetic sort buffer (PBS, 0.1%FBS, 2mM EDTA, w/o 
Ca2+ & Mg2+). 
3. Split the 60mL of cells into 2 50mL tubes and added 300µL of CD4 Dynabeads to 
each, 600µL total (Dynabeads suggests 25uL per 1x107 cells we would need 
1.5mL of beads). 
4. Rotated for 30 min at 4oC. 
5. Placed on magnet 2 min. 
6. Counted cells – total after depletion 4.8x108 
7. Add another 500µL of beads split into 2 tubes. 
8. Rotated for 30 min at 4oC. 
9. Placed on magnet 2 min – spun down and re-suspended in 25mL. 
10. Placed in magnet again – counted 2.6x108 total cells after second round of 
depletion. 
 
Staining for Double Negative Sort 
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11. Re-suspended 1x108 in FACS buffer (PBS, 2% FBS w/o Ca2+ & Mg2+). 
12. Added 200µL of antibody mix from Untouched Human T-cell kit. 
13. Incubated on ice for 15 min. 
14. Washed and re-suspended in 10mL. 
15. Added 200µL of anti-mouse PE (BD suggests 20µL per 1x106 cells for a total of 
2mL). 
16. Incubated 10 min on ice. 
17. Washed re-suspended in 10mL. 
18. Added 200 uL anti-CD4 FITC and 140µL anti-CD8 APC (BD suggests 20 uL per 
1x106 cells a total of 2 mL). 
19. Washed and re-suspended in 4mL. 
 
Part C- Double Positive Sorting 
 
A- Took 5x107 cells and re-suspended in 5mL FACS buffer. 
B- Added 120µL of anti-CD4 FITC (BD suggestion 1 mL). 
C- Added 80µL anti-CD8 APC (BD suggestion 1 mL). 
D- Incubated for 10 min on ice. 
E- Wahed and re-suspended in 2mL of FACS buffer. 
 
Single Stain Controls 
 
1x106 unstained cells in 500µL FACS buffer 
1x106 2µL anti-CD4 in 500µL FACS buffer 
1x106 2µL anti-CD8 in 500µL FACS buffer 
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